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ABSTRACT

Serotonin (5-HT) is a ubiquitous neurotransmitter in the brain that is involved
in various physiologic functions including the regulation of hypothalamic
hormones and has been implicated in various mood disorders such as depression.
Preclinical and clinical data from studies in adults have shown that
antidepressant drugs produce time-dependent changes in serotonergic and other
systems and can also normalize dysfunction associated with the hypothalamicpituitary-adrenal (HPA) axis. To date, our understanding of the mechanisms of
5-HT receptor signaling and the actions of drugs on serotonergic function have
been derived from extensive preclinical research carried out using cell lines in
vitro or in adult animal models in vivo. Fewer studies have investigated
serotonergic signaling mechanisms or the effects of antidepressants (i.e., selective
serotonin reuptake inhibitors (SSRIs)) in animal models prior to sexual
maturation. This is a scientific and clinically relevant issue as (1) SSRIs, the most
effective pharmacological option for treating mood disorders in children and
adolescents, are being increasingly prescribed and may be associated with
suicidal thoughts or behaviors in these age groups and (2) preclinical studies in
rodents indicate that SSRI-induced modulation of the serotonergic system prior
xv

to sexual maturation produces effects that are distinct and more long-lasting than
those produced in adults. To date, few if any studies have investigated
mechanisms of 5-HT receptor signal transduction in peripubertal hypothalamic
neurons in vivo and their regulation by SSRIs, despite a wealth of existing
comparative data on serotonin 1A (5-HT1A) receptor signaling in adult
hypothalamic rat paraventricular nucleus (PVN).
Given the clinical relevance of potential age-dependent differences in
serotonergic signaling and regulation of hypothalamic function, the objective of
the studies in this dissertation was to identify and characterize the mechanisms
of 5-HT1A receptor signaling in the peripubertal hypothalamic PVN.
The data generated by studies in this dissertation project provide the first in
vivo evidence that 5-HT1A receptors in the peripubertal PVN can activate
multiple responses: (1) oxytocin and adrenocorticotropic hormone (ACTH)
plasma hormone responses, (2) activation of extracellular signal-regulated kinase
(ERK), and (3) activation of protein kinase B (Akt). The data also demonstrate
that these pathways may be differentially responsive to different classes of 5HT1A receptor agonists.

(+)8-OH-DPAT (an aminotetralin), acted as a “full”

agonist on each of the respective pathways, while tandospirone (an azapirone)
exhibited “partial” agonist activity on activation of Akt but exhibited “full”
agonist activity on neuroendocrine responses and activation of ERK. 5-HT1A
receptors produce a rapid and prolonged activation of ERK in the peripubertal
xvi

PVN, unlike the rapid but more transient response in the adult PVN. In addition,
the 5-HT1A activation of ERK may be expressed only in certain populations of
neuroendocrine cells in the peripubertal PVN. These studies have also revealed
some unique aspects that Gα proteins in the peripubertal PVN, since: (1) there
are age-dependent increases only in Gαo levels, (2) Gαi3 and Gαo are not
reduced by intra-PVN injection with pertussis toxin, and (3) Gαz proteins are not
reduced by 7 or 14 days of fluoxetine treatment. We also have determined that
chronic

fluoxetine

treatment

desensitizes

5-HT1A

receptor-mediated

phosphorylation of GSK3β in the absence of changes in its canonical upstream
kinase, Akt. These data suggest fluoxetine may induce changes in phosphatase
activity or that there may be a different upstream kinase mediating the
phosphorylation of GSK3β in the peripubertal PVN.
In conclusion, the present studies determined the mechanisms of 5-HT1A
receptor-mediated signaling in peripubertal PVN and identified some aspects of
5-HT1A receptor signaling that differ from those previously identified in adults.
These findings may be clinically relevant with respect to facilitating a better
understanding of mechanisms mediating the therapeutic and/or side effects of
SSRIs prescribed to young patients or to identify novel drug targets to treat
mood disorders in children and adolescents.

xvii

CHAPTER 1
INTRODUCTION
Serotonin

(5-hydroxytryptamine,

5-HT)

is

primarily

found

in

the

gastrointestinal tract, platelets, and central nervous system, where it acts as a
monoamine neurotransmitter.

In the brain, 5-HT can function as a

“developmental signal” to direct biochemical and morphological differentiation
of 5-HT-containing cells localized in the raphe nuclei (Lauder 1990; Rubenstein
1998). The raphe nuclei are discrete groups of cells located in the brainstem that
contain perikarya of serotonergic neurons that constitute the ascending and
descending serotonergic projections to almost every area of the central nervous
system.

Two prominent ascending projections that innervate various brain

regions (including the hypothalamus) arise from neurons located in the dorsal
and median raphe nuclei.
5-HT plays a prominent role in the regulation of behavior, mood, appetite,
perception, circadian rhythms, body temperature, and cognitive functions such
as memory and learning (Berger et al., 2009).

Many studies have linked

dysfunction of the serotonergic system with psychological disorders such as
depression and anxiety, and many classes of psychotropic drugs used to treat
these disorders alter serotonergic signaling.
1

2
To date, seven families (5-HT1-7) of receptors encompassing a total of 15
subtypes have been identified that mediate the various effects of 5-HT. The
serotonin 1A (5-HT1A) receptor was one of the first 5-HT receptor subtypes to be
identified and cloned (Albert et al., 1990), and has been extensively investigated
with respect to its pharmacology and regional distribution in brain. 5-HT1A
receptors on serotonergic neurons are localized to the soma and dendrites and
function as inhibitory autoreceptors to regulate cell firing. This population of
somatodendritic autoreceptors has generated a great deal of attention since the
desensitization of these receptors (i.e., an attenuation of a receptor-mediated
response despite the presence of agonist) plays a prominent role in the
therapeutic efficacy of various drugs used to treat mood disorders.

5-HT1A

receptors also are localized post-synaptically on non-serotonergic cells in various
brain regions such as the hippocampus, frontal cortex, and hypothalamus, where
they can initiate a variety of signal transduction cascades (Kia et al., 1996a; Kia et
al., 1996b; Blier and Ward 2003; Marvin et al., 2010). 5-HT1A receptors in the
hypothalamus are involved in the serotonergic stimulation of various hormones
and regulation of the hypothalamic-pituitary-adrenal (HPA) axis, the interface
between the brain and body in response to stress (reviewed in Sullivan-Hanley
and Van de Kar, 2003 and Carrasco and Van de Kar et al., 2003). Dysregulation
of the HPA axis has been associated with mood disorders, and normalization of

3
the HPA axis has been suggested to contribute to some of the therapeutic actions
of antidepressants (Nemeroff 1996; Holsboer 1999, 2000).
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac ®)
have completely revolutionized the field of adult psychiatry since they are
comparable in effectiveness to tricyclic antidepressant (TCA) and monoamine
oxidase inhibitor (MAOI) drug classes in treating several mood disorders but
exhibit a more favorable side effect profile than the TCAs or MAOIs (Hirschfeld
1999; Papakostas and Fava, 2006). It is noteworthy that SSRIs, but not tricyclic
antidepressants or MAOIs (Ryan 2003; Bostic et al., 2005), have been shown to be
effective in treating childhood and adolescent clinical disorders such as
depression,

obsessive-compulsive

disorders,

eating

disorders,

Tourette’s

syndrome, autism, and panic disorder (Cohen 2007; Rushton and Whitmire, 2001;
Wong et al., 2004). Although SSRIs remain one of the only pharmacological
options for treating childhood and adolescent mood disorders, their use has been
controversial due to a reported increase in suicidal thoughts or behavior (USFDA,
2004). In the United Kingdom, most SSRI use in children and adolescents has
been banned (European Medicines Agency, 2004), while in the United States, the
Food and Drug Administration has issued a ‘black box’ warning for SSRI use in
children and adolescents. However, in the years since these restrictions were
enacted, suicide among child and adolescent age groups significantly increased,
indicating an inverse relationship between SSRI prescription rates and suicide

(Gibbons et al., 2007).
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Therefore, although the use of SSRIs in children and

adolescents may pose an increased risk of suicidal thoughts or behavior in some
individuals (Reeves and Ladner 2010), it is likely that these drugs will continue
to be prescribed with caution to children and adolescents. These clinical findings
suggest that some aspects of SSRI effects on the immature brain may be different
than those demonstrated in the adult brain.
Preclinical studies indicate that SSRI-induced modulation of the serotonergic
system prior to sexual maturation in rodents produces effects that are distinct
and more long-lasting than those produced in adults. For example, in contrast
to adult treatment, administration of SSRIs to young animals results in: (1)
decreased levels of the serotonin (5-HT) transporter and tryptophan hydroxylase
that persist into adulthood (Maciag et al., 2006), (2) increased anxiety-like
behavior that persists into adulthood (Ansorge et al., 2004), (3) altered aggressive
behavior around the time of sexual maturation (Taravosh-Lahn et al., 2006) and
(4) paradoxical anxiogenic responses in several behavioral tests (Oh et al., 2009).
These studies demonstrating differences in the way that antidepressants induce
neuroadaptations and behavioral effects in the developing brain suggest inherent
differences in the mechanisms of serotonergic signaling in the immature vs. adult
brain.
The objective of this dissertation is to identify the mechanisms of 5-HT1A
receptor signaling and regulation in the peripubertal brain in order to discern

any aspects of 5-HT1A

5
receptor signaling that may be unique to this age relative

to mechanisms operative in the adult brain. Several studies in the adult brain
indicate that the time necessary for clinical efficacy of antidepressants (~2-3
weeks) corresponds to the time necessary to desensitize 5-HT1A autoreceptors on
serotonergic neurons (Le Poul et al., 2000; Czachura and Rasmussen 2000).
Desensitization of post-synaptic 5-HT1A receptors on non-serotonergic neurons,
also a time-dependent response observed with chronic antidepressant treatment,
may contribute to the long-term therapeutic effects of anxiolytic and
antidepressant drugs (Borsini 1994).

However, the majority of studies

investigating the mechanisms of 5-HT1A receptor signaling and desensitization
have been primarily conducted either in cell cultures or in vivo in the adult brain.
These studies have revealed that the 5-HT1A receptor has the capacity to couple
to a variety of signal transduction pathways (e.g., inhibition of adenylyl cyclase,
activation of potassium channels, and activation of phopholipase C), with the
specificity of 5-HT1A receptor responses dependent on various factors such as cell
type, brain region, availability of second messengers, and/or intracellular milieu
(reviewed in Barnes and Sharp 1999; Raymond et al., 2001; Filip and Bader 2009;
Polter and Li 2010).

A number of recent reports have demonstrated post-

synaptic 5-HT1A receptors in vivo can also activate mitogenic signaling pathways,
including activation of the mitogen-activated protein kinase (MAPK) pathway

6
(Chen et al., 2002; Sullivan et al., 2005; Crane et al., 2007; Buritova et al., 2009) and
the protein kinase B (Akt) pathway (Polter et al., 2010).
In the adult rat hypothalamic paraventricular nucleus (PVN), 5-HT1A
receptors can activate independent signaling pathways, utilizing different
subsets of Gα proteins as shown in figure 1. Pertussis toxin-insensitive Gαz
proteins mediate the 5-HT1A receptor-induced increase in plasma levels of
oxytocin and adrenocorticotropic hormone (ACTH) (Serres et al., 2000a), whereas
pertussis toxin-sensitive Gαi/o proteins mediate 5-HT1A receptor-induced
activation of extracellular signal-regulated kinase (ERK) (Crane et al., 2007;
Garcia et al., 2006; Sullivan et al., 2005).

These responses to acute 5-HT1A

receptor activation are independent, since complete blockade of ERK signaling
does not alter 5-HT1A signaling of hormone responses (Jia et al., 2007). These
respective 5-HT1A receptor-mediated signaling pathways are also differentially
responsive to desensitization by SSRIs. Chronic treatment with SSRIs decreases
hypothalamic levels of Gαz proteins and desensitizes 5-HT1A receptor-mediated
oxytocin and ACTH hormone responses (Raap et al., 1999) but does not
desensitize

the

5-HT1A

receptor-Gαi/o-mediated

increase

in

activated

(phosphorylated) ERK (pERK) in the PVN (Jia et al., 2006). However,
pharmacological blockade of the ERK signaling pathway, either by inactivation
of Gαi/o proteins or via blockade of MAPK kinase (the activating kinase for ERK)
during SSRI treatment abolishes both the SSRI-induced desensitization of 5-HT1A

7
receptor signaling of hormone responses from oxytocin and corticotrophin
releasing hormone (CRH)-containing neurons and the reductions in associated
Gαz proteins (Jia et al., 2007).

These recent novel findings suggesting the

requirement of MAPK in the desensitization of 5-HT1A receptor-mediated
hormone responses highlight the complexity of 5-HT1A receptor signaling in
adult hypothalamic PVN, and indicate the important role of kinases in
depression and the effects of antidepressant drugs.
Multiple lines of evidence have implicated protein kinases/phosphatases in
the pathology of mood disorders and the effects of antidepressants.

As

previously mentioned, intact ERK signaling is required for SSRI-induced
desensitization of 5-HT1A receptor-mediated neuroendocrine responses (Jia et al.,
2007). Furthermore, in the adult rodent brain, ERK and its regulators have also
been shown to be involved with stress-induced behavioral responses (Gourley et
al., 2008) and antidepressant-induced amelioration of depressive behavior
(Duman et al., 2007; Duric et al., 2010).

Another kinase pathway, the

phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/glycogen synthase
kinase-3β (GSK3β) pathway, has also been recently implicated in the pathology
of

psychological

disorders

including

chronic

stress,

depression,

and

schizophrenia. The Akt pathway also plays a prominent role in the effects of
lithium, SSRIs, and other classes of psychotropic drugs (Zhang et al., 2003; Li et
al, 2004; Basta-Kaim et al., 2005; Li et al., 2007; Amar et al., 2008; Reddy et al,

2008; Szymanska et al., 2009).
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For example, increased levels of activated

(phosphorylated) Akt (pAkt) have been found in animals subjected to chronic
stress (Lee et al., 2006), and the activity of PI3K and Akt were significantly
decreased in the occipital cortex of suicide victims when compared to controls
(Hsiung et al., 2003).

Furthermore, SSRIs increase levels of inactivated (i.e.,

phosphorylated) GSK3β in the adult mouse frontal cortex, possibly via 5-HT1A
receptor activation (Li et al., 2004).
To date, no studies have elucidated the specific pathways or mechanisms of
5-HT1A receptor signaling in the immature hypothalamus. Therefore, the overall
purpose of this dissertation is to identify and characterize the 5-HT1A receptormediated signaling pathways that are operative in the hypothalamic PVN of
peripubertal rats (see figure 2).

The determination of hypothalamic 5-HT1A

receptor signaling mechanisms, and any aspects that may be unique to the
immature brain, should contribute to a better understanding of differences in
therapeutic and/or side effects of SSRIs in adult vs. young patients and may
identify novel drug targets to treat mood disorders in children and adolescents.
The HYPOTHESIS for this dissertation is that, in the peripubertal rat
hypothalamic PVN:

(1) 5-HT1A receptors on oxytocin- or CRH-containing

neurons stimulate oxytocin and ACTH plasma hormone responses and activate
ERK and Akt via different subsets of Gα proteins; (2) different structural classes
of agonists may exhibit biased agonism of 5-HT1A receptor-mediated signaling

responses; and (3) 5-HT1A
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receptor-mediated activation of protein kinase

pathways will be resistant to desensitization by SSRIs (in contrast to
neuroendocrine responses). The main objectives of the dissertation studies in the
peripubertal rat hypothalamic PVN are to determine: (1) if different structural
classes of 5-HT1A receptor agonists (i.e., an aminotetralin and/or an azapirone)
that stimulate oxytocin and ACTH responses can concomitantly activate the ERK
and/or Akt protein kinase pathways; (2) the onset and longevity of the
respective 5-HT1A receptor-mediated responses activated by two different classes
of agonists; (3) the efficacy and potency of two agonist classes on each of the
respective 5-HT1A receptor-mediated responses; (4) potential “agonist-dependent
selectivity” or targeting of any specific response pathway by either class of
agonist; (5) levels of the respective Gα protein subtypes at peripubertal versus
younger (prepubertal) and adult ages, (6) the role of PTX-sensitive and PTXinsensitive Gα proteins in the respective 5-HT1A receptor-mediated responses; (7)
the regulation of hypothalamic Gα proteins and 5-HT1A receptor-mediated
activation of ERK, Akt, and its downstream effector GSK3β in PVN upon chronic
SSRI treatment paradigms (7 or 14 days); and (8) if 5-HT1A receptors can activate
ERK in oxytocin- and CRH-containing cells and if the profile of ERK activation is
qualitatively similar to that in adult PVN.

ADULT PVN
A

B
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Acute ↑ 5-HT
or
5-HT1A receptor agonist

Prolonged ↑ 5-HT
via
SSRIs

Figure 1.
5-HT1A
receptor signaling (A) and SSRI-induced desensitization (B) in the adult rat PVN. In the ADULT
PVN, 5-HT1A receptor activation results in increases in plasma levels of oxytocin and ACTH and
increases in pERK levels in PVN. These pathways are mediated by different subsets of Gα
proteins and are independent with respect to acute 5-HT1A receptor activation, yet intact ERK
signaling is required for SSRIs to desensitize 5-HT1A receptor-mediated neuroendocrine
responses and decrease hypothalamic levels of Gαz proteins (white dashed line).
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PERIPUBERTAL PVN

Figure 2. Proposed 5-HT1A receptor signaling mechanisms in the PERIPUBERTAL rat PVN. 5HT1A receptors can potentially activate oxytocin and ACTH plasma hormone responses and
protein kinase (ERK and Akt) activation in peripubertal PVN. In these dissertation studies, the
potential agonist specificity to activate these respective responses, the role of Gα proteins, cellular
localization of ERK responses, and regulation of kinase activity by fluoxetine will be determined.

CHAPTER 2
REVIEW OF RELATED LITERATURE
The serotonergic system
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter
that can also function as a “developmental signal” in early postnatal
development (Lauder 1990; Rubenstein 1998). In the brain, serotonergic cell
bodies are localized along the midline of the brainstem (medulla, pons, and
midbrain) and are organized in 9 distinct nuclei designated B1-B9 by Dahlstrom
and Fuxe in 1964. These cell groups generally correspond to the raphe nuclei
defined by Taber et al. in 1960, although not all raphe neurons are serotonergic.
In the rat, expression of the serotonergic phenotype begins on embryonic day 12
and continues on until embryonic day 15, when generation of 5-HT neurons in
the raphe is complete (Lauder 1990; Rubenstein 1998). Serotonergic cells send
ascending projections to almost every area of the brain as well as descending
projections to the spinal cord. Two prominent and morphologically different
ascending pathways arise from the dorsal and median raphe nuclei to innervate
the forebrain. Although these pathways have distinct patterns of innervation,
projections from both dorsal and median raphe nuclei innervate the
hypothalamus (Tork 1990; Hensler 2006).
12

5-HT mediates its effects via 7
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families of receptors (5-HT1-7) containing at least 15 subtypes to regulate a wide
variety of functions including behavior, mood, appetite, perception, circadian
rhythms, body temperature, and cognitive functions such as memory and
learning (Berger et al., 2009).
5-HT synthesis, release, and reuptake
5-HT does not pass the blood brain barrier easily; therefore, most brain 5-HT
is synthesized within the raphe nuclei.

The amino acid precursor to 5-HT,

tryptophan, is transported into the central nervous system via a neutral amino
acid transporter located on brain capillary endothelial cells (Boado et al., 1999).
Brain levels of tryptophan depend on its total concentration in blood, as well as
its levels relative to other neutral amino acids. Tryptophan is converted to 5hydroxytryptophan by tryptophan hydroxylase (TPH). TPH is the rate-limiting
enzyme in 5-HT synthesis and is synthesized only in 5-HT-containing cells. TPH
exists in two isoforms: TPH1 and TPH2.

TPH2 is primarily expressed in

brainstem while TPH1 is expressed in the gut, pineal gland, spleen, and thymus
(Walther and Bader, 2003).

5-hydroxytryptophan is converted to 5-

hydroxytryptamine (5-HT) by the enzyme aromatic amino acid decarboxylase
(AAADC). AAADC is not specific to 5-HT-containing cells, as this enzyme can
also convert L-dopa to dopamine.

5-HT is packaged into vesicles by the

vesicular monoamine transporter 2 (VMAT2) (Hensler in Siegel text, 2006). After
synaptic release of 5-HT via exocytosis, the major means of terminating the
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signal is reuptake back into the cell by the serotonin transporter (SERT). SERT is
localized to neurons, although some astrocytes in culture can take up 5-HT. 5HT is metabolized to 5-hydroxyindoleacetic acid (5-HIAA) by monoamine
oxidase (MAO), which is primarily localized in mitochondria. 5-HT can also be
converted to melatonin in the pineal gland (Hensler in Siegel text, 2006).
With regards to developmental levels of some of these regulators of 5-HT
synthesis and reuptake, TPH and SERT immunoreactivity in rat raphe neurons
are high in early postnatal development but decrease to stable levels by postnatal
day 21 (Liu and Wong-Riley, 2010).
Mechanism of action of selective serotonin reuptake inhibitors (SSRIs)
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac ®)
comparable in effectiveness to other antidepressants, such as tricyclic
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), in treating
several mood disorders but exhibit a more favorable side effect profile than the
TCAs and MAOIs (Hirschfeld 1999; Papakostas and Fava, 2006). SSRIs initially
function to block the reuptake of 5-HT by SERT at the synapse, which increases
synaptic levels of 5-HT. Therefore, acute administration of SSRIs increases 5-HT
and triggers 5-HT1A autoreceptors (located on the soma and dendrites of 5-HT
cells) to inhibit further cell firing (Newman et al., 2004).

Upon continued

treatment with an SSRI, increased levels of 5-HT desensitizes (i.e., an attenuation
of a receptor-mediated response despite the presence of agonist) the inhibitory
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somatodendritic 5-HT1A autoreceptors, thereby reestablishing or strengthening 5HT cell firing. The time necessary for desensitization of 5-HT1A autoreceptors is
consistent with the 2-3 week delay in therapeutic response to SSRIs.
Desensitization of post-synaptic 5-HT1A receptors on non-serotonergic neurons in
other brain regions is also observed with antidepressant drug treatment and may
be involved in the long-term therapeutic effect of anxiolytic and antidepressant
drugs (Borsini 1994). SSRIs can also attenuate increases in SERT protein levels in
the raphe nuclei of chronically stressed rats (Abumaria et al., 2007) and in a rat
model of depression (Saitoh et al., 2007).
The hypothalamic-pituitary-adrenal (HPA) axis
The serotonergic system exerts significant control over the hypothalamicpituitary-adrenal (HPA) axis, the main interface between the brain and body in
response to both psychological and physiological stressors (Carrasco and Van de
Kar, 2003; Sullivan-Hanley and Van de Kar, 2003; Jorgensen 2007; Pompili et al.,
2010). Alterations in HPA function have been associated with mood disorders
(Modell and Holsboer, 2005; Papiol et al., 2007; Thomson and Craighead, 2008;
Bao et al., 2008; Holsboer and Ising, 2010), and antidepressants used to treat these
disorders produce changes in HPA function in both humans and animal models
(Conti et al., 2007, Lerer et al., 1999, Li et al., 1997, Li et al., 1996, Serres et al.,
2000b, Young et al., 2004). The hypothalamus, a major component of the HPA
axis, is a limbic structure involved in a number of vital functions such as
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circadian rhythms, body temperature regulation, appetite, and the regulation of
mood (Adamec 1990, Kruk 1991). The paraventricular nucleus (PVN) is one of
several nuclei in the hypothalamus and is a center of control over many
neuropeptides/hormones. Oxytocin and corticotrophin releasing hormone
(CRH) are two hormones that are subject to serotonergic regulation via 5-HT1A
receptors in hypothalamic PVN (Osei-Owusu et al., 2005). 5-HT1A receptors in
the PVN mediate hormone release via direct (e.g., oxytocin) and sequential (e.g.,
CRH → adrenocorticotropic hormone (ACTH)) pathways (Armstrong 2004).
Measuring plasma levels of ACTH and oxytocin after in vivo injection of 5-HT1A
receptor agonists (i.e., “neuroendocrine challenge test”) is a viable means of
assessing

5-HT1A

receptor

function

in

animal

models.

Furthermore,

neuroendocrine challenge tests are clinically relevant because they may be used
in human patients to assess alterations in receptor function due to
neuropsychiatric conditions or the effects of psychotropic drugs (Cowen 1998;
Lee et al., 2003; Almeida et al., 2010).
The reactivity of the HPA axis is modulated by pubertal development. Basal
levels of HPA function remain unchanged, but stress-induced increases in the
activation of the HPA axis are significantly elevated and prolonged in
peripubertal rats compared to adults. With regards to continued exposure to
stressors, peripubertal animals habituate, or adapt, more rapidly than adult
animals exposed to the same chronic stressors (Romeo et al., 2006).

Lastly,
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exposure to stressors during critical periods of maturation can induce long term
changes in HPA reactivity (Romeo, 2010). Changes in gonadal hormone levels
are responsible for some of these differences between peripubertal and adult
animals. For example, testosterone attenuates HPA reactivity in response to an
acute stressor (Goel et al., 2011). Testosterone also decreases activation of c-fos in
brain regions with inhibitory feedback on the PVN (Williamson et al., 2010; Goel
et al., 2011). Therefore, lower levels of testosterone in a peripubertal animal
could lead to hyperactivity of the HPA axis.
Neuropeptides and mental illness
Oxytocin. Various studies have indicated that neuropeptides may play a
major role in the pathology associated with mood disorders and stress responses.
Neuropeptides may serve as local, autocrine, paracrine, or regulatory agents in
nearby cells (Sawchenko et al., 1984b). Oxytocin, a nine-amino acid residue
neuropeptide, was first isolated in 1953 (Du Vigneaud et al., 1953). Oxytocin is
mainly synthesized within the soma of magnocellular neurons located in the
PVN and supraoptic nucleus in the hypothalamus. Oxytocin is then transported
down the axon, packaged in neurosecretory vesicles, and released directly from
nerve terminals located in the posterior pituitary, arcuate nucleus, lateral
septum, medial amygdaloid nucleus and median eminence. Although oxytocin
is most often associated with the effects it has on maternal behavior, pair
bonding, and lactation (Marazziti and Catena Dell’Osso 2008), oxytocin is also a
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potent neuromodulator and has been found to be anxiolytic in males and females
(Newman, 2008; Scantamburlo et al., 2009; Slattery and Neumann 2010). For
example, intracerebroventricular infusion of oxytocin into the mouse brain
decreases anxiety behavior (Yoshida et al., 2009), and depressed patients show
lower plasma oxytocin than controls (Frasch et al., 1995; Ozsoy et al., 2009).
Intranasal administration of oxytocin has shown to be clinically useful in certain
depressed individuals (Heinrichs and Gaab 2007).

Although the anxiolytic

effects of oxytocin may be at least partially mediated through the serotonergic
system (Yoshida et al., 2009), chronic treatment with SSRIs has no effect on basal
plasma levels of oxytocin in rats (Uvnas-Moberg et al., 1999) or in depressed
human patients (Ozsoy et al., 2009). However, basal plasma levels of oxytocin
may not reflect changes in central levels of oxytocin (Armstrong et al., 1980) that
may occur following chronic SSRI treatment.
CRH. The interactions of CRH, the HPA axis, and depressive disorders have
been more extensively investigated than the involvement of oxytocin in
depressive disorders. One of the key players in the HPA axis is CRH, a 41 amino
acid residue neuropeptide that was first characterized in 1981 (Vale et al., 1981).
Although CRH may access the general circulation (Sawchenko et al., 1984b), the
classical mechanism of HPA function is triggered by CRH release from the
hypothalamus into the hypothalamo-hypophyseal portal system, where it
interacts with one of two types of CRH receptors on corticotrophic cells (CRH-

R1) in the anterior pituitary (Papadimitriou and Priftis, 2009).
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Upon CRH

receptor stimulation, corticotrophic cells release ACTH into the periphery, where
it acts on its receptors in the adrenal cortex to synthesize and release
corticosteroids (namely cortisol in humans and corticosterone in rats).

The

corticosteroids act throughout the body to affect a variety of mechanisms
necessary to cope with stressors, including regulating plasma glucose levels,
metabolism, and CNS effects.

There are corticosteroid receptors at multiple

levels (e.g., hypothalamus and pituitary) that bind corticosteroids providing a
negative feedback mechanism in order to attenuate the stress responses (Barrett
2003).
Although most CRH immunoreactivity is localized to parvocellular neurons
in the PVN, CRH is detected in a multitude of other brain regions, which
strongly suggests that CRH may act as a neuromodulator in extra-hypothalamic
circuits (Swanson et al., 1983; Liposits et al., 1985; Sakanaka et al., 1987). Studies
in both humans and animal models have implicated the CRH system in mood
disorders and the effects of antidepressants (Nemeroff 1996; Holsboer 1999, 2000;
Arborelius et al., 1999; Bale and Vale, 2004; Madaan and Wilson, 2009). Acute
fluoxetine elevates CRH in hypophyseal portal plasma and subsequently
increases ACTH in plasma in rats (Gibbs and Vale 1983). Chronic stress or
intracerebroventricular injection of CRH induces depressive behaviors in a
rodent model (Swiergiel et al., 2008). In the human brain, the ratio of the two
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subtypes of CRH receptors, CRHR1 to CRHR2, was found to be decreased in the
brains of suicide victims as compared to controls (Hiroi et al., 2001). In one
human study (albeit one with a limited sample size), a certain genetic variant of
the CRHR1 gene was associated with an increased risk for developing a seasonal
pattern of depression and an earlier age of onset for the first depressive episode.
A genetic variant of the CRHR2 gene predicted a poorer outcome when
individuals expressing this variant were given the SSRI citalopram (Papiol et al.,
2007). Although these studies represent just a few of the adaptations observed in
the CRH system associated with stress and mental illness, it is important to note
that most human studies are performed in adults. However, studies of HPA
function in children and adolescents are steadily increasing, and some recent
studies have also demonstrated HPA alterations in response to stress and mental
illness in these younger age groups.

For example, children that are bullied

(Vaillancourt et al., 2007), have been subjected to sexual abuse (Trickett et al.,
2010), have had lost a parent in the September 11, 2001 terrorist attacks (Pfeffer et
al., 2007), or who have been displaced by Hurricane Katrina (Vigil et al., 2010)
have decreased cortisol levels and risk for depressive disorders. Pituitary gland
volume is increased in adolescents with mood disorders as compared to controls
(MacMaster et al., 2008). Although these studies provide strong evidence for the
involvement of the HPA in depressive behavior in children and adolescents,
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preclinical studies of HPA function and the effects of antidepressants in the
immature brain are lacking.
Neuroanatomy of the PVN
The PVN is localized in the medial hypothalamus and is located rostrally at
the level of the optic chiasm. The nucleus is localized laterally to the third
ventricle near its dorsal surface (Kiss 1988; Paxinos and Watson, 1998). Each half
of the PVN receives input from the contralateral side of the PVN (Silverman et
al., 1981). The PVN is a center for complex autonomic and neuroendocrine
control of the periphery and central nervous system (Swanson and Sawchenko
1980; Sawchenko and Swanson 1983) and consists of several independently
controlled subdivisions—medial and lateral magnocellular (large cell) groups;
anterior and medial parvocellular (small cell) cell groups; and ventral, posterior,
and dorsomedial cap divisions. The PVN is often subdivided based on the
cellular content of neuroactive peptides and neurotransmitters; however,
neurons in the PVN are also organized into subnuclei based on common output,
size, density, and dendritic morphology (Armstrong 2004).
Magnocellular neurosecretory cells. The medial magnocellular region of the
PVN contains primarily oxytocin-containing and arginine vasopressin (AVP)containing cells. AVP-containing cells are localized in a ball-shaped cluster in
the lateral magnocellular group located posterior and dorsolateral in the PVN.
Oxytocin-containing cells are localized in the medial magnocellular portion
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located anteromedially in the PVN, and also form a ring of cells around the ballshaped AVP neuron group. Magnocellular cells are relatively large (i.e., 20-35
μm) and send their axons to the neural lobe of the hypophysis, forming the
hypothalamoneurohypophyseal system.

Oxytocin and AVP are transported

down these axons for release into the plasma (Armstrong, 2004). Although most
CRH-containing cells are localized in the parvocellular cell groups, oxytocin and
CRH do moderately colocalize in a discrete anterior part of the magnocellular
division of the nucleus (Sawchenko et al., 1984b).
Parvocellular neurosecretory cells.

Parvocellular groups are chemically

diverse (e.g., containing CRH, oxytocin, AVP, and many other neuropeptides)
and can be divided into anterior and medial cell groups (Armstrong, 2004).
There is also significant colocalization of CRH with AVP in the PVN (Sawchenko
et al., 1984a). Cells from each of the anterior and medial subnuclei project to and
synapse on the median eminence. Factors released from parvocellular groups
are released into the tuberohypophyseal system, where they influence the
secretion of anterior lobe hormones (e.g. ACTH).
Although CRH is the classical releasing hormone for ACTH, AVP also plays a
role in ACTH stimulation (Papadimitriou and Priftis, 2009). However, although
5-HT regulates the release of AVP, it is most likely stimulated by 5-HT2C, 5-HT4,
and 5-HT7 receptors (Jorgensen, 2007) and not 5-HT1A receptors (Bagdy et al.,
1992; Li et al., 1993).
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Nonendocrine projection cells. In the PVN, there are also some cell groups
that send significant descending projections to the brainstem and spinal cord.
These cells are organized into ventral, posterior, and dorsomedial cap subnuclei
(Armstrong, 2004).

Projections from these cells also innervate some

circumventricular organs, pineal gland, and specific nuclei of the thalamus,
amygdala, and other areas of the hypothalamus (Pittmann et al., 1981).
Retrograde tracing of neurons reveals that the dorsomedial part of the PVN
projects to the spinal cord and the dorsolateral cap of the PVN projects to the
pituitary, indicating that separate cell populations in the PVN project to pituitary
vs. spinal cord (Swanson and Kuypers 1980). Oxytocin receptors have been
found on 5-HT containing cells in the raphe nuclei (Yoshida et al., 2009),
indicating that oxytocin has the capacity to regulate serotonin release and
possibly anxiolytic effects via direct activation of oxytocin receptors in the raphe
nuclei.
Inputs to PVN. Neurons in the PVN are highly responsive to both peripheral
and central stimuli (Saphier and Feldman 1985; Hatton 1990), receiving input
from the brain stem, most other hypothalamic areas, the amygdala, and other
forebrain areas (Armstrong 2004).

The PVN receives significant amounts of

monoamine innervation, primarily by 5-HT (raphe nuclei) and norepinephrine
(locus coeruleus). Serotonergic projections arise from the raphe nuclei, and fibers
from these neurons are found in both oxytocinergic cell groups (Sawchenko et
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al., 1983) and parvocellular regions. Considering that 5-HT-containing axons
overlap with CRH-immunoreactive neurons in the PVN, it is likely that there are
direct synapses between serotonergic terminals and dendrites and cell bodies of
CRH cells (Liposits et al., 1987).

Dendrites of both parvocellular and

magnocellular secretory neurons rarely leave the PVN, but often cross into
adjacent subnuclei, where they can locally secrete peptide (Armstrong, 2004).
5-HT1A receptor signaling in the hypothalamic paraventricular nucleus (PVN)
The serotonin 1A (5-HT1A) receptor was one of the first 5-HT receptor
subtypes to be identified and investigated with respect to its pharmacology,
function, and regional distribution in brain. It was also the first 5-HT receptor to
be cloned (Albert et al., 1990). 5-HT1A receptors are 7-transmembrane-spanning
and are part of the G-protein coupled receptor (GPCR) family. 5-HT1A receptors
on serotonergic neurons are localized to the soma and dendrites where they
function as inhibitory autoreceptors to regulate cell firing. This population of
receptors has generated a great deal of attention since the desensitization of these
receptors plays a prominent role in the therapeutic efficacy of various drugs used
to treat mood disorders. 5-HT1A receptors are also associated with anxiolytic
properties, and knock-out mice lacking this receptor show increased anxiety
behavior (Celada et al., 2004; Gross et al., 2002).

5-HT1A receptors also are

expressed on non-serotonergic cells in various brain regions such as the
hippocampus, frontal cortex, and hypothalamus, where they are postsynaptic
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receptors that can initiate a variety of signal transduction cascades in response to
5-HT or an agonist (Kia et al., 1996a; Kia et al., 1996b; Blier and Ward 2003;
Marvin et al., 2010).

In the paraventricular nucleus, 5-HT1A receptor

immunoreactivity was localized in the medial parvocellular subnucleus as well
as in the medial magnocellular subnucleus (Marvin et al., 2010).
5-HT1A receptors have the capacity to couple to the broadest array of G
proteins and second messengers. 5-HT1A receptors in hypothalamus can couple
to Gαi/o and Gαz proteins (Garnovskaya et al., 1996; Raymond et al., 1993;
Serres et al., 2000a) and localize to at least two populations of cells in the PVN of
the hypothalamus: oxytocin- and CRH-containing cells (Zhang et al., 2004). In
adult rats, post-synaptic 5-HT1A receptors in the PVN mediate separate and
distinct signal transduction pathways mediated by separate subsets of Gα
proteins (see Chapter 1, figure 1). Gαz proteins mediate the 5-HT1A receptorinduced increase of ACTH and oxytocin into the plasma (Li et al., 1994; Li et al.,
1993; Serres et al., 2000a; Vicentic et al., 1998; Zhang et al., 2004) while pertussis
toxin-sensitive Gαi/o proteins mediate the activation of the mitogen activated
protein kinase (MAPK) cascade via the phosphorylation of extracellular signalregulated kinase (ERK) (Chen et al., 2002; Crane et al., 2007; Garcia et al., 2006;
Sullivan et al., 2005).
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Description of different structural classes of 5-HT1A receptor agonists
There are several structural classes of 5-HT1A receptor agonists. In the current
studies, representative members of the aminotetralin class ((+)8-OH-DPAT) and
the azapirone class (tandospirone) are used to determine how these different
structural classes compare with regards to potency and efficacy with respect to
the different 5-HT1A receptor responses in the peripubertal PVN. More details
regarding the structure, molecular weight, etc. is shown in table 1.
(+)8-OH-DPAT has a high affinity and selectivity for 5-HT1A receptors.
Tandospirone also has a high affinity for 5-HT1A receptors, and has similar
potency to other members of the azapirone class on the inhibition of neuronal
cell firing. Tandospirone is most selective for 5-HT1A than other subtypes of
receptors (5-HT1A > 5-HT2C > 5-HT1C > α1 and α2 adrenergic > dopamine D1 and
D2 receptors (Hamik et al., 1990). Tandospirone has lower affinity for dopamine
D2 receptors than buspirone (Seymour et al., 1990).
In rat septal nuclei cultures, 8-OH-DPAT had full agonist activity on neuron
hyperpolarization while buspirone (an azapirone) only had partial activity (Van
den Hooff and Gavan, 1992). 8-OH-DPAT is also more potent than azapirones
on the inhibition of cAMP formation in primary culture of mouse hippocampus
(Dumuis et al., 1988). In rat and guinea pig hippocampal membranes, buspirone
also produced inhibition of forskolin-induced adenylyl cyclase activity, but the
maximal inhibition was less than that induced by 5-HT, indicating that
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azapirones display partial agonist activity in this response (DeVivo and Maayani,
1986). Tandospirone also displays 60% of the maximal effect of 8-OH-DPAT on
inhibition of adenylyl cyclase activity (Hamik et al., 1990).

However,

tandospirone has been shown to act as a full agonist in inducing 5-HT1A receptormediated hypothermia in rats (Millan et al., 1993). These studies demonstrate
that the agonist efficacy at 5-HT1A receptors is not dictated exclusively by
structural class and may vary with respect to signal transduction pathway
associated with 5-HT1A receptors.
SSRI-induced desensitization of 5-HT1A receptors in the hypothalamic PVN
Although several studies have linked the clinical efficacy of antidepressants
with the time necessary to desensitize 5-HT1A autoreceptors in serotonergic
neurons of the hindbrain, time-dependent desensitization of post-synaptic 5HT1A receptors on non-serotonergic neurons is also observed with long-term
treatment and may be involved in the therapeutic effects of anxiolytic and
antidepressant drugs (Borsini 1994). Desensitization of 5-HT1A receptors can
occur after prolonged elevations of extracellular 5-HT produced by uptake
blocking drugs or following prolonged exposure to specific 5-HT1A receptor
agonists (Albert et al., 1996). Receptor desensitization may occur after receptor
phosphorylation by protein kinase C in a complex with calmodulin (Raymond
1991; Turner et al., 2004). Receptor desensitization differs from drug tolerance in
that drug tolerance refers to the attenuation of clinical responsiveness to a drug
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after repeated administration, while receptor desensitization refers to the
attenuation in receptor signaling after repeated agonist administration (Bourne
and von Zastrow, 2004).
In vivo studies in adult rats have revealed that chronic SSRI treatment has
specific effects on 5-HT1A receptor signaling pathways in the PVN. Chronic
exposure to fluoxetine decreases levels of Gαz proteins in the PVN and
desensitizes 5-HT1A receptor-mediated hormone responses (Raap et al., 1999).
However, the Gαi/o-mediated ERK signaling pathway is not desensitized by
long-term SSRI treatment (Jia et al., 2006). In fact, maintaining MAPK signaling
is essential for desensitization of 5-HT1A receptor-mediated neuroendocrine
responses since blockade of MAPK kinase (MEK), the activating kinase for ERK,
abolishes SSRI-mediated desensitization of hormone response and associated
reductions in Gαz proteins (Jia et al., 2007).
5-HT receptor regulation in the postnatal period
5-HT receptor expression occurs very early in fetal development; mRNA
transcripts for the 5-HT1 receptor family can be detected as early as embryonic
day 14.5 in the mouse brain (Bonnin et al., 2006). Regional and subtype-specific
changes in 5-HT receptor mRNA levels continue past the day of birth and persist
into the early postnatal period (Basura and Walker, 2000; Volgin et al., 2003). 5HT1 and 5-HT2 receptor density in the primate brain increases rapidly in the
postnatal period and reaches its peak around 2-4 months of age. In general, the
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density of cortical 5-HT receptors then begins to decline, reaching adult levels
right around the time of puberty (~3 years of age in the primate) (Lidow and
Rakic 1992). However, there have been few studies examining developmental
changes in 5-HT receptor density in the hypothalamus. There was no change in
the density of 5-HT2A receptors in the neonatal rat hypothalamus over the second
postnatal week of life, but the density of 5-HT1A receptors increased during this
time in the hypothalamus (Ferrari et al., 1999).

However, the density or

regulation of 5-HT1A receptors in the hypothalamus around the time of puberty
has not been determined.
G proteins
5-HT1A receptors are part of the G protein coupled receptor family.

G

proteins are heterotrimeric and mediate signaling from the level of the receptor
to a variety of intracellular signaling pathways in the cell. 5-HT1A receptors
specifically couple to members of the Gαi/o protein family: Gαi1, Gαi2, Gαi3,
Gαo, and Gαz (Mannoury la Cour et al., 2006; Raymond et al., 1992; Serres et al.,
2000a) and mediate 5-HT1A receptor signaling pathways in the hypothalamic
PVN (i.e., oxytocin and ACTH responses and phosphorylation of ERK).
Dysfunction of G protein-mediated signaling has been recently linked to
psychiatric disorders. The activity and/or protein content of the intermediates of
G protein-mediated signaling pathways have shown to be disturbed in patients
with bipolar disorder (Friedman and Wang 1996; Spleiss et al., 1998; Dowlatshahi
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et al., 1999; Emamghoreishi et al., 2000), schizophrenia (Jope et al., 1998; Yang et
al., 1998) and alcohol dependence (Jope et al., 1998).

Measuring G protein

content in mononuclear leukocytes in patients with mood disorders may be a
viable option to measure the effectiveness of various drug treatments (Avissar et
al 2001).
Levels of Gα proteins are known to change throughout several brain regions
during early postnatal development. For example, Gαi1, Gαi2, and Gαo proteins
steadily increase between postnatal days 1 and 25 in the cortex, thalamus, and
hippocampus of the rat brain, whereas Gαi3 proteins decrease in these regions
over the same time period (Ihnatovych et al., 2002). However, no studies have
determined the developmental regulation of these subtypes of Gα proteins or
Gαz proteins in the hypothalamus, and no studies have examined the time right
around puberty, which is an important period for brain growth and maturation.
Any age-dependent differences in the levels of Gα proteins or mechanisms of
intracellular signal transduction of these proteins have implications for the
function of G protein-mediated signaling in both health and disease states in a
population at different stages in development.
The MAPK ERK
Mitogen activated protein kinases (MAPK) make up a family of protein
kinases that respond to extracellular stimuli (typically by growth factors). This
protein family regulates various cellular activities, including gene expression,

mitosis,

differentiation,

cell

survival/apoptosis,

learning,
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memory,

neuroplasticity, and receptor desensitization (Marshall 1995; Pouysségur and
Lenormand 2003; Trincavelli et al., 2002).

The activation mechanism of

extracellular signal-regulated kinase (ERK) is classically initiated by receptor
tyrosine kinases, although it can be activated by GPCRs, including 5-HT1A
receptors in vitro (Garnovskaya et al., 1996) and in vivo (Chen et al., 2002; Crane
et al., 2007; Sullivan et al., 2005).

More recently, MAPK function has been

implicated in stress and the effects of antidepressants. Acute blockade of MAPK
signaling produces a depressive-like phenotype and blocks behavioral actions of
antidepressants in mice (Duman et al., 2007; Qi et al., 2009), while chronic
corticosterone treatment of mice increases depressive-like behaviors and reduces
levels of activated ERK in the dentate gyrus (Gourley et al., 2008). Also, acute
stress alters levels of activated ERK in several regions of the rat brain (Shen et al.,
2004; Qi et al., 2006), which can be reversed by fluoxetine (Qi et al., 2008). These
findings are consistent with findings from our laboratory demonstrating that, in
adult rat hypothalamus, ERK activation is required for SSRIs to desensitize 5HT1A receptor signaling of neuroendocrine responses (Jia et al., 2007).
Furthermore, a small post-mortem study determined that several intermediate
proteins of ERK signaling as well as ERK itself, were decreased in content and/or
activity in the frontal cortex and hippocampus in patients with psychiatric
disorders, including schizophrenia and major depressive disorder (Yuan et al.,
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2010) and in subjects who had committed suicide (Dwivedi et al., 2001; Dwivedi
et al., 2006). Similarly, the activity of MEK (the upstream activating kinase for
ERK), but not relative protein levels, was decreased in the frontal cortex and
hippocampus of suicide victims when compared to controls (Dwivedi et al.,
2009).
The PI3K/Akt/GSK3 signaling pathway
Multiple lines of evidence indicate that the PI3K/Akt/GSK3 pathway plays a
role in the pathology of psychological disorders including chronic stress,
depression, and schizophrenia (Beaulieu et al., 2009). Akt (protein kinase B,
previously known as RAC-PK (related to PKA and C protein kinases)) is a
protein kinase involved with cell survival, apoptosis, protein synthesis, insulin
signaling, and glucose transport (Franke et al., 2003).

Akt, a 57 kDa

serine/threonine protein kinases, was first cloned in 1991 (Coffer and Woodgett,
1991; Jones et al., 1991; Bellacosa et al., 1991). Akt exists in three isoforms, Akt1
(PKBα), Akt2 (PKBβ), and Akt3 (PKBγ), with Akt1 having the highest expression
in brain tissue (Coffer and Woodgett, 1991). Akt can be activated by receptor
tyrosine kinases or by G protein-coupled receptors (GPCRs). In either case,
receptor activation activates phosphoinositide 3-kinase (PI3K), which catalyzes
the formation of the phosphatidylinoisitol(3,4,5)P3 (PIP3) molecule. PIP3 attracts
phosphoinositide dependent kinase 1 (PDK1) and Akt to the cell membrane,
where PDK1 phosphorylates Akt at Thr308 (Alessi et al., 1997; Stephens et al.,

1998).
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Akt also must be phosphorylated at Ser473 for full activation of the

protein (Alessi et al., 1996). The kinase mammalian target of rapamycin (mTOR)
is considered to be the candidate responsible for this phosphorylation (Sarbassov
et al., 2005), although other kinases like integrin-linked kinase may function to
phosphorylate Akt at Ser473 in transfected cell lines (Delcommenne et al., 1998).
Although phosphorylation of Akt at Thr308 and Ser473 appear to be
autonomously regulated (Coffer et al., 1998), phosphorylation at Ser473 may
assist in the recruitment of Akt to the plasma membrane and to subsequent
phosphorylation at Thr308 by PDK1 (Andjelkovic et al., 1997; Scheid and
Woodgett, 2003). Downstream, activated Akt phosphorylates and inhibits the
constitutively active glycogen synthase kinase 3 (GSK3), an enzyme that
regulates the function of a multitude of proteins, including metabolic, signaling,
and structural proteins (Grimes and Jope 2001). There are 2 isoforms of GSK3,
GSK3α and GSK3β, which are both expressed at high levels in the brain
(Woodgett 1990).
The Akt signaling pathway been linked to the pathology of mood disorders
and the effects of antidepressants and other psychotropic drugs in both humans
and animal models.

For example, the activities of PI3K and Akt were

significantly decreased in the occipital cortex of suicide victims when compared
to controls (Hsiung et al., 2003). Chronic stress increases levels of activated
(phosphorylated) Akt (pAkt) in the rat hypothalamus, hippocampus, and
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striatum, with the largest increases observed in the hypothalamus (Lee et al.,
2006).

Alterations were observed in both the activity of Akt and GSK3 in

schizophrenic patients (Emamian et al., 2004) and in a mouse model of
schizophrenia (Beaulieu et al., 2004). Furthermore, acute injection with SSRIs
increases the levels of phosphorylated GSK3, which serves to inactivate this
kinase (Li et al., 2004). Lithium, commonly used in the treatment of bipolar
disorder, has been shown to activate Akt and/or inhibit the activation of GSK3 in
vitro and in vivo (Klein and Melton, 1996; Chalecka-Franaszek and Chuang, 1999;
DeSarno et al., 2002; Zhang et al., 2003; O’Brien et al., 2004; Gould et al., 2004).
Other psychotropic drugs have also been shown to regulate this pathway,
including sodium valproate, used in the treatment of bipolar disorder (De Sarno
et al., 2002; Roh et al., 2005); imipramine, a tricyclic antidepressant (Li et al., 2004;
Basta-Kaim et al., 2005; Roh et al., 2005); risperidone, an atypical antipsychotic (Li
et al., 2007); and sertraline, fluoxetine, and fluvoxamine, all SSRIs (Reddy et al.,
2008; Fatemi et al., 2009; Nakano et al., 2010).
5-HT1A receptor agonists increase the phosphorylation of Akt in both
neuronal (Adayev et al., 1999; Cowen et al., 2005) and non-neuronal (Hsiung et
al., 2005) cell cultures as well as in adult rat hippocampus in vivo (Polter et al.,
2010). 5-HT1A receptor activity has also been shown to stimulate mitochondrial
movement in hippocampal axons in vitro, possibly via activation of Akt and
blockade of GSK3β (Chen et al., 2007). Acute injection with the SSRI fluoxetine
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has also been shown to increase phosphorylated GSK3β in the frontal cortex in
vivo, possibly via 5-HT1A receptor activation (Li et al., 2004).
Rationale for developmental time point chosen for these studies
In this dissertation, a “peripubertal” time period (around postnatal day 42)
was chosen to further examine the 5-HT1A receptor signaling and drug-induced
regulation of this receptor in the hypothalamic PVN.

This age roughly

corresponds to “adolescence” in humans (Spear 2000). Endocrine studies have
established that sexual maturation in the male rat begins around postnatal days
25-30 and is usually complete by postnatal days 50-60 (Pak and Handa, 2007).
We have also chosen this timeframe due the extensive amount of brain changes,
neuroplasticity, and behavioral changes occurring during this time.

For

example, prior to and during puberty, monoamine receptors and synapses (e.g.,
serotonin, dopamine) are being overproduced in the brain, which are later
pruned to adult levels (Andersen 2003). Axonal projections from monoamine
cell bodies also reach adult levels around the time of puberty (Andersen and
Navalta, 2004).

There are also transformations in the adolescent brain with

regards to (1) reductions in energy utilization (Spear, 2000), (2) increases in
cortical white matter (Villablanca et al., 2000; Sowell et al., 2003), and (3) regiondependent decreases in the relative size of gray matter (Geidd et al., 1999;
Rapoport et al., 1999). These changes contribute to the transformation of “the
more energy utilizing, seemingly less efficient brain of the child into a more
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rapidly communicative and more energy efficient brain of the adult” (Spear,
2007). Considering these global and regional changes, it may be possible that 5HT1A receptor signaling may undergo transitional changes during this time
frame and differ mechanistically from that observed in the adult brain.
It is important to establish the parameters that constitute “normal” functional
processes that exist around the time of sexual maturation because both human
and rodent studies have provided evidence that stress before sexual maturation
induces permanent changes to the brain and body. For example, rats exposed to
early life stress displayed blunted responses of ERK activation along with other
markers of synaptic signaling in adulthood (Musazzi et al., 2010) and also
displayed disturbances in other MAPK signaling pathways that were attenuated
with antidepressant treatment (Budziszewska et al., 2010). Chronic social stress
of peripubertal rats alters fat distribution in adulthood, but these changes were
reversed with SSRI treatment (Schmidt et al., 2009). In human studies, exposure
to early life stress before maturity (death of a close relative, parental depression
or divorce, etc.) can increase sensitivity to depression upon later stressful events
(Bouma et al., 2008), increase immune activity to psychosocial stress, particularly
with those suffering from major depressive disorder (Pace et al., 2006), and have
long-lasting effects on the HPA axis such as decreased cortisol responses as
adults (Meinlschmidt and Heim 2005). Individuals exposed to early life stress
who later developed depressive disorders as adults had increased plasma ACTH
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responses to challenge with dexamethasone/CRH (a type of neuroendocrine
challenge test), and the increases were associated with the severity, onset, and
duration of early abuse (Heim et al., 2008).

The long term implications for

studying brain changes induced by stress or drug treatment (not to mention the
functioning of the brain in a basal state) is that clinical interventions or therapies
could be designed to optimally treat individuals with specific pathologies (Agid
et al., 2000; Heim et al., 2004).
Summary and clinical significance
Depressive disorders can occur in up to 4.6% of children and 8.0% of
adolescents (Nobile et al., 2003).

SSRIs have been shown to be effective in

treating childhood and adolescent clinical disorders such as depression,
obsessive-compulsive disorders, eating disorders, Tourette’s syndrome, autism,
and panic disorder (Cohen 2007; Rushton and Whitmire, 2001; Wong et al., 2004).
Although the effectiveness and side effect profile of SSRI use in children and
adolescent populations is still highly debatable, fluoxetine (Prozac®) is still an
effective option for treating clinical disorders in younger populations. Therefore,
at this point in time, the benefits of these drugs may outweigh the risks, and it is
highly likely that SSRIs will continue to be prescribed to children and
adolescents. Given the involvement of 5-HT, the HPA axis, and protein kinases
in the pathogenesis of mood disorders and the effects of antidepressants in
adults, more research is necessary to determine the role these systems may play
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in the occurrence and treatment of mood disorders in younger individuals.
Determining the aspects of these systems that differ during development may
also provide better or more effective targets for the treatment of mood disorders
in children and adolescents.

Although 5-HT1A receptor signaling and drug-

induced regulation of 5-HT1A receptors have been extensively investigated in
adult animals, to date no studies have elucidated the specific pathways or
mechanisms of 5-HT1A receptor signaling and drug-induced desensitization in
the peripubertal hypothalamic PVN.
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Drug used in these studies

Aminotetralin

Azapirone

(+)8-OH-DPAT

Tandospirone

Structure
H
H

O
N

N

H H

N

O
N

N

H
O

N

H

Activity at 5-HT1A receptor-

Full

Partial

Molecular weight

247.38 g/mol

383.49 g/mol

Molecular formula

C16H25NO

C21H29N5O2

Prototypical 5-HT1A

One of several preclinically

receptor agonist

used azapirones; anxiolytic,

(preclinical); not approved

antipsychotic augmentation

for clinical use

(Japan)

mediated inhibition of
adenylyl cyclase

Usage

Table 1. Comparison of the properties of the 5-HT1A receptor agonists used in the current
studies.

CHAPTER 3
SEROTONIN 1A RECEPTORS ACTIVATE MULTIPLE SIGNALING
RESPONSES IN THE PERIPUBERTAL RAT HYPOTHALAMIC
PARAVENTRICULAR NUCLEUS: EFFECTS OF DIFFERENT STRUCTURAL
CLASSES OF AGONISTS ON THE TIME- AND DOSE-DEPENDENT
STIMULATION OF NEUROENDOCRINE REPONSES AND ACTIVATION OF
EXTRACELLULAR SIGNAL-REGULATED KINASE.
ABSTRACT
In the adult rat hypothalamic paraventricular nucleus (PVN), (+)8-OH-DPAT
(an aminotetralin full agonist) and tandospirone (an azapirone partial agonist)
increase plasma levels of oxytocin and ACTH and activate extracellular signal
regulated kinase (ERK) in the adult PVN (Sullivan et al., 2005; Crane et al., 2007).
The present studies investigated 5-HT1A receptor signaling in the peripubertal rat
hypothalamic PVN to determine: (1) if different structural classes of 5-HT1A
receptor agonists can mediate signaling of both hormone release and kinase
activation; (2) the onset and longevity of the respective 5-HT1A receptor-mediated
responses; (3) the efficacy and potency of (+)8-OH-DPAT and tandospirone in
activating the respective 5-HT1A receptor- mediated responses, (4) potential
agonist-dependent targeting of any specific response, and (5) an optimal agonist
dose and post-injection time to investigate the multiple 5-HT1A receptormediated responses in subsequent studies. With respect to the time-dependent
40

activation of 5-HT1A
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receptor-mediated responses, (+)8-OH-DPAT (0.20 mg/kg)

and tandospirone (10 mg/kg) induced rapid (≤ 5 minutes) increases in plasma
levels of oxytocin that were comparable (~200 pg/ml) and maintained for 15
minutes before declining to baseline (> 30 minutes). Both 5-HT1A agonists also
induced rapid (≤ 5 minutes) increases in plasma levels of ACTH that reached
comparable maximal levels (~1000 pg/ml) at 10 minutes and remained elevated
throughout the 30 minute testing period. (+)8-OH-DPAT and tandospirone also
produced rapid (≤ 5 minutes) increases in activated (i.e., phosphorylated) ERK
(pERK) that persisted for at least 30 minutes. The dose response data indicate
that both drugs exhibited comparable maximal efficacies in elevating plasma
oxytocin, but (+)8-OH-DPAT was a more potent agonist than tandospirone. The
maximal efficacies of (+)8-OH-DPAT and tandospirone on ACTH responses
were also comparable. With respect to ERK activation in the PVN, (+)8-OHDPAT was more potent than tandospirone and maximally effective doses of the
aminotetralin or azapirone agonists produced comparable increases in pERK. In
summary, these studies in peripubertal hypothalamic PVN demonstrated
different structural classes of 5-HT1A receptor agonists activated both
neuroendocrine responses (i.e., oxytocin and ACTH) from different cell types
and concomitantly kinase (i.e., pERK) responses, indicating no agonistdependent targeting of responses. While (+)8-OH-DPAT was more potent than
tandospirone at each of the respective responses, both structural classes of 5-

HT1A

receptor

agonists

produced

rapid

and

prolonged
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activation of

neuroendocrine and kinase responses and similar maximal efficacies.
INTRODUCTION
In adult rats, 5-HT1A receptors are localized on oxytocin-containing and
corticotrophin releasing hormone (CRH)-containing cells (Zhang et al., 2004),
and activation of these receptors produces respective increases in plasma levels
of oxytocin and ACTH hormones (Bagdy and Kalogeras, 1993; Gilbert et al., 1988;
Vicentic et al., 1998). 5-HT1A receptor stimulation concomitantly activates the
mitogen-activated protein kinase (MAPK) cascade in the adult PVN (Crane et al.,
2007; Sullivan et al., 2005). The 5-HT1A receptor-mediated activation of ERK by
the aminotetralin full agonist (+)8-OH-DPAT is rapid but transient, since levels
of activated ERK are increased at 5 minutes but return to basal levels by 15
minutes post-injection (Crane et al., 2007).

In contrast, 8-OH-DPAT-induced

elevations in plasma hormone levels of oxytocin and ACTH are more prolonged,
since hormone levels reach a peak at 15 minutes and remain significantly
elevated 30 minutes after agonist injection (Di Sciullo et al., 1990; D’Souza et al.,
2004). In addition to differences in onset and longevity, the respective 5-HT1A
receptor-mediated responses also differ in terms of the dose-dependence of
activation.

In the adult, 5-HT1A receptor-mediated oxytocin and ACTH

neuroendocrine responses occur at doses of (+)8-OH-DPAT lower than doses
required to significantly increase the levels of pERK in the PVN. Tandospirone,

an azapirone “partial” agonist at postsynaptic 5-HT1A
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receptors, also increases

plasma levels of oxytocin and ACTH and increases pERK in the adult rat PVN
(Sullivan et al., 2005). However, it remains to be determined if this class of 5HT1A receptor agonist exhibits potency, efficacy, and a time-course of activation
comparable to (+)8-OH-DPAT at each of the respective 5-HT1A receptormediated responses.

We have previously reported (Garcia et al., 2006) that

hypothalamic 5-HT1A receptors in the adult PVN mediate neuroendocrine versus
kinase responses via different subsets of Gα proteins and that these responses
can be activated independent of each other. Consequently, different classes of
receptor agonists may preferentially or exclusively activate one of these multiple
5-HT1A receptor-mediated responses. This is referred to as “biased agonism,” a
phenomenon observed in receptor systems where different classes of receptor
agonists may induce a variety of conformational changes in a receptor that
facilitates signaling via one or more distinct pathways (Kenakin 1995; Berg et al.,
1998; Galandrin and Bouvier, 2006; Rajagopal et al., 2010; Whalen et al., 2011).
For example, in a cell line expressing 5-HT2C receptors, the piperazine derivative
3-trifluoromethylphenyl-piperazine preferentially activates the phospholipase C
pathway, whereas lysergic acid diethylamide (LSD), a member of the ergoline
family, preferentially activates the phospholipase A2 pathway (Berg et al., 1998).
To date, no in vivo studies have investigated the phenomenon of “biased
agonism” for 5-HT1A receptor-mediated signaling pathways in hypothalamic
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PVN at any age. Furthermore, no studies have examined, in vivo, the multiplicity
of responses mediated by 5-HT1A receptors nor the time-course, efficacy, and
potency of different classes of agonists in simulating respective neuroendocrine
and kinase responses in the peripubertal hypothalamic PVN.
The first experiment described in this chapter will determine the time-course
of classes of 5-HT1A receptor agonists that differ in chemical structure ((+)8-OHDPAT, an aminotetralin, and tandospirone, an azapirone) to stimulate: (A)
increases in plasma oxytocin, (B) increases in plasma ACTH, and (C) increases in
pERK in the peripubertal rat hypothalamic PVN. The second experiment will
test the dose-dependent effects of the two different agonists on signaling of 5HT1A receptor-mediated: (A) oxytocin hormone responses, (B) ACTH hormone
responses, and (C) increases in pERK in the peripubertal rat hypothalamic PVN.
These studies will provide information regarding: (1) the onset and longevity
of the respective 5-HT1A receptor-mediated responses, (2) differences in agonist
potency and efficacy for the respective 5-HT1A receptor-mediated responses, (3)
potential agonist-dependent preference or exclusive activation of any of the
respective 5-HT1A receptor-mediated pathways in the hypothalamic PVN of
peripubertal rats, and (4) an optimal agonist dose and post-injection time to
obtain multiple 5-HT1A receptor-mediated responses for subsequent studies.
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MATERIALS AND EXPERIMENTAL PROCEDURES (for detailed methods,
see Chapter 7)
Animals.Peripubertal male Sprague-Dawley rats (postnatal day 35; 100-125 g)
were purchased from Harlan (Indianapolis, IN). The determination of post-natal
day zero (day of birth) was carried out by the supplier.
Drugs. (+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide [(+)8-OHDPAT] was purchased from Tocris Cookson Inc. (Ellisville, MO). Tandospirone
citrate was a generous gift of Dr. K. Matusubara, Asahikawa Medical College,
Japan. All drugs were dissolved in saline (0.9% NaCl). For the dose-response
experiment, the highest dose of drug was dissolved in saline and lower
concentrations were made by serial dilution.

The drugs were injected at a

volume of 1 ml/kg and were freshly prepared immediately prior to the injections.
Experiment 1:

Time-dependent activation of 5-HT1A receptor-mediated

responses. At least 3 days of handling preceded any injections. Peripubertal
male Sprague-Dawley rats (post-natal day 42) were injected with either saline (1
ml/kg, s.c.), the aminotetralin full agonist (+)8-OH-DPAT (0.20 mg/kg, s.c.), or
the azapirone partial agonist tandospirone (10 mg/kg, s.c.). These agonist doses
have been shown to significantly elevate plasma oxytocin and ACTH
concentrations in peripubertal rats (Battaglia et al., 2002; Petrunich et al., 2008)
and significantly increase plasma levels of oxytocin and ACTH and increase
pERK in the PVN of adult rats (Crane et al., 2007; Sullivan et al., 2005). The

46
animals were sacrificed by decapitation at 5, 10, 15, 20, or 30 minutes postinjection. The brains were carefully removed from the skull within one minute of
the decapitation and were quickly frozen by submersion in chilled 2methylbutane (-35°C) for 1 minute and then subsequently kept in dry ice for an
additional 10 minutes. Each brain was then securely wrapped and stored at
-80°C prior to dissection for Western blot studies for the determination of
pERK/ERK levels in the PVN. The trunk blood was collected and prepared for
subsequent determination of plasma levels of oxytocin, ACTH, and testosterone.
Experiment 2:

Dose-dependent activation of 5-HT1A receptor-mediated

responses. At least 3 days of handling preceded any injections. Peripubertal
male Sprague-Dawley rats (post-natal day 42) were injected with either saline (1
ml/kg, s.c.), (+)8-OH-DPAT (0.04, 0.10, 0.20, or 0.50 mg/kg, s.c.), or tandospirone
(1, 3, 10, or 20 mg/kg, s.c.) and were sacrificed by decapitation at 10 minutes
post-injection. These agonist doses have been shown to produce dose-dependent
responses in plasma levels of oxytocin and ACTH and pERK in the PVN of adult
rats (Battaglia et al., 2009; Sullivan et al., 2005).

The brains were carefully

removed from the skull within one minute of the decapitation and were quickly
frozen by submersion in chilled 2-methylbutane (-35°C) for 1 minute and then
subsequently kept in dry ice for an additional 10 minutes. Each brain was then
securely wrapped and stored at -80°C prior to dissection for Western blot studies
for the determination of pERK/ERK levels in the PVN. The trunk blood was
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collected and prepared for subsequent determination of plasma levels of
oxytocin, ACTH, and testosterone.
RESULTS
1.

Experiment 1:

Time-dependent activation of 5-HT1A receptor-mediated

responses. The specific objectives of this experiment were: (1) to determine the
onset and longevity of the 5-HT1A receptor-mediated increases in (A) plasma
levels of oxytocin, (B) plasma levels of ACTH, and (C) phosphorylation of ERK in
PVN; (2) to identify potential agonist-dependent differences in onset and
longevity of the respective 5-HT1A receptor-mediated signaling pathways; and (3)
establish one optimal post-injection time (for use in subsequent studies) to
measure agonist-induced increases in these functional markers.
A.

Time-course of (+)8-OH-DPAT and tandospirone-induced increases in

plasma oxytocin in the peripubertal rat. As shown in figure 3, (+)8-OH-DPAT
(0.20 mg/kg) and tandospirone (10 mg/kg) induced rapid (≤ 5 minutes) and
comparable increases in plasma levels of oxytocin that were maintained for 15
minutes before gradually approaching baseline.

Although (+)8-OH-DPAT-

induced increases in plasma oxytocin attenuate more rapidly than tandospirone,
plasma oxytocin responses induced by either agonist did not return to baseline
within the time period tested.
The two-way ANOVA for oxytocin indicated a significant main effect of acute
challenge injection (saline, (+)8-OH-DPAT, or tandospirone) [F2,115 = 269.13, p <

0.0001] and a significant main effect of post-injection time [F4,115
0.0001].
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= 24.46, p <

There was also a significant interaction between acute challenge

injection and post-injection time [F8,115 = 8.51 p < 0.0001]. A Newman-Keuls’ test
indicated that (+)8-OH-DPAT increased plasma oxytocin levels above saline at 5,
10, 15, 20 minutes (p < 0.01) and 30 minutes (p < 0.05). Tandospirone increased
plasma oxytocin levels above saline at 5, 10, 15, 20, and 30 minutes (p < 0.01).
These data indicate that (+)8-OH-DPAT (0.20 mg/kg) and tandospirone (10
mg/kg) elicit comparable changes in plasma oxytocin with respect to the
magnitude and general overall time-course of the response (although (+)8-OHDPAT approached baseline more rapidly than tandospirone).
B. Time-course of (+)8-OH-DPAT and tandospirone-induced increases in plasma
ACTH in the peripubertal rat. As shown in figure 4, (+)8-OH-DPAT (0.20 mg/kg)
and tandospirone (10 mg/kg) induced rapid (≤ 5 minutes) increases in plasma
levels of ACTH that reached comparable maximal levels at 10 minutes and
remained elevated throughout the testing period.
The two-way ANOVA for ACTH indicated a significant main effect of acute
challenge injection (saline, (+)8-OH-DPAT, or tandospirone) [F2,120 = 412.46, p <
0.0001] and a significant main effect of post-injection time [F4,120 = 10.18, p <
0.0001].

There was also a significant interaction between acute challenge

injection and post-injection time [F8,120 = 3.04 p = 0.004]. A Newman-Keuls’ test
indicated that (+)8-OH-DPAT significantly increased (p < 0.01) plasma ACTH

levels above saline at 5, 10, 15, 20, and 30 minutes.
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Tandospirone also

significantly increased (p < 0.01) plasma ACTH levels above saline at 5, 10, 15, 20,
and 30 minutes.

These data indicate that (+)8-OH-DPAT (0.20 mg/kg) and

tandospirone (10 mg/kg) elicit comparable changes in plasma levels of ACTH
with respect to the magnitude and overall time-course of the response (e.g., peak
levels around 10 minutes with a slight attenuation and plateau for subsequent
time points for both drugs).
C. Time-course of (+)8-OH-DPAT-induced increases in phosphorylated ERK in
the peripubertal PVN.

As shown in figure 5, (+)8-OH-DPAT (0.20 mg/kg)

induced a rapid (≤ 5 minutes) increase in pERK levels in the PVN that was
maintained for 20 minutes before declining to baseline (> 30 minutes).
The two-way ANOVA for (+)8-OH-DPAT-induced increases of pERK in the
PVN indicated a significant main effect of acute challenge injection (saline or
(+)8-OH-DPAT) [F1,78 = 43.92, p < 0.0001] but no significant main effect of postinjection time [F4,78 = 1.02, p = 0.4022]. There was also no significant interaction
between acute challenge injection and post-injection time [F4,78 = 1.02, p = 0.4022].
A Newman-Keuls’ test indicated that (+)8-OH-DPAT significantly increased (p <
0.01) pERK in the PVN over saline at 5, 10, 15, and 20 minutes. These data
indicate that (+)8-OH-DPAT rapidly increases activated ERK in the peripubertal
PVN, and that this response is sustained for a longer response time than
previously published for the adult PVN (Crane et al., 2007).
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D. Time-course of tandospirone-induced increases in phosphorylated ERK in the
peripubertal PVN. As shown in figure 6, tandospirone (10 mg/kg) induced a
rapid (≤ 5 minutes) increase in pERK in the PVN that was maintained
throughout the testing period, although the magnitude of the response induced
by tandospirone (↑ ~50% above basal) was much less than that induced by (+)8OH-DPAT (↑ ~200% above basal, see figure 5).
The two-way ANOVA for tandospirone-induced increases of pERK in the
PVN indicated a significant main effect of acute challenge injection (saline or
tandospirone) [F1,75 = 25.87, p < 0.0001] but no significant main effect of postinjection time [F4,75 = 0.05, p = 0.944]. There was also no significant interaction
between acute challenge injection and post-injection time [F4,75 = 0.05, p = 0.944].
A Newman-Keuls’ test indicated that tandospirone significantly increased (p <
0.05) pERK over saline at 5, 10, and 20 minutes.
E. Optimal sacrifice time for future experiments. These results indicate that a
sacrifice time of 10 minutes post-injection can be used in subsequent studies to
measure robust increases in 5-HT1A receptor-mediated increases in plasma
oxytocin and ACTH and increases in pERK in the PVN of peripubertal rats
produced by injection with (+)8-OH-DPAT.
F. Single injection of (+)8-OH-DPAT or tandospirone does not alter testosterone
levels in the peripubertal rat. As shown in figure 7, neither (+)8-OH-DPAT (0.20
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mg/kg) nor tandospirone (10 mg/kg) had any effect on plasma levels of
testosterone at any time point tested.
The two-way ANOVA for plasma testosterone levels indicated no significant
main effect of acute challenge injection (saline, (+)8-OH-DPAT, or tandospirone)
[F2,97 = 0.42, p = 0.66] and no significant main effect of post-injection time [F4,97 =
1.94, p = 0.11]. There was also no significant interaction between acute challenge
injection and post-injection time [F8,97 = 0.68, p = 0.71]. These data indicate that
the stage of sexual maturation was comparable between treatment groups and
that the in vivo challenge injections and sacrifice times did not alter the
testosterone levels in these animals.
2.

Experiment 2:

Dose-dependent activation of 5-HT1A receptor-mediated

responses. The objectives of this experiment were: (1) to determine potency and
efficacy of agonists from two different structural drug classes ((+)8-OH-DPAT,
an aminotetralin and tandospirone, an azapirone) on (A) oxytocin hormone
responses, (B) ACTH hormone responses, and (C) phosphorylation of ERK in
PVN; (2) to determine if either agonist preferentially activates any one of the
multiple 5-HT1A receptor-mediated responses; and (3) to establish one optimal
dose of (+)8-OH-DPAT that evokes 5-HT1A receptor-mediated increases in
plasma levels of oxytocin and ACTH and increases pERK in the PVN (to be used
in subsequent studies).

A.
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Dose-response of (+)8-OH-DPAT and tandospirone on plasma levels of

oxytocin in the peripubertal rat. As shown in figure 8, (+)8-OH-DPAT and
tandospirone dose-dependently increase plasma oxytocin levels above those in
saline-challenged peripubertal rats. The maximal responses induced by both
agonists were similar; however, (+)8-OH-DPAT is more potent agonist than
tandospirone, since lower doses of (+)8-OH-DPAT were sufficient to induce
oxytocin responses. In addition, the dosing range (less than 1 log unit) required
by (+)8-OH-DPAT to achieve a maximal effect on oxytocin responses was much
narrower than the dosing range (over 1 log unit) required by tandospirone for
maximal effects on plasma levels of oxytocin.
The two-way ANOVA for oxytocin indicated a significant main effect of acute
challenge injection (saline, (+)8-OH-DPAT, or tandospirone) [F2,103 = 182.82, p <
0.0001] and a significant main effect of agonist dose [F3,103 = 44.24, p < 0.0001].
There was also a significant interaction between acute challenge injection and
agonist dose [F6,103 = 13.73 p < 0.0001]. A Newman-Keuls’ test indicated that
(+)8-OH-DPAT significantly increased (p < 0.01) plasma oxytocin levels above
saline-injected controls at 0.10, 0.20, and 0.50 mg/kg, but not 0.04 mg/kg.
Tandospirone significantly increased (p < 0.01) plasma oxytocin levels above
saline-injected controls at all doses tested (1, 3, 10, and 20 mg/kg). These data
suggest that the highest doses of each agonist elicit similar maximal responses
with regard to 5-HT1A receptor-mediated increases of plasma oxytocin levels,
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although the potency and dosing range necessary to induce maximal responses
differ between these two drugs.
B.

Dose-response of (+)8-OH-DPAT and tandospirone on plasma levels of

ACTH the peripubertal rat. As shown in figure 9, all tested doses of (+)8-OHDPAT and tandospirone increased plasma ACTH levels over saline-challenged
peripubertal rats. The maximal responses induced by both agonists were similar,
with (+)8-OH-DPAT inducing a dose-dependent increase in plasma ACTH over
a narrow dosing range (less than 1 log unit). As all tested doses of tandospirone
elicited a maximal response, neither the potency nor the dosing range could be
determined for tandospirone.
The two-way ANOVA for ACTH indicated a significant main effect of acute
challenge injection (saline, (+)8-OH-DPAT, or tandospirone) [F2,102 = 526.44, p <
0.0001] and a significant main effect of agonist dose [F3,102 = 43.20, p < 0.0001].
There was also a significant interaction between acute challenge injection and
agonist dose [F6,102 = 23.09, p < 0.0001]. A Newman-Keuls’ test indicated that
(+)8-OH-DPAT significantly increased plasma ACTH levels over saline at 0.04
mg/kg (p < 0.05), 0.10, 0.20, and 0.50 mg/kg (p < 0.01).

Tandospirone

significantly increased (p < 0.01) plasma ACTH levels above saline-injected
controls at all doses tested (1, 3, 10, and 20 mg/kg). These data suggest that the
highest doses of each agonist elicit similar maximal responses (Emax) with regards
to 5-HT1A receptor-mediated increases of plasma ACTH levels, although the
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potency and dosing ranges was not obvious for tandospirone and cannot be
easily compared to the values obtained for (+)8-OH-DPAT.
C.

Dose-response of (+)8-OH-DPAT on levels of pERK in peripubertal rat

hypothalamic PVN. As shown in figure 10, the highest doses of (+)8-OH-DPAT
tested increased pERK levels in the peripubertal PVN over saline-challenge.
Within the dosing range tested, these responses approximate the maximal
response, although the additional data points at higher doses would better
substantiate the respective Emax values. (+)8-OH-DPAT is a potent agonist on 5HT1A receptor-mediated pERK responses in the PVN, with a more narrow dosing
range (≤ 1 log unit).
The two-way ANOVA for (+)8-OH-DPAT-induced increases of pERK in the
PVN indicated a significant main effect of acute challenge injection (saline or
(+)8-OH-DPAT) [F1,71 = 11.55, p = 0.0012] and a significant main effect of agonist
dose [F3,71 = 4.90, p = 0.0039]. There was also a significant interaction between
acute challenge injection and agonist dose [F3,71 = 4.90, p = 0.0039]. A NewmanKeuls’ test indicated that (+)8-OH-DPAT increased levels of pERK in the PVN
over saline at 0.20 mg/kg (p < 0.05) and at 0.50 mg/kg (p < 0.01).
D. Dose-response of (+)8-OH-DPAT and tandospirone on levels of pERK in
peripubertal rat hypothalamic PVN. As shown in figure 11, the highest doses of
tandospirone tested increased pERK levels in the peripubertal PVN over salinechallenge. Again, within the dosing range tested, these responses approximate
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the maximal response, although the additional data points at higher doses would
better substantiate the respective Emax values. These dose-response data indicate
that (+)8-OH-DPAT (figure 10) is a more potent agonist than tandospirone on 5HT1A receptor-mediated pERK responses in the PVN, with a more narrow dosing
range (≤ 1 log unit) compared to tandospirone (≥ 1 log unit).
The two-way ANOVA for tandospirone-induced increases of pERK in the
PVN indicated a significant main effect of acute challenge injection (saline or
tandospirone) [F1,69 = 19.66, p < 0.0001] but no significant main effect of agonist
dose [F3,69 = 1.22, p = 0.3085]. There was also no significant interaction between
acute challenge injection and agonist dose [F3,69 = 1.22, p = 0.3085]. A NewmanKeuls’ test indicated that tandospirone increased levels of pERK in the PVN over
saline-injected controls at 10 and 20 mg/kg (p < 0.05).
E. Optimal challenge dose of (+)8-OH-DPAT for future experiments. These
results indicate that 0.20 mg/kg of (+)8-OH-DPAT can be used in subsequent
studies to produce robust increases in 5-HT1A receptor-mediated plasma
oxytocin and ACTH and levels of pERK in the peripubertal rat hypothalamic
PVN.
F.

Single injection of (+)8-OH-DPAT or tandospirone at any dose does not

change testosterone levels in the peripubertal rat. As shown in figure 12, neither
(+)8-OH-DPAT nor tandospirone had any effect on plasma levels of testosterone
at any dose tested.
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The two-way ANOVA for plasma testosterone levels indicated no significant
main effect of acute challenge injection (saline, (+)8-OH-DPAT, or tandospirone)
[F2,91 = 0.07, p = 0.94] and no significant main effect of agonist dose [F3,91 = 0.34, p
= 0.79].

There was also no significant interaction between acute challenge

injection and agonist dose [F6,91 = 0.19, p = 0.98]. These data indicate that stage of
sexual maturation was comparable between treatment groups and that the in vivo
challenge injections and doses did not alter the testosterone levels in these
animals.
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Figure 3. Time-course of (+)8-OH-DPAT and tandospirone-induced increases in plasma levels of
oxytocin in the peripubertal rat. *, ** indicates significant difference (p < 0.05 and p < 0.01,
respectively) from the respective saline-challenged group; #, ## indicates significant difference (p
< 0.05 and p < 0.01, respectively) from the respective (+)8-OH-DPAT-challenged group; +, ++
indicates significant difference (p < 0.05 and p < 0.01, respectively) from corresponding response
at 5 minute post-injection (two-way ANOVA and Newman-Keuls multiple-range test). N = 7-10
per group.
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Figure 4. Time-course of (+)8-OH-DPAT and tandospirone-induced increases in plasma levels of
ACTH in the peripubertal rat. ** indicates significant difference (p < 0.01) from the respective
saline-challenged group; # indicates significant difference (p < 0.05) from the respective (+)8-OHDPAT-challenged group; ++ indicates significant difference (p < 0.01) from corresponding
response at 5 minute post-injection (two-way ANOVA and Newman-Keuls multiple-range test).
N = 7-10 per group.
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Figure 5. (A) Time-course of (+)8-OH-DPAT-induced elevations of pERK in peripubertal PVN. **
indicates significant difference (p < 0.01) from the saline-challenged group (two-way ANOVA
and Newman-Keuls multiple-range test). (B) Representative western blot of pERK (above) and
ERK (below) from the PVN of rats treated with either saline or (+)8-OH-DPAT. N = 7-8 per group.
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Figure 6. (A) Time-course of tandospirone-induced elevations of pERK in peripubertal PVN.
* indicates significant difference (p < 0.05) from the saline-challenged group (two-way ANOVA
and Newman-Keuls multiple-range test). (B) Representative western blot of pERK (above) and
ERK (below) from the PVN of rats treated with either saline or tandospirone. N = 6-8 per group.
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Figure 7. Injection with either (+)8-OH-DPAT (0.20 mg/kg) or tandospirone (10 mg/kg) had no
effect on plasma levels of testosterone in the peripubertal rat at any post-injection time point
(two-way ANOVA). N = 3-9 per group.

62

Oxytocin (pg/ml)

500

Saline
##
++ ##
** ++
**

400
300
200

++
**

(+)8-OH-DPAT

@
@ ++
++ **
**

Tandospirone

**
**

100
0
0.01

0.1

1

10

100

Agonist dose (mg/kg)
Figure 8. Effects of different doses of (+)8-OH-DPAT and tandospirone on plasma levels of
oxytocin in the peripubertal rat. ** indicates significant difference (p < 0.01) from the salinechallenged group; ++ indicates significant difference (p < 0.01) from corresponding lowest-dose
challenge injection; ## indicates significant difference (p < 0.01) from the 0.01 mg/kg (+)8-OHDPAT-challenged group; @ indicates significant difference (p < 0.05) from the 3 mg/kg
tandospirone-challenged group (two-way ANOVA and Newman-Keuls multiple-range test). N =
7-11 per group.
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Figure 9. Effects of different doses of (+)8-OH-DPAT and tandospirone on plasma levels of
ACTH in the peripubertal rat. *,** indicates significant difference (p < 0.05 and p < 0.01,
respectively) from the saline-challenged group; ++ indicates significant difference (p < 0.01) from
corresponding lowest-dose challenge injection; ## indicates significant difference (p < 0.01) from
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from the 3 mg/kg tandospirone-challenged group (two-way ANOVA and Newman-Keuls
multiple-range test). N = 7-10 per group.
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Figure 10. (A) Effects of different doses of (+)8-OH-DPAT on levels of pERK in peripubertal PVN.
*, ** indicates significant difference (p < 0.05 and p < 0.01, respectively) from the salinechallenged group; +, ++ indicates significant difference (p < 0.05 and p < 0.01 respectively) from
the 0.04 mg/kg (+)8-OH-DPAT-challenged group; #, ## indicates significant difference (p < 0.05
and p < 0.01 respectively) from the 0.01 mg/kg (+)8-OH-DPAT-challenged group (two-way
ANOVA and Newman-Keuls multiple-range test). (B) Representative western blot of pERK
(above) and ERK (below) from the PVN of rats treated with either saline or (+)8-OH-DPAT. N =
6-12 per group.
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Figure 11. (A) Effects of different doses of tandospirone on levels of pERK in peripubertal PVN.
* indicates significant difference (p < 0.05) from the saline-challenged group (two-way ANOVA
and Newman-Keuls multiple-range test). (B) Representative western blot of pERK (above) and
ERK (below) from the PVN of rats treated with either saline or tandospirone. N = 4-12 per group.
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Figure 12. Injection with different doses of either (+)8-OH-DPAT or tandospirone had no effect
on plasma levels of testosterone in the peripubertal rat (two-way ANOVA). N = 4-10 per group.
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DISCUSSION
Several immunohistochemical studies have determined that 5-HT1A receptors
are expressed on many types of neuroendocrine-containing cells (e.g.,
neuropeptide Y-, proopiomelanocortin-, orexin-containing, etc.) throughout the
hypothalamus (Collin et al., 2002; Aznar et al., 2003; Muraki et al., 2004; Marvin
et al., 2010). 5-HT1A receptors have also been localized to glial cells in other brain
regions (Whitaker-Azmitia et al., 1993; Azmitia et al., 1996; Paterson et al., 2004).
In the adult PVN, oxytocin-containing and CRH-containing cells express 5-HT1A
receptors (Zhang et al., 2004).

Stimulation of these receptors with different

classes of 5-HT1A receptor agonists such as (+)8-OH-DPAT (an aminotetralin) or
tandospirone (an azapirone) can increase plasma levels of oxytocin and ACTH
hormones (Bagdy and Kalogeras, 1993; Gilbert et al., 1988; Vicentic et al., 1998).
In the adult PVN, these agonists also concomitantly activate ERK (Chen et al.,
2002; Crane et al., 2007; Sullivan et al., 2005). The data from the present studies
are the first to demonstrate in the peripubertal PVN: (1) that both (+)8-OH-DPAT
and tandospirone increased plasma levels of oxytocin and ACTH and increased
levels of pERK (indicating that 5-HT1A receptors also can concomitantly activate
multiple responses prior to sexual maturation) and (2) the pharmacodynamic
properties of these different classes of 5-HT1A receptor agonists at each of the
respective signaling responses. These studies indicate that, although 5-HT1A
receptors activate neuroendocrine responses and ERK in both the adult and
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peripubertal PVN, there are some aspects of 5-HT1A receptor-mediated activation
of ERK that differ between these age groups that may play a role in acute drug
responsivity or to long term drug-induced neuroadaptations.
One notable difference observed between adult and peripubertal 5-HT1A
receptor signaling is in the duration of MAPK responses. In the adult PVN, 5HT1A receptors activate ERK in a rapid and transient manner, as the
aminotetralin agonist (+)8-OH-DPAT significantly elevates levels of activated
ERK at 5 minutes but returns to basal levels by 15 minutes post-injection (Crane
et al., 2007).

The current studies have demonstrated that 5-HT1A receptor-

stimulated pERK in the peripubertal PVN is also rapid, but the response is more
prolonged than in adults. This prolonged activation of ERK occurs following 5HT1A receptor activation by either class of agonist, since both (+)8-OH-DPAT and
tandospirone injections resulted in elevations in pERK lasting up to at least 30
minutes post-injection. In a variety of mammalian cell lines, the duration of ERK
signaling is associated with distinct cell behavior (Traverse et al., 1992; Nguyen
et al., 1993; Mansour et al., 1994; Sharp et al., 1997; Whalen et al., 1997; Murphy et
al., 2002; Murphy et al., 2004; Sinnett-Smith et al., 2004). For example, prolonged
but not transient ERK activation was associated with (1) neuronal differentiation
in PC-12 cells (Traverse et al., 1992), (2) nuclear translocation of ERK in PC12
cells (Nguyen et al., 1993), and (3) c-fos accumulation and DNA synthesis in
Swiss 3T3 cells (Sinnett-Smith et al., 2004). Therefore, developmental differences
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in the longevity of ERK activation may impact a variety of functions under the
control of ERK (e.g., cell survival, gene expression, learning, memory, and
receptor desensitization) (Marshall 1995; Pouysségur and Lenormand 2003;
Trincavelli et al., 2002). Considering that ERK signaling has also recently been
implicated in stress behaviors and the effects of antidepressants in animal
models (Duman et al., 2007; Duric et al., 2010; Gourley et al., 2008; Qi et al., 2006;
Qi et al., 2008; Qi et al., 2009; Shen et al., 2004), a prolonged ERK response in
response to 5-HT1A receptor activation in the peripubertal brain could possibly
influence the mechanism of action of antidepressants in this age group. For
example, Duric et al., (2010) determined that overexpression (by viral vectors or
induction via chronic stress) of MAP kinase phosphatase (MKP-1) in the
hippocampus results in depressive behavior in a rodent model, presumably due
to the more rapid dephosphorylation of ERK and termination of its signal.
Further studies are required to determine if the temporal differences between
peripubertal and adult are due to mechanisms involving ERK activation or
phosphatase activity.
With respect to comparative studies using an aminotetralin versus azapirone
5-HT1A receptor agonists, (+)8-OH-DPAT is classified a “full” agonist and
tandospirone is considered a “partial” agonist at post-synaptic 5-HT1A receptors.
In rat hippocampal homogenates, tandospirone partially inhibits forskolininduced adenylyl cyclase activity (Hamik et al., 1990; Rabin and Winter, 1993).
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Buspirone, another azapirone, also acts as a partial agonist on neuronal
hyperpolarization in vitro (Van den Hooff and Galvan, 1992).

However, in the

peripubertal rat, maximally effective doses of the aminotetralin ((+)8-OH-DPAT)
or azapirone (tandospirone) agonists produce comparable increases in each of
the respective 5-HT1A receptor-mediated responses. The current studies suggest
that tandospirone can act as a full agonist on 5-HT1A receptor-mediated oxytocin
and ACTH plasma hormone responses and activation of ERK in the PVN. This
finding is not unprecedented, given that tandospirone has been shown to act as a
full agonist in inducing 5-HT1A receptor-mediated hypothermia in rats (Millan et
al., 1993).
Given the multiplicity of 5-HT1A receptor signaling responses in peripubertal
PVN, these studies also sought to determine the existence of “biased agonism” of
5-HT1A receptor-mediated responses in the peripubertal PVN. This phenomenon
(which expands upon the two-state model of receptor activation) states that,
whereas one class of receptor agonists stabilize the active conformation (R → R*1)
that favors the activation of pathway 1, another class of receptor agonists
stabilize an alternate active receptor conformation (R → R*2) that favors
activation of pathway 2 (Rozengurt 2007). This phenomenon is observed in other
receptor systems in vitro (Berg et al., 1998; Galandrin and Bouvier, 2006; Kenakin
1995).

Berg et al. demonstrated that a piperazine derivative preferentially

activates the 5-HT2C receptor-mediated phospholipase C pathway, whereas a

member of the ergoline family preferentially activates the 5-HT2C
mediated phospholipase A2 pathway (Berg et al., 1998).
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receptor-

A literature search

revealed that no in vivo studies have investigated this phenomenon of “biased
agonism” for 5-HT1A receptor-mediated signaling pathways. Our results suggest
that 5-HT1A receptor responses in the peripubertal PVN are not subject to “biased
agonism” with respect to azapirone versus aminotetralin agonists since each
agonist elicited similar maximal responses in 5-HT1A receptor-mediated oxytocin,
ACTH, and pERK responses.

However, this finding must be considered

preliminary, considering that it has not been determined whether these receptor
responses in the peripubertal PVN are activated as a result of dependent vs.
multiple independent pathways mediated by separate subsets of second
messenger proteins (e.g., G proteins). The role of pertussis toxin-sensitive G
proteins will be investigated in Chapter 4.
Although both agonists tested in the current experiments had similar
maximal efficacies for 5-HT1A receptor-mediated neuroendocrine responses, (+)8OH-DPAT is generally more potent than tandospirone for 5-HT1A receptormediated oxytocin and pERK responses. The current data also indicate that (+)8OH-DPAT generally has a narrower dosing range for 5-HT1A receptor-mediated
increases in plasma levels of oxytocin than tandospirone. Consequently, (+)8OH-DPAT may be able to occupy a fewer number of receptors to induce 5-HT1A
receptor-mediated responses than tandospirone, suggesting that it more
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efficiently couples receptor occupation to response. A more likely explanation is
that (+)8-OH-DPAT may become more readily bioavailable compared to
tandospirone. Bioavailablity is a pharmacokinetic property that refers to the
percentage of unchanged drug that reaches systemic circulation following any
route of administration (Holford 2004). Therefore, depending on drug class, a
greater percentage of active drug my reach the brain. Although it was been
determined that within 15 minutes of subcutaneous administration of (+)8-OHDPAT, approximately 0.1% of the active drug dose was detected in rat
hypothalamus (Yu and Lewander 1997), comparable studies have not examined
hypothalamic concentrations after acute subcutaneous tandospirone injection in
rats. However, about 0.04% of tandospirone was detected in cortex within 30
minutes of intraperitoneal injection (1-20 mg/kg) in mice (Miller et al., 1992).
Similarly, the clinically prescribed azapirone drug buspirone has been reported
to have a very low bioavailability (Mahmood and Sahajwalla, 1999). Also of note,
lower doses of tandospirone increased maximal plasma levels of ACTH, but not
oxytocin or increased pERK in PVN. This is likely due to the 5-HT1A receptormediated activation of the sequential pathway (e.g. CRH → ACTH) mediated
oxytocin plasma hormone responses. Although not as obvious, lower doses of
(+)8-OH-DPAT also significantly elevated plasma ACTH responses over saline,
but had no significant effect on plasma levels of oxytocin and pERK responses in
PVN.

Lastly, although 5-HT1A
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receptors have been localized to both oxytocin-

containing and CRH-containing cells in the rat PVN (Zhang et al., 2004), it is
unknown whether each of these respective receptor populations are responsible
for mediating both plasma hormone responses and increases in pERK measured
at the level of the whole PVN. Studies in other receptor systems (α1 adrenergic)
have shown that receptor-stimulated pERK in the PVN can be observed in CRHcontaining cells (Khan et al., 2007).

However, although stimulation with

prolactin or IL-1β increases levels of pERK in the hypothalamus, there is little
localization of pERK to oxytocin-containing cells (Blume et al., 2009; Wang et al.,
2006). Cellular localization of 5-HT1A receptor-mediated pERK will be further
examined in Chapter 5 of this dissertation.
From the current experiments, we have determined that a dose of 0.20 mg/kg
(+)8-OH-DPAT and a sacrifice time of 10 minutes post-injection will be used in
future experiments examining 5-HT1A receptor signaling pathways following
acute receptor stimulation since it produces robust increases in each of the
respective endpoints and is devoid of altering testosterone levels which could
complicate any interpretation of the data. Since 0.20 mg/kg of (+)8-OH-DPAT
elicits the maximal 5-HT1A receptor-mediated oxytocin and ACTH responses, the
dose of (+)8-OH-DPAT may not be sensitive to detect desensitization of 5-HT1A
receptor-mediated

hormone

antidepressants or other drugs.
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CHAPTER 4
SEROTONIN 1A RECEPTOR-ASSOCIATED Gα PROTEIN SUBTYPES IN THE
PERIPUBERTAL RAT HYPOTAHLAMIC PARAVENTRICULAR NUCLEUS:
UNIQUE ASPECTS OF MODIFICATION AND REGULATION.
ABSTRACT
In adult rats, injection with Bordetella pertussis toxin (PTX) into the
paraventricular nucleus (PVN) reduces levels of Gαi1, Gαi2, Gαi3, and Gαo
proteins and blocks serotonin 1A (5-HT1A) receptor-mediated extracellular
signal-regulated kinase (ERK) activation but has no effect on Gαz proteins or 5HT1A receptor-mediated plasma oxytocin or ACTH responses (Garcia et al., 2006).
These data indicate that 5-HT1A receptors in the adult PVN activate separate and
distinct signal transduction pathways.

Consistent with these data, chronic

treatment of adult rats with fluoxetine, a selective serotonin reuptake inhibitor
(SSRI), selectively reduces hypothalamic levels of Gαz and desensitizes 5-HT1A
receptor-mediated neuroendocrine responses but does not reduce any of the
other Gα proteins or affect 5-HT1A receptor-mediated increases in pERK. In
contrast, chronic fluoxetine treatment of peripubertal rats desensitizes 5-HT1A
receptor-mediated in the absence in reductions of Gαz proteins (Chen et al., 2006),
suggesting that, prior to maturation, Gαz is not the exclusive Gα subtype
mediating hormone responses as it is in adults. Given that 5-HT1A receptor74
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mediated activation of ERK was not determined in that previous study, the Gα
protein subtype(s) specificity for the respective 5-HT1A receptor-mediated
responses prior to sexual maturation has not been identified. The present studies
examined 5-HT1A receptor-associated Gα proteins in the peripubertal rat
hypothalamic PVN with respect to: (1) levels of the respective membraneassociated Gα proteins at peripubertal versus younger (prepubertal) and adult
ages, (2) the role of PTX-sensitive and PTX-insensitive Gα proteins on 5-HT1A
receptor-mediated increases in oxytocin and ACTH and increases of pERK in the
PVN, and (3) the effects of chronic fluoxetine treatment (7 or 14 days) in
regulating Gα protein subtypes and 5-HT1A receptor-mediated activation of ERK
in PVN. The present studies indicate that, in peripubertal rats: (1) Gαo is the
only Gα protein subject to developmental regulation (i.e., Gαo levels increased
with age) whereas Gαi1, Gαi2, Gαi3, and Gαz were present at comparable levels
in PVN, hippocampus, and frontal cortex of the prepubertal, peripubertal, and
adult brain, (2) PTX treatment reduced levels of membrane-associated Gαi1 and
Gαi2, markedly increased levels of Gαo, but did not alter Gαi3 or Gαz in the
peripubertal hypothalamus, (3) PTX-induced reductions in Gαi1 and Gαi2
proteins did not affect 5-HT1A receptor-mediated oxytocin or ACTH responses,
suggesting a role for Gαi3, Gαo, and/or Gαz proteins in 5-HT1A receptormediated signaling, (4) PTX increased basal pERK levels, suggesting an increased
constitutive activity of pERK consistent with increases in Gαo, (5) chronic
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fluoxetine did not reduce levels either cytosol- or membrane-associated Gαz or
any other Gα protein subtype, suggesting a novel mechanism responsible for
fluoxetine-induced desensitization of 5-HT1A receptor-mediated neuroendocrine
responses, and (6) chronic fluoxetine did alter basal levels of pERK but did not
desensitize 5-HT1A receptor-mediated increases in pERK in the PVN.

In

summary, the data from the current studies identify a different profile of Gα
protein sensitivity to PTX and chronic fluoxetine in the peripubertal rat than
previously established in the adult rat. These aspects of Gα protein subtypes not
observed in adults but unique to the peripubertal brain, precluded any effective
use of PTX or fluoxetine to differentiate the role of Gαi/o versus Gαz proteins in
the

respective

roles

of

these

subtypes

in

5-HT1A

receptor-mediated

neuroendocrine versus kinase responses.
INTRODUCTION
5-HT1A receptors can couple to multiple signal transduction pathways
(Raymond et al., 2001) via different subsets of PTX-sensitive Gα proteins (Gαi1,
Gαi2, Gαi3, and Gαo) or PTX-insensitive Gαz proteins (Mannoury la Cour et al.,
2006; Raymond et al., 1992; Serres et al., 2000a). The in vivo signal transduction
pathways mediated by these two subsets of proteins in hypothalamic PVN and
their regulation by different drug treatments have thus far only been
investigated in adult rats.

In the adult PVN, Gαz proteins (insensitive to

pertussis toxin) mediate the 5-HT1A receptor-induced increases in plasma ACTH
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and oxytocin (Serres et al., 2000a). In contrast, one or more subtypes of Gαi/o
proteins mediate the 5-HT1A receptor-induced increase in activated ERK in
hypothalamus, since intra-PVN injection with PTX completely inhibits 5-HT1A
receptor activation of ERK and reduces Gαi1, Gαi2, Gαi3, and Gαo proteins. In
contrast, intra-PVN injection with PTX does not alter 5-HT1A receptor-mediated
stimulation of neuroendocrine responses or reduce levels of Gαz proteins (Garcia
et al., 2006). Thus, in the adult rat, PTX provides a useful tool to differentiate
signaling by these respective subsets of G proteins (i.e., PTX-sensitive or PTXinsensitive). These 5-HT1A receptor-mediated pathways in the adult PVN were
also differentially regulated by chronic drug treatment: fluoxetine consistently
produced reductions in Gαz and desensitized 5-HT1A receptor-mediated
neuroendocrine responses but did not alter 5-HT1A receptor-mediated activation
of ERK or levels of Gi/o proteins in adult rats (Jia et al., 2006). Therefore, it is
likely that Gαi/o and Gαz proteins mediate signaling of separate and distinct
pathways following acute activation of 5-HT1A receptors in the adult rat PVN.
A preliminary study from our laboratory suggested that the signaling of 5HT1A receptor-mediated responses in peripubertal animals occurred via
mechanism(s) that differ from adult animals.

In peripubertal rats, chronic

fluoxetine treatment produced desensitization of 5-HT1A receptor-mediated
hormone responses and also decreased levels of hypothalamic Gαi3 and Gαo
proteins but had no effect on hypothalamic levels of Gαz proteins (Chen et al.,
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2006). This differential profile of reductions in Gα protein subtypes and the lack
of reduction in Gαz despite a desensitization of 5-HT1A receptor-mediated
hormone responses suggest that, prior to sexual maturation, other G proteins or
mediators are responsible for the desensitization of hormone responses.
Consequently, reductions in Gαz are not responsible for desensitization of
hormone responses.
Differences observed in fluoxetine-induced reductions in G proteins in
peripubertal vs. adult hypothalamus may be simply due to developmental
differences in the levels of Gα proteins, which could affect the subtype associated
with hormone stimulation.

Gα protein levels vary in early postnatal

development in several brain regions.

For example, Gαi1, Gαi2, and Gαo

proteins increase between postnatal day 1 and 25 in the cortex, thalamus, and
hippocampus, where Gαi3 proteins decrease in these regions over the same time
period (Ihnatovych et al., 2002).

However, no studies have determined the

developmental regulation of Gαz in any brain region, or any Gα protein subset
in the hypothalamus.

In addition, no studies have examined the regional

distribution of Gα proteins in brain during peripubertal development, an
important period for brain growth and remodeling. Any developmental change
in the availability of 5-HT1A receptor-coupled Gα proteins may impact the role
that these Gα proteins play in 5-HT1A receptor-mediated signaling of
neuroendocrine vs. kinase responses.
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Fluoxetine is one of two SSRIs currently approved for clinical use for the
treatment of depressive disorders in children and adolescents (National
Institutes of Health, 2010). Fluoxetine is one of the most commonly used SSRI in
preclinical studies, particularly those involving peripubertal animal models (Oh
et al., 2009; Iniguez et al., 2010).
The objectives of the experiments described in this chapter were to determine:
(1) if the relative levels of Gα protein subtypes in different regions in the
peripubertal brain vs. younger (prepubertal) and adult brains, (2) the role of
PTX-sensitive Gα proteins in 5-HT1A receptor-mediated neuroendocrine
responses and phosphorylation of ERK in the peripubertal PVN using an intraPVN injection of PTX, and (3) the regulation Gα proteins and 5-HT1A receptormediated activation of ERK in the peripubertal PVN upon chronic (7 and 14 day)
fluoxetine treatment.
MATERIALS AND EXPERIMENTAL PROCEDURES (for detailed methods,
see Chapter 7)
Animals.

Prepubertal, peripubertal and adult male Sprague-Dawley rats

were purchased from Harlan (Indianapolis, IN). The determination of post-natal
day zero (day of birth) was carried out by the supplier.
Drugs. Pertussis toxin (PTX; Bordetella pertussis) was purchased from EMD
Chemicals, Gibbstown, NJ (catalog number 516560), and was diluted to a
concentration of 1 μg/μl with ddH2O.

Fluoxetine hydrochloride (FLX) was
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purchased from LKT Laboratories, Inc., St. Paul, MN (catalog number F4780),
and was dissolved in saline (0.9% NaCl) to 10 mg/kg and was injected at a
volume

of

2

ml/kg.

(R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin

hydrobromide [(+)8-OH-DPAT] was purchased from Tocris Cookson Inc.,
Ellisville, MO (catalog number 1080) and was dissolved in saline (0.9% NaCl) to
0.20 mg/ml and was injected at a volume of 1 ml/kg. All drugs were freshly
prepared immediately prior to the injections.
Experiment 1:

Age-dependent brain levels of Gα protein subtypes that

mediate signaling of 5-HT1A receptors.

Male Sprague-Dawley rats at three

different ages (prepubertal, peripubertal, and adult) were handled for several
days to reduce the stress of handling upon sacrifice. Each rat was sacrificed by
decapitation on postnatal day (PD) 28 (prepubertal), PD 42 (peripubertal), or PD
70 (adult), and the brains were quickly removed and frozen on dry ice for
western blot determination of Gα protein levels in different brain regions. The
trunk blood was collected in tubes and prepared for subsequent determination of
plasma levels of testosterone.
Experiment 2: Pertussis toxin inactivation of Gα proteins in the peripubertal
rat hypothalamic PVN. Cannula implantation and administration of PTX was
performed according to procedures previously established in adult rats (Garcia
et al., 2006), and detailed in Chapter 7. Seventy-two hours after intracerebral
injection of vehicle (100 mM sodium phosphate + 500 mM NaCl, 0.5 μl/side) or

81
PTX (1 μg/μl, 0.5 μl/side), the rats were given a systemic challenge injection of
saline (1 ml/kg) or (+)8-OH-DPAT (0.20 mg/kg) and were sacrificed by
decapitation 15 minutes later (postnatal day 42).

The brains were carefully

removed from the skull within one minute of the decapitation and were quickly
frozen by submersion in chilled 2-methylbutane (-35°C) for 1 minute and then
subsequently kept in dry ice for an additional 10 minutes. Each brain was then
securely wrapped and stored at -80°C prior to dissection for Western blot studies
for the determination of Gα protein levels and pERK/ERK levels in the PVN.
The trunk blood was collected in tubes and prepared for subsequent
determination of plasma levels of oxytocin, ACTH, and testosterone.
Experiment 3:

Determination of fluoxetine-induced effects on 5-HT1A

receptor-associated G proteins and 5-HT1A receptor-mediated increases of
pERK in the peripubertal PVN. Rats were weighed on a digital scale daily and
were subsequently given an i.p. injection of saline (2 ml/kg) or fluoxetine (10
mg/kg), once per day for either 7 (PD 35-41) or 14 days (PD 28-41).

This

fluoxetine dosing regimen has been previously shown to desensitize 5-HT1A
receptor-mediated oxytocin and ACTH responses and to inhibit weight gain in
peripubertal rats (Chen et al., 2006). Eighteen hours after the last injection, the
rats (postnatal day 42) were given a systemic challenge injection of saline (1
ml/kg) or (+)8-OH-DPAT (0.20 mg/kg) and were sacrificed by decapitation 10
minutes later. The brains were carefully removed from the skull within one
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minute of the decapitation and were quickly frozen by submersion in chilled 2methylbutane (-35°C) for 1 minute and then subsequently kept in dry ice for an
additional 10 minutes. Each brain was then securely wrapped and stored at
-80°C prior to dissection for Western blot studies for the determination of Gα
protein levels and pERK/ERK levels in the PVN. The trunk blood was collected
in tubes and prepared for subsequent determination of plasma levels of oxytocin,
ACTH, and testosterone.
RESULTS
1. Experiment 1: Determination of relative levels of Gα proteins in the PVN and
other brain regions at different developmental stages.

The objective of this

experiment was to determine the levels of the respective Gα proteins at
peripubertal versus younger (prepubertal) and adult ages in various brain
regions. The body weights and plasma testosterone levels were also measured
for each rat.
A. Average body weight of prepubertal, peripubertal, and adult rats. Rats
gained weight with age. Prepubertal rats weighed, on average, 76.96 ± 0.76 g,
peripubertal rats weighed about twice as much as prepubertal rats (164.76 ± 0.91
g), and adult rats weighed about four times as much as prepubertal rats (325.79 ±
1.36 g) (figure 13).
The one-way ANOVA for body weight indicated a significant main effect of
age [F2,29 = 14608.16, p < 0.0001].

A Newman-Keuls’ test indicated that

83
peripubertal rats weighed significantly more than prepubertal rats (p < 0.01) and
that adults weighed significantly more than both prepubertal and peripubertal
rats (p < 0.01).
B.

Plasma testosterone levels of prepubertal, peripubertal, and adult rats.

Plasma levels of testosterone increased with age.

Prepubertal rats

had an

average plasma testosterone level of 13.56 ± 2.04 ng/dl, peripubertal rats had
about 4.5 times higher levels than prepubertal rats (61.30 ± 9.73 ng/dl), and adult
rats had about 17.5 times higher levels than prepubertal rats (236.97 ± 25.80
ng/dl) (figure 14).
The one-way ANOVA for plasma testosterone levels indicated a significant
main effect of age [F2,29 = 54.31, p < 0.0001]. A Newman-Keuls’ test indicated that
peripubertal rats had greater levels of plasma testosterone than prepubertal rats
(p < 0.05) and that adults had greater levels of plasma testosterone than both
prepubertal and peripubertal rats (p < 0.01).
C. Gα protein levels in the PVN of prepubertal, peripubertal, and adult rats. In
the PVN, Gαo proteins, but not Gαi1, Gαi2, Gαi3, or Gαz proteins, increased with
age. Gαo proteins were present in the prepubertal PVN at about 40% adult
levels and in the prepubertal PVN at about 68% adult levels (figure 15, table 2).
The one-way ANOVA for Gαi1 (figure 15A) indicated no significant main
effect of age [F2,23 = 0.12, p = 0.8856]. The one-way ANOVA for Gαi2 (figure 15B)
indicated no significant main effect of age [F2,22 = 0.94, p = 0.4082]. The one-way
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ANOVA for Gαi3 (figure 15C) indicated no significant main effect of age [F2,19 =
0.06, p = 0.9407].

The one-way ANOVA for Gαz (figure 15D) indicated no

significant main effect of age [F2,19 = 0.73, p = 0.4969]. The one-way ANOVA for
Gαo (figure 15E) indicated a significant main effect of age [F2,20 = 5.53, p =
0.0123]. A Newman-Keuls’ test indicated that the adults had significantly higher
levels of Gαo proteins than prepubertal rats (p < 0.01).
D.

Gα protein levels in the hippocampus of prepubertal, peripubertal, and

adults rats. In the hippocampus, Gαo proteins, but not Gαi1, Gαi2, Gαi3, or Gαz
proteins, increased with age.

Gαo proteins were present in the prepubertal

hippocampus at about 26% adult levels and in the prepubertal PVN at about 58%
adult levels (table 3).
The one-way ANOVA for Gαi1 indicated no significant main effect of age
[F2,21 = 1.55, p = 0.237]. The one-way ANOVA for Gαi2 indicated no significant
main effect of age [F2,19 = 0.25, p = 0.7805]. The one-way ANOVA for Gαi3
indicated no significant main effect of age [F2,21 = 0.06, p = 0.9463]. The one-way
ANOVA for Gαo indicated a significant main effect of age [F2,22 = 14.52, p =
0.0001]. A Newman-Keuls’ test indicated that peripubertal rats had significantly
more Gαo protein levels in the hippocampus than prepubertal rats (p < 0.05) and
that adults had significantly higher levels of Gαo proteins than prepubertal rats
and peripubertal rats (p < 0.01). The one-way ANOVA for Gαz indicated no
significant main effect of age [F2,22 = 0.16, p = 0.8506].
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E. Gα protein levels in the frontal cortex of prepubertal, peripubertal, and adult
rats.

In the frontal cortex, Gαo proteins, but not Gαi1, Gαi2, Gαi3, or Gαz

proteins, increased with age.

Gαo proteins were present in the prepubertal

frontal cortex at about 45% adult levels and in the prepubertal PVN at about 62%
adult levels (table 4).
The one-way ANOVA for Gαi1 indicated no significant main effect of age
[F2,20 = 0.15, p = 0.8652]. The one-way ANOVA for Gαi2 indicated no significant
main effect of age [F2,21 = 0.47, p = 0.6326]. The one-way ANOVA for Gαi3
indicated no significant main effect of age [F2,22 = 0.26, p = 0.7728]. The one-way
ANOVA for Gαo indicated a significant main effect of age [F2,22 = 43.66, p <
0.0001]. A Newman-Keuls’ test indicated that peripubertal rats had significantly
more Gαo protein levels in the frontal cortex than prepubertal rats (p < 0.01) and
that adults had significantly higher levels of Gαo proteins than prepubertal rats
and peripubertal rats (p < 0.01). The one-way ANOVA for Gαz indicated no
significant main effect of age [F2,20 = 0.44, p = 0.6522].
2. Experiment 2: Determination of the role of PTX-sensitive Gi/o proteins in
5-HT1A receptor-mediated signaling in peripubertal hypothalamic PVN.

The

objective of this experiment was to use pertussis toxin (PTX) as previously
demonstrated in adult rats (Garcia et al., 2006) to ADP ribosylate and
functionally inactivate Gαi/o proteins to determine if this subset of proteins
plays a role in 5-HT1A receptor-induced increases of plasma levels of oxytocin
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and ACTH and increases in pERK in the peripubertal PVN.
A. Effects of PTX treatment on hypothalamic levels of Gα proteins. Intra-PVN
injection of PTX in peripubertal rats reduced hypothalamic levels of Gαi1 and
Gαi2 (by 36% and 47%, respectively), increased levels of Gαo (by 96%), and had
no effect on the levels of Gαi3 and Gαz (figure 16).
The Student’s t-test indicated that PTX treatment significantly decreased Gαi1
proteins [t value = 4.03, p = 0.0007]. The Student’s t-test indicated that PTX
treatment significantly decreased Gαi2 proteins [t value = 3.49, p = 0.0026]. The
Student’s t-test for Gαi3 indicated no effect of PTX treatment [t value = 0.98, p =
3411]. The Student’s t-test indicated that PTX treatment significantly increased
Gαo proteins [t value = -3.86, p = 0.0012]. The Student’s t-test for Gαz indicated
no effect of PTX treatment [t value = -1.06, p = 0.3030].
B. Effects of PTX treatment on 5-HT1A receptor-mediated increases in plasma
levels of oxytocin in the peripubertal rat. (+)8-OH-DPAT increased plasma levels
of oxytocin over 20 times that over saline injection.

Intra-PVN injection with

PTX in peripubertal rats did not significantly reduce (+)8-OH-DPAT-induced
increases in plasma oxytocin levels over saline injection (figure 17).
The two-way ANOVA for oxytocin indicated no main effect of PTX treatment
[F1,64 = 1.38, p = 0.2448] but a significant main effect of challenge injection [F1,64 =
452.23, p < 0.0001]. There was no significant interaction between treatment and
challenge injection [F1,64 = 2.47, p = 0.121]. A Newman-Keuls’ test indicated that
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(+)8-OH-DPAT challenge significantly elevated plasma oxytocin levels over
saline-challenged in both vehicle-treated and PTX-treated groups (p < 0.01).
C. Effects of PTX treatment on 5-HT1A receptor-mediated increases in plasma
levels of ACTH in the peripubertal rat. (+)8-OH-DPAT increased plasma levels
of ACTH roughly 10 times that over saline injection.

Intra-PVN injection with

PTX in peripubertal rats slightly increased basal levels of ACTH but did not
significantly reduce the (+)8-OH-DPAT-induced increase in ACTH over saline
injection (figure 18).
The two-way ANOVA for ACTH indicated no main effect of PTX treatment
[F1,65 = 1.00, p = 0.3207] but a significant main effect of challenge injection [F1,65 =
672.81, p < 0.0001]. There was no significant interaction between treatment and
challenge injection [F1,65 = 3.76, p = 0.0571]. A Newman-Keuls’ test indicated that
(+)8-OH-DPAT challenge significantly elevated plasma ACTH levels over salinechallenged in both vehicle-treated and PTX-treated groups (p < 0.01).
D. Effects of PTX treatment on basal and 5-HT1A receptor-mediated increases in
levels of pERK in PVN. Challenge with (+)8-OH-DPAT increased pERK in the
PVN in the vehicle-treated group about 97% over saline challenge. Intra-PVN
injection with PTX in peripubertal rats increased basal (saline) levels of
phosphorylated ERK in the PVN increased about 95%. (+)8-OH-DPAT mediated
a further increase of only 40% over its respective basal (figure 19). Therefore,
injection with PTX either attenuated 5-HT1A receptor-mediated phosphorylation
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of ERK in the PVN or increased basal levels of pERK to a degree that further
receptor stimulation did not induce a statistically significant change over basal.
The two-way ANOVA for levels of phosphorylated ERK in the PVN
indicated a main effect of PTX treatment [F1,28 = 4.36, p = 0.0471] and a significant
main effect of challenge injection [F1,28 = 4.51, p = 0.0438].

There was no

significant interaction between treatment and challenge injection [F1,28 = 0.06, p =
0.8148]. Although the basal levels of phosphorylated ERK in the PVN increased
by about 95% with PTX treatment, this did not reach statistical significance, nor
did 5-HT1A receptor-stimulated elevations of pERK in vehicle-treated (↑97% over
respective basal) and PTX-treated (↑40% over respective basal) groups.
E. Effects of PTX on plasma levels of testosterone in the peripubertal rat. IntraPVN injection with PTX or challenge injection with (+)8-OH-DPAT in
peripubertal rats had no effect on the plasma levels of testosterone. The average
plasma testosterone levels of all treatment groups ranged between 15-28 ng/dl
(figure 20).
The two-way ANOVA for plasma testosterone levels indicated no significant
main effect of PTX treatment [F1,37 = 1.11, p = 0.3005] and no significant main
effect of challenge injection [F1,37 = 1.65, p = 0.2073].

There was also no

significant interaction between PTX treatment and challenge injection [F1,37 = 0.13,
p = 0.7165].
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3. Experiment 3: Determination of SSRI-induced regulation of 5-HT1A receptorcoupled Gα proteins and 5-HT1A receptor-mediated ERK signaling in
peripubertal hypothalamic PVN. The objective of this experiment was to use
chronic fluoxetine (FLX) injections (once per day for 7 or 14 days) to selectively
reduce Gαi3 and Gαo proteins (as previously observed in Chen et al., 2006) to
determine if these Gα proteins play a role in 5-HT1A receptor-mediated pERK
responses in the peripubertal PVN. In the peripubertal rat, 14 days of chronic
FLX induced desensitization of 5-HT1A receptor-mediated increases of plasma
levels of both oxytocin and ACTH in response to challenge with a dose of (+)8OH-DPAT (0.04 mg/kg) that is submaximal for 5-HT1A receptor-mediated
neuroendocrine responses (Chen et al., 2006). In the current experiment, we used
a higher challenge dose of (+)8-OH-DPAT (0.20 mg/kg) in order to measure
pERK responses in the PVN. However, this dose is near the maximal dose
necessary to elicit neuroendocrine responses (see chapter 3). Therefore, we did
not expect to observe a blunted neuroendocrine response in response to
fluoxetine treatment at this dose of (+)8-OH-DPAT.
A. Effect of chronic fluoxetine treatment of peripubertal rats on body weight
gain. Rats from all chronic treatment groups gained weight with age. Chronic
fluoxetine (7 and 14 days) treatment attenuated body weight gain in peripubertal
rats, with significant effects emerging around treatment day 4 (figure 21).
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For 7 days of treatment, a repeated measures ANOVA indicated that there
was no significant main effect of treatment [F1,407 = 0.42, p = 0.5188] but a
significant main effect of 7 days treatment time [F7,407 = 3433.34, p < 0.0001].
There was also a significant interaction between treatment group and treatment
time [F7,407 = 12.71, p < 0.0001]. A Newman-Keuls’ test indicated that fluoxetine
significantly attenuated weight gain as compared to saline-treated rats on
injection days 4 (p < 0.05) and 5-7 (p < 0.01).
For 14 days of treatment, a repeated measures ANOVA indicated that there
was no significant main effect of treatment [F1,719 = 2.02, p = 0.1624] but there was
a significant main effect of 14 days treatment time [F14,719 = 4642.33, p < 0.0001].
There was also a significant interaction between treatment group and treatment
time [F14,719 = 4.06, p < 0.0001]. A Newman-Keuls’ test indicated that fluoxetine
significantly attenuated weight gain as compared to saline-treated rats on
injection days 5 (p < 0.05) and 7-14 (p < 0.01).
B. Effect of chronic fluoxetine treatment of peripubertal rats on membrane-

associated and cytosol-associated Gα proteins in PVN.

In peripubertal rats,

chronic fluoxetine treatment for either 7 days (figure 22) or 14 days (figure 23)
did not reduce membrane-or cytosol-associated Gαi1, Gαi2, Gαi3, Gαo, or Gαz
protein levels in the PVN.
The Student’s t-test for membrane-bound Gα proteins in the PVN after 7 days
of saline or FLX injections indicated as follows: no effect on Gαi1 proteins [t
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value = -1.70, p = 0.1109], no effect on Gαi2 proteins [t value = -0.49, p = 0.6318],
no effect on Gαi3 proteins [t value = 0.25, p = 0.8105], no effect on Gαo proteins [t
value = -0.39, p = 0.7001], and no effect on Gαz proteins [t value = -0.34, p =
0.7354].
The Student’s t-test for cytosol-associated Gα proteins in the PVN after 7 days
of saline or FLX injections indicated as follows: no effect on Gαi1 proteins [t
value = -0.29, p = 0.7796], no effect on Gαi2 proteins [t value = -1.04, p = 0.598],
no effect on Gαi3 proteins [t value = -0.53, p = 0.6069], no effect on Gαo proteins
[t value = 0.36, p = 0.7215], and no effect on Gαz proteins [t value = 0.47, p =
0.6472].
The Student’s t-test for membrane-bound Gα proteins in the PVN after 14
days of saline or FLX injections indicated as follows: no effect on Gαi1 proteins [t
value = -1.46, p = 0.1669], no effect on Gαi2 proteins [t value = 1.11, p = 0.8952],
no effect on Gαi3 proteins [t value = -0.11, p = 0.9157], no effect on Gαo proteins
[t value = -1.00, p = 0.3337], and no effect on Gαz proteins [t value = 0.08, p =
0.939].
The Student’s t-test for cytosol-associated Gα proteins in the PVN after 14
days of saline or FLX injections indicated as follows: no effect on Gαi1 proteins [t
value = 3.11, p = 0.1576], no effect on Gαi2 proteins [t value = 1.22, p = 0.8015], no
effect on Gαi3 proteins [t value = -0.94, p = 0.3642], no effect on Gαo proteins [t
value = -0.01, p = 0.994], and no effect on Gαz proteins [t value = -0.79, p =
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0.4403].
C. Effects of chronic fluoxetine treatment of peripubertal rats on 5-HT1A
receptor-mediated oxytocin responses. (+)8-OH-DPAT increased plasma levels
of oxytocin around 18 times compared with saline. Chronic fluoxetine treatment
for either 7 or 14 days did not alter (+)8-OH-DPAT (0.20 mg/kg) induced
increases in plasma levels of oxytocin in the peripubertal rat (figure 24).
The two-way ANOVA for oxytocin for 7 days of treatment indicated no main
effect of FLX [F1,49 = 0.16, p = 0.6889] but a significant main effect of challenge
injection [F1,49 = 475.22, p < 0.0001]. There was no significant interaction between
treatment and challenge injection [F1,49 = 0.14, p = 0.7122]. A Newman-Keuls’ test
indicated that (+)8-OH-DPAT challenge significantly elevated plasma oxytocin
levels over saline-challenged in both chronic saline-treated and FLX-treated
groups (p < 0.01).
The two-way ANOVA for oxytocin for 14 days of treatment indicated no
main effect of FLX [F1,46 = 1.57, p = 0.2167] but a significant main effect of
challenge injection [F1,46 = 839.85, p < 0.0001].

There was no significant

interaction between treatment and challenge injection [F1,46 = 0.92, p = 0.344]. A
Newman-Keuls’ test indicated that (+)8-OH-DPAT challenge significantly
elevated plasma oxytocin levels over saline-challenged in both chronic salinetreated and FLX-treated groups (p < 0.01).
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D. Effects of chronic fluoxetine treatment of peripubertal rats on 5-HT1A
receptor-mediated ACTH responses. (+)8-OH-DPAT increased plasma levels of
ACTH around 8 times compared with saline.

Chronic fluoxetine treatment

increased (+)8-OH-DPAT (0.20 mg/kg)-induced increases in plasma levels of
ACTH in the peripubertal rat over its respective saline-treated/(+)8-OH-DPATchallenged group (15% over 7 day and 23% over 14 day) (figure 25).
The two-way ANOVA for ACTH for 7 days of treatment indicated no main
effect of FLX [F1,48 = 3.43, p = 0.0707] but a significant main effect of challenge
injection [F1,48 = 385.02, p < 0.0001]. There was a significant interaction between
treatment and challenge injection [F1,48 = 6.29, p = 0.0158]. A Newman-Keuls’ test
indicated that (+)8-OH-DPAT challenge significantly elevated plasma ACTH
levels over saline-challenged in both chronic saline-treated and FLX-treated
groups (p < 0.01). Additionally, (+)8-OH-DPAT challenge elicited a significantly
higher ACTH response in those rats treated with 7 days of FLX over those
treated chronically with saline (p < 0.05).
The two-way ANOVA for ACTH for 14 days of treatment indicated a main
effect of FLX [F1,44 = 20.40, p < 0.0001] and a significant main effect of challenge
injection [F1,44 = 1084.84, p < 0.0001]. There was also a significant interaction
between treatment and challenge injection [F1,44 = 25.61, p < 0.0001]. A NewmanKeuls’ test indicated that (+)8-OH-DPAT challenge significantly elevated plasma
ACTH levels over saline-challenged in both chronic saline-treated and FLX-

treated groups (p < 0.01).
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Again, (+)8-OH-DPAT challenge elicited a

significantly higher ACTH response in those rats treated with 14 days of FLX
over those treated chronically with saline (p < 0.01).
E. Effects of chronic fluoxetine treatment of peripubertal rats on 5-HT1A
receptor-mediated and basal levels of pERK in the PVN. In the rats treated for 7
days with fluoxetine, (+)8-OH-DPAT injection increased levels of pERK in the
PVN (↑ 200% above basal). (+)8-OH-DPAT challenge after treatment for 14 days
with saline (PD 28-41) increased pERK in the PVN, although this response was
not as robust (↑ ~50%). For both 7 day and 14 day chronic treatments, FLX had
no significant effect on (+)8-OH-DPAT-induced increases in pERK, although
basal levels were increased (↑ ~80%) with 7 day treatment (figure 26).
The two-way ANOVA for levels of phosphorylated ERK in the PVN
indicated no significant main effect of 7 days of FLX treatment [F1,23 = 1.75, p =
0.2011] but a significant main effect of challenge injection [F1,23 = 31.30, p <
0.0001]. There was no significant interaction between treatment and challenge
injection [F1,23 = 1.48, p = 0.2373]. The Newman-Keuls’ test indicated that the
(+)8-OH-DPAT challenge significantly elevated pERK in the PVN over the
saline-challenged group in both chronic saline-treated (p < 0.01) and chronic
FLX-treated (p < 0.05). Although the basal levels of phosphorylated ERK in the
PVN increased by about 79% with FLX treatment, this did not reach statistical
significance.
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The two-way ANOVA for levels of phosphorylated ERK in the PVN
indicated no significant main effect of 14 days of FLX treatment [F1,23 = 0.76, p =
0.3934] but a significant main effect of challenge injection [F1,23 = 5.19, p = 0.0338].
There was no significant interaction between treatment and challenge injection
[F1,23 = 0.28, p = 0.6047]. Although the basal levels of phosphorylated ERK in the
PVN decreased by about 31% with chronic fluoxetine treatment, this did not
reach statistical significance, nor did 5-HT1A receptor-stimulated elevations of
pERK in chronic saline-treated (↑39%) and chronic FLX-treated (↑91%) groups.
F. Effect of chronic fluoxetine of peripubertal rats on plasma levels of
testosterone. Neither 7 nor 14 days of chronic FLX treatment of peripubertal rats
had any effect on the plasma levels of testosterone. All treatment groups had
average plasma testosterone levels between 50-75 ng/dl (figure 27).
The two-way ANOVA for plasma testosterone levels indicated no significant
main effect of treatment time [F1,90 = 1.12, p = 0.2918] and no significant main
effect of treatment [F1,90 = 0.04, p = 0.8415].

There was also no significant

interaction between treatment time and treatment [F1,90 = 1.24, p = 0.2679].
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Figure 13. Rat body weights in prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70)
rats. ** indicates significant difference (p < 0.01) from the prepubertal age group; ## indicates
significant difference (p < 0.01) from the peripubertal age group (one-way ANOVA and
Newman-Keuls multiple-range test). N = 10 per group.
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Figure 14. Plasma testosterone levels in prepubertal (PD 28), peripubertal (PD 42), and adult (PD
> 70) rats. *, ** indicates significant difference (p < 0.05 and p < 0.01, respectively) from the
prepubertal age group; ## indicates significant difference (p < 0.01) from the peripubertal age
group (one-way ANOVA and Newman-Keuls multiple-range test). N = 10 per group.
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Figure 15. PVN levels of membrane-associated (A) Gαi1, (B) Gαi2, (C) Gαi3, (D) Gαz, and (E)
Gαo proteins in prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) rats. ** indicates
significant difference (p < 0.01) from the prepubertal age group (one-way ANOVA and NewmanKeuls multiple-range test). N = 5-8 per group. (F) Representative western blots of Gi1, Gi2,
Gi3/Go, and Gz from the PVN of prepubertal, peripubertal, and adult rats.
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Gα proteins in PVN
Gαi1
Gαi2
Gαi3
Gαo
Gαz

Prepubertal
Average ± SEM
97.2 ± 12.1
79.9 ± 9.1
117.5 ± 16.5
43.7 ± 11.6
96.4 ± 17.2

N
8
8
7
8
6

Peripubertal
Average ± SEM
105.5 ± 14.8
78.1 ± 9.2
123.7 ± 25.0
76.2 ± 14.4
97.9 ± 22.0

N
8
8
5
7
8

Adult
Average ± SEM
102.9 ± 9.2
96.2 ± 12.2
113.9 ± 17.4
111.4 ± 17.4**
126.3 ± 13.5

N
8
7
8
8
6

Table 2. PVN levels of membrane-associated Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins in
prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) rats. ** indicates significant
difference (p < 0.01) from the prepubertal (PD 28) age group (one-way ANOVA and NewmanKeuls multiple-range test).

Gα proteins in Hippocampus
Gαi1
Gαi2
Gαi3
Gαo
Gαz

Prepubertal
Average ± SEM
77.6 ± 11.4
80.5 ± 14.6
95.1 ± 11.0
25.7 ± 3.3
94.1 ± 15.9

N
7
8
7
7
8

Peripubertal
Average ± SEM
102.7 ± 12.1
91.3 ± 16.8
95.7 ± 17.9
56.7 ± 11.6*
89.3 ± 20.9

N
7
6
7
8
8

Adult
Average ± SEM
107.7 ± 14.2
93.6 ± 10.3
100.4 ± 7.7
97.3 ± 9.8**,##
101.9 ± 9.3

N
8
6
8
8
8

Table 3. Hippocampal levels of membrane-associated Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins
in prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) rats. *, ** indicates significant
difference (p< 0.05 and p < 0.01, respectively) from the prepubertal (PD 28) age group; ##
indicates significant difference (p < 0.01) from the peripubertal age group (PD 42) (one-way
ANOVA and Newman-Keuls multiple-range test).

Gα proteins in Frontal Cortex
Gαi1
Gαi2
Gαi3
Gαo
Gαz

Prepubertal
Average ± SEM
106.3 ± 18.6
88.4 ± 19.9
104.8 ± 7.3
44.9 ± 2.9
102.0 ± 11.5

N
6
7
7
7
6

Peripubertal
Average ± SEM
96.0 ± 13.4
83.8 ± 9.6
97.8 ± 6.9
62.3 ± 4.4**
114.2 ± 17.6

N
7
7
8
8
7

Adult
Average ± SEM
101.1 ± 7.8
102.1 ± 11.7
102.5 ± 6.9
100.3 ± 4.9 **,##
97.1 ± 6.5

N
8
8
8
8
8

Table 4. Frontal cortex levels of membrane-associated Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins
in prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) rats. ** indicates significant
difference (p < 0.01) from the prepubertal (PD 28) age group; ## indicates significant difference (p
< 0.01) from the peripubertal age group (PD 42) (one-way ANOVA and Newman-Keuls multiplerange test).
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Figure 16. (A) The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on
hypothalamic levels of Gαi1, Gαi2, Giα3, Gαo, and Gαz proteins. ** indicates significant
difference (p < 0.01) from the respective vehicle-treated group (Student’s t-test). N = 9-12 per
group. (B) Representative western blots of Gi1, Gi2, Gi3/Go, and Gz from the
hypothalamus of peripubertal rats 72 hours after intra-PVN injection of vehicle or PTX.
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Figure 17. The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on basal
and 5-HT1A receptor-mediated increases in plasma oxytocin. ** indicates significant difference (p
< 0.01) from the respective saline-challenged group (two-way ANOVA and Newman-Keuls
multiple-range test). N = 10-23 per group.
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Figure 18. The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on basal
and 5-HT1A receptor-mediated increases in plasma ACTH. ** indicates significant difference (p <
0.01) from the respective saline-challenged group (two-way ANOVA and Newman-Keuls
multiple-range test). N = 11-23 per group.
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Figure 19. (A) The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on
basal and 5-HT1A receptor-mediated increases in pERK in the PVN (two-way ANOVA and
Newman-Keuls multiple-range test). N = 5-9 per group. (B) Representative western blot of pERK
(above) and ERK (below) from the PVN of peripubertal rats given an intra-PVN injection of
either vehicle or PTX and, 72 hours later, given a challenge injection of either saline or (+)8-OHDPAT.
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Figure 20. Plasma testosterone levels were not significantly altered by pertussis toxin (PTX)
treatment or acute injection of (+)8-OH-DPAT (two-way ANOVA). N = 8-10 per group.
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Figure 21. The effects of (A) 7 day and (B) 14 day treatment with either saline or fluoxetine on rat
body weight. *, ** indicates significant difference (p < 0.05 and p < 0.01, respectively) from the
saline-treated group (repeated measures ANOVA and Newman-Keuls multiple-range test). N =
24-27 per group.
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Figure 22. The effects of 7 day treatment with either saline or fluoxetine on (A) membraneassociated and (B) cytosol-associated levels of Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins
(Student’s t-test). N = 6-8 per group. (C) Representative western blots of membrane-associated
(left) and cytosol-associated (right) Gi1, Gi2, Gi3/Go, and Gz from the PVN of peripubertal
rats treated with either saline or FLX for 7 days.
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Figure 23. The effects of 14 day treatment with either saline or fluoxetine on (A) membraneassociated and (B) cytosol-associated levels of Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins
(Student’s t-test). N = 7-8 per group. (C) Representative western blots of membrane-associated
(left) and cytosol-associated (right) Gi1, Gi2, Gi3/Go, and Gz from the PVN of peripubertal
rats treated with either saline or FLX for 14 days.
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Figure 24. The effects of (A) 7 day and (B) 14 day treatment with saline or fluoxetine on basal and
5-HT1A receptor-mediated increases in plasma oxytocin. ** indicates significant difference (p <
0.01) from the respective saline-challenged group (two-way ANOVA and Newman-Keuls
multiple-range test). N = 8-18 per group.
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Figure 25. The effects of (A) 7 day and (B) 14 day treatment with saline or fluoxetine on basal and
5-HT1A receptor-mediated increases in plasma ACTH. ** indicates significant difference (p < 0.01)
from the respective saline-challenged group, ## indicates significant difference (p < 0.01) from the
saline-treated/(+)8-OH-DPAT-challenged group (two-way ANOVA and Newman-Keuls
multiple-range test). N = 8-18 per group.
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Figure 26. The effects of (A) 7 day and (B) 14 day treatment with saline or fluoxetine on basal and
5-HT1A receptor-mediated increases in levels of pERK in the PVN. *, ** indicates significant
difference (p < 0.05 and p < 0.01, respectively) from the respective saline-challenged group). N =
6 per group. (C) Representative western blot of pERK (above) and ERK (below) from the PVN of
rats treated with Sal or FLX and subsequently challenged with either saline or (+)8-OH-DPAT.
7D treatment is on the left and 14D treatment is on the right.
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Figure 27. Plasma testosterone levels were not significantly altered by treatment with fluoxetine
for either 7 or 14 days (two-way ANOVA). N = 22-24 per group.
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DISCUSSION
5-HT1A receptors on hypothalamic neurons stimulate the release of various
hormones and contribute to the serotonergic activation of the hypothalamicpituitary-adrenal (HPA) axis (Sullivan-Hanley and Van de Kar 2003). 5-HT1A
receptors in the hypothalamus also activate the mitogen-activated protein kinase
(MAPK) ERK pathway (Sullivan et al., 2005; Crane et al., 2007). However, most
in vivo studies on 5-HT1A receptor signaling in the hypothalamic PVN have
focused on adult animal models. In the adult rat PVN, 5-HT1A receptors mediate
increases in plasma levels of oxytocin and ACTH via pertussis toxin (PTX)insensitive Gαz proteins, whereas 5-HT1A receptor-mediated increases in
activated ERK (pERK) in the PVN occurs via one or more subtypes of PTXsensitive Gα proteins (i.e., Gαi1,2,3 and Gαo proteins). However, prior to sexual
maturation, it is not known if these respective signaling pathways are mediated
by the dichotomy of G protein subunits that can be identified as PTX-sensitive
vs. PTX-insensitive. Differences in the density or in the regulation of Gα protein
subtypes may underlie any observed developmental differences between
peripubertal and adult 5-HT1A receptor signaling and receptor desensitization in
the PVN.

Therefore, in the present studies, we investigated the density,

signaling, and regulation of Gα proteins that have the capacity to couple 5-HT1A
receptors in the peripubertal rat PVN.
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With regards to density, Gα protein levels vary in early postnatal
development in several brain regions. Gαi1, Gαi2, and Gα3 proteins reach adult
levels around postnatal day 18 in the cortex, thalamus, and hippocampus,
whereas Gαo proteins continue to increase past early postnatal development in
these regions (Ihnatovych et al., 2002). However, until the present dissertation
studies, no studies had examined developmental regulation of Gαz in any brain
region, or Gα protein levels in the immature hypothalamus. The current data
revealed that, consistent with the findings in other brain regions (Ihnatovych et
al., 2002), Gαo proteins increased with age. Gαo was present at lower levels in
prepubertal (PD 28) and peripubertal (PD 42) PVN, hippocampus, and frontal
cortex compared to adult. Also consistent with the literature, levels of Gi1, Gi2,
and Gi3 in both prepubertal and peripubertal brain were similar to levels
observed in adult brain. We also determined that Gαz levels in the prepubertal
and peripubertal PVN, hippocampus, and frontal cortex were comparable to
adult. Global changes in Gαo, but no other Gα protein, may be important with
regards to signaling because a relatively lower density of Gαo proteins may lead
to a decrease in Gαo coupling to the 5-HT1A receptor in the hypothalamus and
other brain regions of younger aged rats as compared to that previously
established in the adult rat brain (Mannoury la Cour et al., 2006). Therefore, Gαo
proteins may be prevented from performing its specific signaling function.
However, multiple Gα proteins may subserve the same function in 5-HT1A

114
receptor-mediated signaling pathways in the peripubertal brain (i.e., redundancy
in Gα mediated pathways); therefore, a lower level of Gαo proteins in younger
developmental groups may not necessarily alter 5-HT1A receptor signaling if
other Gα protein subtypes compensate for the lack of Gαo proteins.

The

limitation of the western blotting technique used in this experiment is that
relative levels of Gα proteins cannot be compared to one another. Comparisons
can only be made of the levels of a single Gα protein at different ages. Another
possibility for developmental increases in Gαo is that the other Gα proteins
(Gαi1, Gαi2, Gαi3, and Gαz) may be able to perform a wider array of functions in
the pre-adult brain, and the “pruning” of functions as the animal ages only then
necessitates an increase in Gαo.

It also should be noted that the cytosol-

associated proteins were not examined in this study. The increase in membraneassociated Gαo protein levels may be due to a redistribution of Gαo proteins
from cytosol to membrane as the animal ages rather than a total increase in Gαo.
However, if Gαo proteins are redistributed from cytosol to membrane in the
respective brain regions after sexual maturation, then it would corroborate the
evidence indicating the unique regulation of Gαo proteins in the developing
brain.
In addition to developmental regulation of Gα protein levels, the present
studies also indicated that Gα proteins exhibit unique responses to drug
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treatments. Using a PTX treatment paradigm that had previously been shown to
be effective in adult rats, we investigated, in the peripubertal PVN, the role of
PTX-sensitive Gαi/o proteins in 5-HT1A receptor signaling of neuroendocrine
responses and phosphorylation of ERK. In adult rats, intra-PVN injection of PTX
reduced Gαi1, Gαi2, Gαi3, and Gαo, but not Gαz in the hypothalamus and
inhibited 5-HT1A receptor-mediated phosphorylation of ERK in the PVN (Garcia
et al., 2006). Therefore, PTX had been shown to be a useful tool to differentiate
signaling by these respective subsets of G proteins (i.e., PTX-sensitive or
insensitive). The current data indicate that, in peripubertal rats, an intra-PVN
injection of PTX did not reduce all subsets of Gαi/o proteins in the
hypothalamus (as in the adult) but only reduced Gαi1 and Gαi2, increased Gαo
protein levels, and did not change Gαi3 and Gαz protein levels in the
hypothalamus.

Therefore, this study revealed that G proteins in the

peripubertal hypothalamus may be subject to unique regulation by PTX that
prevents reductions in Gi3 and increases Go. However, although Gα protein
levels were measured at the level of the hypothalamus and not the PVN, there
may have been changes in specific Gα proteins at the level at the PVN that were
masked by changes in the whole hypothalamus. However, considering that
there

were

no

significant

reductions

in

5-HT1A

receptor-mediated

neuroendocrine responses, these data suggest that Gαi3, Gαo, and/or Gαz could
potentially mediate 5-HT1A receptor stimulation of hormone responses in the

PVN of peripubertal rats.
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We cannot rule out Gαi3 and Gαo proteins in

mediating the 5-HT1A receptor activation of ERK considering that there was no
clear effect of PTX on (+)8-OH-DPAT-induced increases in pERK in the PVN,
due to the elevation in basal levels of pERK. However, PTX-induced increases in
Gαo may be responsible for the elevations observed in basal levels of activated
ERK in the PVN. A difference in the Gαi3/Gαo protein structure or binding
ability could be preventing ADP-ribosylation in the peripubertal rat brain. In
peripubertal prostate tissue, the ability of PTX to ADP-ribosylate Gi/o proteins
was reduced compared to adults, which may be attributed to reduced binding
ability of the G proteins to guanosine triphosphate (GTP) in the peripubertal rats
(Chen et al., 1995). Another possibility is that there is a difference in posttranslational modifications of the proteins. Fatty acylation of Gαo has been
observed in the cortex of postnatal rats (Li et al., 1995); however, a search of the
literature suggests there has not been much other research on Gα protein posttranslational modifications in the developing brain. Another possibility for the
differences observed in the peripubertal hypothalamus with PTX treatment is
that a 72-hour incubation time is not sufficient (or is perhaps too short) to
functionally inactivate Gαi3 and Gαo proteins. It could be that these proteins are
more resilient to ADP-ribosylation and begin to reverse the effect of the toxin or
are replenished by transcription and translation of their respective genes before
the end of the 3-day time period. Similarly, Gαi3 and Gαo may be compensating
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for the loss of Gαi1 and Gαi2 proteins. Compensatory increases in levels of Gαo
have been observed with knockdown of Gα1-3 proteins in vitro (Krumins and
Gilman, 2006). There may also be developmental differences in the effects of PTX.
In the literature, there has been only one other study comparing the effects of
PTX in peripubertal vs. adult brain: using adult rat brain membranes in vitro,
GABAB receptor/G protein binding was reduced upon incubation with PTX in
cortex, hippocampus, and cerebellum but not the striatum. However, when PTX
was incubated with peripubertal rat brain membranes, GABAB receptor/G
protein binding was reduced in striatum and hippocampus but not cortex or
cerebellum (Knott et al., 1993). In sum, Gα proteins (namely Gαi3 and Gαo) may
not have functionally matured in the peripubertal brain and may possibly impact
the signaling of the 5-HT1A receptor in the PVN and other regions in the brain.
To determine the specific Gα protein contribution to 5-HT1A receptor-mediated
signaling pathways in the peripubertal PVN, a more selective method is
necessary, such as adenoviral-delivered siRNA for Gαi3 and Gαo proteins.
In the pertussis toxin experiment, we also observed a trend towards lower
plasma levels of testosterone in all treatment groups, which approximated
prepubertal levels as determined in experiment 1. This may be due to additional
stress effects of surgery and recovery that all rats from the experiment
experienced.

Increased activity of the HPA axis via intracerebroventricular

injections of CRH or a CRH receptor agonist was shown to delay the onset of
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puberty in female rats (Kinsey-Jones et al., 2010). If CRH signaling also plays a
role in pubertal timing in male rats, then additional stress may account for this
slight reduction in testosterone levels in the cannulated rats.
In a previous study conducted in peripubertal rats, chronic fluoxetine (FLX)
injections (once per day for 14 days) reduced 5-HT1A receptor-mediated
neuroendocrine responses and selectively reduced Gαi3 and Gαo proteins (Chen
et al., 2006); however, any effects of FLX-induced reductions of Gαi3 and Gαo on
5-HT1A receptor-mediated ERK activation were not examined.

Therefore,

peripubertal rats were given chronic fluoxetine (7 and 14 days) to determine the
role of these proteins in 5-HT1A receptor-mediated phosphorylation of ERK in the
PVN.

Since FLX-induced desensitization of 5-HT1A receptor-mediated

neuroendocrine responses had already been established in peripubertal rats, the
dose of the challenge drug, (+)8-OH-DPAT, was set at 0.20 mg/kg. This dose is
submaximal for the 5-HT1A receptor-mediated phosphorylation of ERK but near
the maximum dose necessary for 5-HT1A receptor-mediated neuroendocrine
responses (Chapter 3). Therefore, we did not expect to observe a desensitization
of either oxytocin or ACTH hormone responses. Although neither 7 nor 14 days
of FLX had any effect on (+)8-OH-DPAT (0.20 mg/kg)-induced increases in
plasma levels of oxytocin, this combination of either 7 or 14 days FLX treatment
with 0.20 mg/kg (+)8-OH-DPAT challenge may have elicited a supersensitive
plasma ACTH response. Since this supersensitivity was not observed in the
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plasma oxytocin responses, FLX may be inducing changes specific to the CRH
receptor system, downstream of 5-HT1A receptor activation on CRH-containing
cells in the PVN. FLX treatment has shown to increase CRH mRNA in the PVN
(Jorgensen et al., 2002), which could potentially lead to increased release of CRH
from the PVN with a maximal dose of the 5-HT1A receptor agonist (+)8-OHDPAT. With regards to the effects of chronic FLX on ERK activation, neither 7
nor 14 days of FLX had any significant effect on either basal or 5-HT1A receptormediated phosphorylation of ERK in the PVN. However, in contrast to the
preliminary study that indicated that chronic fluoxetine reduces Gαi3 and Gαo in
peripubertal hypothalamus (Chen et al., 2006), the current study revealed that
there were no significant changes in any Gα protein subtype (cytosol-associated
or membrane-associated) in the PVN with chronic FLX treatment. However, we
did replicate the finding that Gαz proteins were not reduced with chronic
fluoxetine in the peripubertal hypothalamus. Considering that, in adults, Gαz is
the exclusive Gα protein mediator of 5-HT1A receptor-mediated neuroendocrine
responses and the only Gα protein that is decreased in the PVN upon chronic
FLX treatment, the results from this study indicate very strongly that, in the
peripubertal hypothalamus, either Gαz is not the exclusive mediator of 5-HT1A
receptor-mediated neuroendocrine responses or FLX-induced desensitization of
neuroendocrine responses occur via a different mechanism than that operative in
the adult PVN. However, there is also the possibility that the activity, but not
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protein level, of Gz proteins are being reduced with chronic FLX treatment.
Phosphorylation of Gz, which has been observed in other systems (Carlson et
al., 1989; Lounsbury et al., 1991), could potentially block its association with Gβγ
proteins (Fields and Casey 1995) and subsequent activation by 5-HT1A proteins.
If chronic FLX did induce a phosphorylation of Gz rather than a reduction in
protein levels (as observed in the adult hypothalamus), then Gz proteins could
still play a role in 5-HT1A receptor-mediated responses in the peripubertal PVN.
Chronic FLX attenuates weight gain in both adult and peripubertal rats. The
findings from the current study are in agreement with the current literature that
suggests that peripubertal rats are more resilient to the attenuation in weight
gain that is prominent in adult rats treated with chronic fluoxetine (Iniguez et al.,
2010; Homberg et al., 2011), since the average body weight of peripubertal rats
treated for 14 days saline vs. FLX differed by only about 2%. Published studies
in adult rats indicate that the average body weight of rats treated for 14 days of
saline vs. FLX differ between 5-10% (Raap et al., 1999; Homberg et al., 2010).
Not only do 5-HT1A receptors signal to phosphorylate the protein kinase ERK
in the PVN via a different time-course than that previously established in adults
(see Chapter 3 and Crane et al., 2007), but we also have established that the Gα
proteins associated with this receptor are subject to both developmental and
drug-induced regulation that differ from mechanisms previously established in
the adult PVN. These findings have far-reaching implications for the global

signaling of the 5-HT1A

121
receptor in the peripubertal PVN and also for the

receptor desensitization and regulation induced by antidepressants and other
serotonergic modulators.

CHAPTER 5
IMMUNOHISTOCHEMICAL DETECTION OF OXYTOCIN AND SEROTONIN
1A RECEPTOR-MEDIATED INCREASES IN PHOSPHORYLATED
EXTRACELLULAR SIGNAL-REGULATED KINASE ARE LOCALIZED TO
DIFFERENT REGIONS OF THE PERIPUBERTAL HYPOTHALAMIC
PARAVENTRICULAR NUCLEUS.
ABSTRACT
Serotonin

1A

(5-HT1A)

receptor

activation

in

the

hypothalamic

paraventricular nucleus (PVN) stimulates increases in plasma levels of oxytocin
and adrenocorticotropic hormone (ACTH) and also increases levels of activated
extracellular signal-regulated kinase (ERK). In adult rat PVN, 5-HT1A receptors
are localized on oxytocin-containing and CRH-containing cells (Zhang et al.,
2004); however, the specific cellular localization of 5-HT1A receptor-mediated
activation of ERK in these neuroendocrine cells has not been determined.
Blockade of mitogen activated protein kinase (MAPK) kinase (the upstream
activating kinase for ERK) abolishes SSRI-induced desensitization of 5-HT1A
receptor-mediated increases of plasma oxytocin responses (Jia et al., 2007).
Therefore, it is possible that 5-HT1A receptors can activate ERK in oxytocincontaining cells in the PVN. However, other studies indicating low levels of ERK
phosphorylation in oxytocin-containing cells in adult brain (Blume et al., 2009;
Wang et al., 2006) suggest otherwise. Previous studies in this dissertation project
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demonstrated that 5-HT1A
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receptor activation can also stimulate increases in

plasma hormone responses (oxytocin and ACTH) and phosphorylation of ERK in
the peripubertal PVN. However, these studies did not determine the cellular
localization of receptor activated ERK in the hypothalamus of peripubertal rats.
Therefore, the objective of the current study was to determine, at the cellular
level, if 5-HT1A receptor-mediated pERK responses can be detected in oxytocincontaining cells in the peripubertal hypothalamic PVN. In the present study,
peripubertal (PD 42) rats received an injection of saline or the 5-HT1A receptor
agonist (+)8-OH-DPAT (0.20 mg/kg) 10 minutes prior to sacrifice. Injection with
(+)8-OH-DPAT produced marked increases in pERK immunoreactivity in the
PVN in peripubertal PVN; however, we did not find any evidence that pERKpositive cells were also immunoreactive for oxytocin.

Preliminary data

presented here suggest that, in the adult brain, oxytocin and 5-HT1A receptormediated pERK were also localized to distinct regions of the PVN.

These

findings are consistent with previously published data that suggest that pERK
stimulation is minimal in oxytocin-containing cells.
In the adult rat hypothalamic PVN, an intact ERK signaling pathway is
necessary for SSRI-induced desensitization of 5-HT1A receptor-mediated oxytocin
responses.

The data from the present studies suggest that SSRI-induced

desensitization of 5-HT1A receptor-mediated oxytocin responses occur via ERK
activation on non-oxytocin-containing cells and involve transynaptic vs.

intracellular mechanisms. This indicates that 5-HT1A
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receptor-mediated ERK

signaling may play a more widespread role in PVN control, since it could
potentially affect the function of cells outside of the small population of cells
where ERK is directly activated.
INTRODUCTION
The paraventricular nucleus (PVN) is one of several cell groups of the medial
hypothalamus and is a center for complex neuroendocrine and autonomic
control of the CNS and periphery (Swanson and Sawchenko 1980; Sawchenko
and Swanson 1983). The PVN consists of both magnocellular and parvicellular
divisions (Swanson and Kuypers 1980).

The magnocellular region contains

many oxytocin cells, whereas the parvicellular region (medial portion) includes
CRH-containing cells as well as some oxytocin-containing cells. Although there
are distinct populations of oxytocin-containing and CRH-containing cells within
the PVN, oxytocin and CRH do moderately colocalize in a discrete anterior part
of the magnocellular division of the nucleus (Sawchenko et al., 1984).
In adult rat PVN, 5-HT1A receptors localize to both oxytocin-containing and
CRH-containing cell types (Zhang et al., 2004).

5-HT1A receptor activation

increases levels of phosphorylated ERK at the level of the whole PVN in the
adult rat (Crane et al., 2007; Sullivan et al., 2005) and peripubertal rat (Chapter 3);
however, the cellular localization of 5-HT1A receptor-mediated ERK activation in
the hypothalamic PVN has not been determined in any age group. In CRH-
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containing cells in the adult rat PVN, increases in pERK have been observed
upon stimulation with (1) norepinephrine (via activation of α1 receptors; Khan et
al., 2007) and (2) prolactin (Blume et al., 2009). Since blockade of MAPK kinase
(the activating kinase for ERK) abolishes SSRI-induced desensitization of 5-HT1A
receptor-mediated increases in ACTH responses (Jia et al., 2007), increases in
pERK mediated by 5-HT1A receptor activation are most likely contained in CRHcontaining cells.

MAPK kinase inhibition also abolishes SSRI-induced

desensitization of 5-HT1A receptor-mediated oxytocin responses; therefore, it is
also likely that 5-HT1A receptors can activate ERK in oxytocin-containing cells in
the PVN. However, a study from the literature reveals that, while around 70% of
CRH-containing cells also contained phosphorylated ERK, only about 15% of
oxytocin-containing cells contained prolactin-stimulated pERK (Blume et al.,
2009). A low level of pERK stimulation in oxytocin-containing cells (around 10%)
was also demonstrated upon injection with the cytokine interleukin 1β (IL-1β;
Wang et al., 2006). Together, these data suggest that oxytocin-containing cells
contain low levels of MAPK activity.
5-HT1A receptor activation results in a rapid and prolonged elevation of
phosphorylated ERK at the level of the whole PVN in the peripubertal brain
(Chapter 3); however, no studies have investigated if 5-HT1A receptor-activated
ERK is localized to specific neuroendocrine cells in the PVN of peripubertal rats.
Therefore, the purpose of the current study was to determine, at the cellular level,

if 5-HT1A

126
receptor-mediated increases in pERK can be detected in oxytocin-

containing cells in the peripubertal hypothalamic PVN.

Specifically, the

objective was to determine (1) if (+)8-OH-DPAT induces a measurable or
significant increase in phosphorylated ERK in peripubertal PVN using
immunohistochemistry

and,

if

so,

(2)

if

5-HT1A

receptor-mediated

phosphorylation of ERK is localized to oxytocin-containing cells in the PVN. We
also performed preliminary studies to determine the localization of 5-HT1A
receptor-stimulated pERK immunoreactivity in oxytocin-containing cells in the
adult PVN.

In addition, plasma oxytocin and ACTH concentrations were

determined to confirm activation of 5-HT1A receptor-mediated responses.
Plasma levels of testosterone were also determined to ensure that the stage of
sexual maturation were not different between different challenge injection
groups.
MATERIALS AND EXPERIMENTAL PROCEDURES (for detailed methods,
see Chapter 7)
Animals. Peripubertal (100-125 g; postnatal day 35) and adult (275-300 g;
postnatal day 63) male Sprague-Dawley rats were purchased from Harlan
(Indianapolis, IN). The determination of post-natal day zero (day of birth) was
carried out by the supplier.
Drugs. (+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide [(+)8-OHDPAT] was purchased from Tocris Cookson Inc. (Ellisville, MO) and was
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dissolved in saline (0.9% NaCl). (+)8-OH-DPAT was injected at a volume of 1
ml/kg and was freshly prepared immediately prior to the injections.
Experiment 1: Localization of 5-HT1A receptor-mediated activation of ERK
in the peripubertal and adult PVN.

Peripubertal and adult animals were

assigned randomly to treatment groups and were handled for at least 3 days
before injections to minimize stress. On postnatal day (PD) 42 for peripubertal
animals and PD 70 for adult animals, the rats were given an injection of saline (1
ml/kg, s.c.) or (+)8-OH-DPAT (0.20 mg/kg, s.c.) with sacrifice occurring 10
minutes after injection for peripubertal rats (the optimal sacrifice time for
observing elevations in pERK in peripubertal PVN with western blotting, see
Chapter 3) or 5 minutes after injection for adult animals (Crane et al., 2007). As
an additional control, two peripubertal animals were also handled for 3 days but
were not injected. The trunk blood was collected in tubes and prepared for
subsequent determination of plasma levels of oxytocin, ACTH, and testosterone.
Brains were harvested within one minute of the decapitation and were preserved
using the immersion fixation procedure (adapted from Khan and Watts, 2004).
RESULTS
1. Experiment 1: Localization of 5-HT1A receptor-mediated activation of ERK in
the PVN. The objectives of this experiment were to determine (1) if (+)8-OHDPAT induces phosphorylation of ERK in the PVN of peripubertal rats using
immunofluorescence and, if so, (2) if 5-HT1A receptor-mediated phosphorylation
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of ERK is localized to oxytocin-containing cells in the PVN. We also performed
preliminary studies to determine the localization of 5-HT1A receptor-stimulated
pERK immunoreactivity in oxytocin-containing cells in the adult PVN.
A. Immunoreactivity for 5-HT1A receptor-mediated phosphorylation of ERK did
not localize to oxytocin-immunoreactive cells in the peripubertal hypothalamic
PVN. As shown in figure 28, injection with (+)8-OH-DPAT increased pERK
immunoreactivity in the peripubertal PVN; however, none of these cells were
also immunoreactive for oxytocin. This finding was also confirmed with higher
powered-magnification using confocal imaging (figure 29).

The oxytocin-

containing cells concentrate more laterally in magnocellular divisions of the PVN,
while the pERK-containing cells were concentrated medially (closer to the third
ventricle) in parvocellular cell groups.
B. The effect of (+)8-OH-DPAT on the measure of integrated density for pERK
and oxytocin labeling in the peripubertal PVN. As shown in table 5, (+)8-OHDPAT had no effect on the integrated density (defined as the product of the pixel
area and the optical density) in the peripubertal PVN. However, due to the
intense baseline signal of fibers and vessels with the pERK antibody in the PVN
(Khan et al., 2007), evaluating the integrated density alone for the whole PVN in
peripubertal rats may not be as sensitive as counting labeled cells (as shown in
section C below).
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The Student’s t-test for oxytocin indicated no significant effect of (+)8-OHDPAT challenge compared to saline challenge [t value = 0.84, p = 0.4204]. The
Student’s t-test for pERK also indicated no significant effect of (+)8-OH-DPAT
challenge compared to saline challenge [t value = -0.07, p = 0.9474].
C.

The effect of (+)8-OH-DPAT on number of cells labeled for pERK and

oxytocin in the PVN of peripubertal rats. As shown in table 6, particle analysis
using ImageJ software (identifying round cells and eliminating narrow fiber or
vessel labeling) indicated that (+)8-OH-DPAT had no effect on the number of
oxytocin-immunoreactive

cells,

but

increased

the

number

of

pERK-

immunoreactive cells ~2.9 fold above saline-injected controls in the peripubertal
PVN.
The Student’s t-test for oxytocin indicated no significant effect of (+)8-OHDPAT injection compared to saline injection [t value = 1.10, p = 0.2975]. The
Student’s t-test for pERK, however, indicated a significant effect of (+)8-OHDPAT challenge compared to saline challenge [t value = -3.19, p = 0.0129].
Therefore, these data suggest that stimulation of 5-HT1A receptors in vivo induces
a measurable increase in the number of pERK immunoreactive cells but has no
effect on the number of cells that were immunoreactive for oxytocin in the
peripubertal PVN.
D.

Immunoreactivity for 5-HT1A receptor-mediated phosphorylation of ERK

was not found in oxytocin-containing cells in the adult hypothalamic PVN.
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Preliminary data suggest that, in the adult PVN, injection with 0.20 mg/kg (+)8OH-DPAT markedly increased pERK-immunoreactivity.

However, none of

these cells were also immunoreactive for oxytocin (figure 30).
E. (+)8-OH-DPAT increased plasma levels of oxytocin in peripubertal and adult
rats. Plasma hormone levels were measured in order to confirm that the in vivo
injection with 0.20 mg/kg (+)8-OH-DPAT stimulated 5-HT1A receptors in the
PVN. As shown in figure 31, challenge with (+)8-OH-DPAT increased plasma
levels of oxytocin in both peripubertal (~36 fold over saline) and adult (~13 fold
over saline) rats.
F. (+)8-OH-DPAT increased plasma levels of ACTH in peripubertal and adult
rats. As shown in figure 32, injection of 0.20 mg/kg (+)8-OH-DPAT increased
plasma levels of ACTH in both peripubertal (~8 fold over saline) and adult (~4
fold over saline) rat groups. These data indicate that the in vivo injection of 0.20
mg/kg

(+)8-OH-DPAT

stimulated

neuroendocrine

responses

in

both

peripubertal and adult rats, presumably via 5-HT1A receptor-mediated activation
in the PVN.
G. (+)8-OH-DPAT had no effect on plasma levels of testosterone in peripubertal
and adult rats. Plasma levels of testosterone were measured in order to ensure
that the state of sexual maturation was consistent within treatment groups and
age groups. (+)8-OH-DPAT had no effect on the plasma levels of testosterone in
peripubertal or adult animals compared to saline-challenged rats or untreated
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rats. As expected, adult rats had higher plasma levels of testosterone than did
peripubertal rats (figure 33).
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Peripubertal PVN
A. Saline-injected

B. (+)8-OH-DPAT-injected

Oxytocin
Phosphorylated ERK
Overlay
Figure 28. Representative images of oxytocin, pERK, and overlays in peripubertal PVN of rats
injected with either (A) saline or (B) 0.20 mg/kg (+)8-OH-DPAT (untreated not shown).
Magnification = 10x; yellow scale bar = 100 μm.

Peripubertal PVN
SAMPLE REGION 1

SAMPLE REGION 2
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SAMPLE REGION3

Oxytocin

pERK

Overlay

Figure 29.
Representative confocal images of oxytocin-immunoreactive cells, pERK
immunoreactive cells, and overlays of immunoreactive cells taken from three different randomly
chosen areas of the PVN from one (+)8-OH-DPAT-injected (0.20 mg/kg) peripubertal rat. Red =
oxytocin-immunoreactive cells; green = pERK-immunoreactive cells.
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Effects of 5-HT1A Receptor Stimulation on Integrated Density
of Immunoreactivity in Peripubertal PVN
Treatment

Oxytocin

pERK

N

Untreated

4.5

1.1

2

Saline

3.8 ± 0.3

3.4 ± 1.2

6

(+)8-OH-DPAT

3.3 ± 0.6

3.5 ± 0.9

6

Table 5. Average integrated density (x100) of oxytocin immunoreactivity and 5-HT1A receptorstimulated pERK immunoreactivity in the peripubertal PVN. Numbers are displayed as the
average integrated density (optical density multiplied by the area of a 850x950 pixel section) of
each group ± SEM for groups with more than 2 rats. Student t-test indicated no effect of (+)8OH-DPAT challenge injection for either oxytocin or pERK integrated density of
immunoreactivity compared to rats injected with saline.
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Effects of 5-HT1A Receptor Stimulation on
Immunoreactive Cell Density in Peripubertal PVN
Treatment

Oxytocin

pERK

N

Untreated

124.7

9.3

2

Saline

115.7 ± 8.9

15.1 ± 5.9

5

(+)8-OH-DPAT

96.2 ± 17.5

44.0 ± 6.9 *

5

Table 6. Average cell density of 850x950 pixel area for oxytocin-immunoreactive cells and cells
immunoreactive for 5-HT1A receptor-stimulated pERK in the PVN of peripubertal rats. Numbers
are displayed as the average cell number of each group ± SEM for groups with more than 2 rats.
* p < 0.05 with respect to saline (Student’s t-test).
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Adult PVN
A. Saline-injected

B. (+)8-OH-DPAT-injected

Oxytocin
Phosphorylated ERK
Overlay
Figure 30. Representative images of oxytocin, pERK, and overlays in adult PVN from animals
that have been injected with (A) saline or (B) (+)8-OH-DPAT (0.20 mg/kg). Magnification = 10x;
white scale bar = 100 μm.
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Untreated

Saline

(+)8-OH-DPAT

Peripubertal Challenge Group
B
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300
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Saline

(+)8-OH-DPAT

Adult Challenge Group

Figure 31. Plasma oxytocin responses in (A) peripubertal and (B) adult rats used in
immunohistochemistry experiments.
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B

ACTH (pg/ml)
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Saline

(+)8-OH-DPAT

Adult Challenge Group
Figure 32. Plasma ACTH responses in (A) peripubertal and (B) adult rats used in
immunohistochemistry experiments.
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Figure 33. Plasma levels of testosterone
immunohistochemistry experiments.

in peripubertal and adult rats used

in
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DISCUSSION
Activation of 5-HT1A receptors via in vivo injection with (+)8-OH-DPAT
increases plasma levels of oxytocin and ACTH and increases levels of pERK in
the PVN (as measured by western blotting) in both peripubertal and adult brains
(Chapter 3 and Crane et al., 2007). Although increases in pERK mediated by
neuroactive ligands such as norepinephrine or prolactin have been identified in
specific neuroendocrine-containing cell types in the PVN, 5-HT1A receptormediated activation of ERK has not been demonstrated in the specific cell types
in the PVN of rats at any age. The study described in this chapter is the first to
demonstrate 5-HT1A receptor-mediated increases in pERK immunoreactivity in
the peripubertal PVN using immunohistochemistry.

The present study

determined that 5-HT1A receptor-mediated increases in pERK immunoreactivity
did not localize to cells that were immunoreactive for oxytocin. Preliminary data
obtained in this study also suggest that 5-HT1A receptor-induced increases in
pERK immunoreactivity and oxytocin immunoreactivity were contained in
distinct cell groups in the adult PVN, indicating this finding is not unique to the
immature brain.
The current preliminary data are consistent with the literature in that
receptor-activated ERK localizes to very few oxytocin-containing cells (Wang et
al., 2006; Blume et al., 2009). Since 5-HT1A receptor-mediated increases in pERK
immunoreactivity and oxytocin immunoreactivity were localized to distinct cell

groups in the peripubertal PVN, 5-HT1A
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receptor-mediated pERK and 5-HT1A

receptor-mediated increases in plasma oxytocin responses are likely mediated by
separate pathways in different cell populations. Similarly, little to no localization
of 5-HT1A receptor-activated ERK on oxytocin-containing cells in the adult PVN
support previous findings indicating that 5-HT1A receptors mediate increases in
plasma levels of oxytocin and increases in ERK activation via independent
pathways in the adult PVN (Garcia et al., 2006).
In

the

adult

desensitization

of

PVN,

ERK

5-HT1A

signaling

is

necessary

receptor-mediated

for

oxytocin

SSRI-induced
(and

ACTH)

neuroendocrine responses, since blockade of MAPK kinase (MEK), the activating
kinase for ERK, abolishes SSRI-induced desensitization of 5-HT1A receptormediated hormone responses and associated reductions in Gαz proteins (Jia et al.,
2007).

The current results imply that activated ERK in the adult PVN may

function via an indirect, cell-to-cell mechanism rather than a direct, intracellular
mechanism to mediate SSRI-induced desensitization of 5-HT1A receptormediated oxytocin responses. In the peripubertal PVN, it is unknown if ERK is
required for SSRI-induced desensitization of 5-HT1A receptor mediated oxytocin
responses. If ERK is necessary, then a similar cell-to-cell mechanism for SSRIinduced desensitization of 5-HT1A receptor-mediated oxytocin responses may be
operant in the immature brain as suggested in the adult brain.
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The labeling of CRH in the PVN has proved to be challenging, and many labs
have found it necessary to treat rats in vivo with colchicine in order to prevent
axonal transport of CRH, thereby concentrating the CRH in the cells. It is also
standard procedure in most labs to perfuse animals rather than post-fix the brain
tissue. These techniques may be necessary to determine the extent of 5-HT1A
receptor-mediated pERK on CRH-containing cells in both peripubertal and adult
PVN. Despite these issues, we have gathered some preliminary data (not shown)
that indicates that 5-HT1A receptor-mediated activation of ERK can occur on
CRH-containing cells in the peripubertal PVN.

5-HT1A receptor-mediated

increases in pERK immunoreactivity may extensively colocalize with CRH
immunoreactivity, since 70% of cells immunopositive for CRH have been shown
to express prolactin-induced ERK activation (Blume et al., 2009).

If 5-HT1A

receptor-mediated pERK extensively localizes to cells that are immunoreactive
for CRH, then it could be possible that ERK activation could potentially lead to 5HT1A receptor-mediated plasma levels of ACTH in the peripubertal age group
(i.e., 5-HT1A receptor-mediated pathways are dependent on one another in CRHcontaining cells in the peripubertal PVN). Furthermore, if we were to find that
ERK is necessary for SSRI-induced desensitization of 5-HT1A receptor-mediated
increases in plasma oxytocin and ACTH responses in the peripubertal PVN,
CRH cells could have the capacity to send out projections or a local agent to
regulate nearby oxytocin-containing cells and their outputs to the pituitary gland
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while using an intracellular mechanism to desensitize CRH-containing cell
outputs. Potentially, the small population of cells in the PVN that contain 5-HT1A
receptor-mediated pERK could exert a wide range of control over multiple cell
subtypes within the PVN and in other areas of the hypothalamus.

CHAPTER 6
INITIAL IDENTIFICATION OF IN VIVO SEROTONIN 1A RECEPTOR
ACTIVATION OF PROTEIN KINASE B (AKT) IN THE HYPOTHALAMIC
PARAVENTRICULAR NUCLEUS OF PERIPUBERTAL RATS.
ABSTRACT
Protein kinase B (Akt) and its downstream signaling effector glycogen
synthase kinase 3β (GSK3β) have been associated with cell survival and may
represent a common target for antidepressants and other drugs used to treat
mood disorders (Beaulieu et al., 2009). Serotonin 1A (5-HT1A) receptor agonists
increase levels of phosphorylated Akt (pAkt) in several cell lines (Adayev et al.,
1999; Cowen et al., 2005; Hsiung et al., 2005) and in adult hippocampus in vivo
(Polter et al., 2010). To date, no preclinical studies have determined 5-HT1A
receptor-mediated activation of the Akt signal transduction pathway in the
hypothalamus in any age group.

Since hypothalamic dysfunction has been

observed in studies of childhood and adolescent stress and depression
(Vaillancourt et al., 2007; Lopez-Duran et al., 2009; Vigil et al., 2010; Hankin et al.,
2010), the present studies investigated 5-HT1A receptor signaling of the Akt
signaling pathway in the peripubertal hypothalamic paraventricular nucleus
(PVN) with respect to: (1) the onset and longevity of increases in pAkt at two
activating residues (Thr308 and Ser473) by two different classes of 5-HT1A
144
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receptor agonists, (2) potential agonist-dependent differences in the potency and
efficacy of different 5-HT1A receptor agonists to phosphorylate Akt at each of the
respective phosphorylation sites, (3) the 5- HT1A receptor selectivity of (+)8-OHDPAT-mediated increases of pAkt, (4) the potential role of pertussis toxinsensitive Gα protein subtypes in 5-HT1A receptor-mediated increases of pAkt, (5)
the effects of chronic (7 and 14 days) fluoxetine (FLX) on 5-HT1A receptormediated increases in phosphorylated Akt, and (6) the effects of chronic (7 and
14 days) FLX on 5-HT1A receptor-mediated increases in GSK3β.
Together, these data provide the first in vivo demonstration in the
peripubertal PVN that 5-HT1A receptors can activate Akt via phosphorylation at
both Thr308 and Ser473. Given the previous studies demonstrating that 5-HT1A
receptors can stimulate hormone responses and also activate ERK in the
peripubertal PVN (Chapter 3), these findings are the first to show that 5-HT1A
receptors can mediate the concomitant activation of three signaling pathways in
peripubertal hypothalamic PVN. (+)8-OH-DPAT had full agonist activity and
tandospirone only partial agonist activity on the phosphorylation of Akt at both
Thr308 and Ser473, despite these both drugs displaying full agonist activity at 5HT1A receptor-mediated neuroendocrine responses and ERK activation in the
peripubertal PVN (Chapter 3). With regards to receptor selectivity, pretreatment
with the 5-HT1A receptor antagonist WAY100635 completely blocked (+)8-OHDPAT-induced elevations of pAkt at Ser473 in the PVN. Intra-PVN injection of
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pertussis toxin (which only reduced Gαi1 and Gα2 proteins in the peripubertal
hypothalamus, see Chapter 4) precluded any significant increase in (+)8-OHDPAT-induced phosphorylation of Akt (at Ser473) compared to its respective
basal level. Therefore, Gαi1 and Gαi2 may play a role in Akt phosphorylation;
however, since pertussis toxin also produced a non-significant 23% increase in
basal levels of phosphorylated Akt at Ser473, this could have precluded
obtaining a significant (+)8-OH-DPAT-induced increase above basal levels.
Lastly, chronic FLX does not alter basal levels of Akt, basal levels of GSK3β, or 5HT1A receptor-mediated activation of Akt. However, chronic FLX can selectively
regulate 5-HT1A receptor-mediated phosphorylation of GSK3β, implicating
phosphatases or a unique mechanism in FLX-induced GSK3β desensitization in
the peripubertal PVN.
INTRODUCTION
Akt (protein kinase B) is a protein kinase involved in cell survival, apoptosis,
protein synthesis, insulin signaling, and glucose transport (Franke et al., 2003).
Receptor tyrosine kinases (RTKs) typically initiate the activation of Akt, although
stimulation of G protein coupled receptors such as dopamine D2 receptors
(Beaulieu et al., 2005) and 5-HT1A receptors (Adayev et al., 1999; Cowen et al.,
2005; Hsiung et al., 2005) has recently been shown to activate this pathway in
vitro. Receptor activation stimulates phosphoinositide 3-kinase (PI3K) to catalyze
the formation of phosphatidylinoisitol(3,4,5)P3 (PIP3). PIP3 binds to and brings
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phosphoinositide-dependent kinase 1 (PDK1) and Akt into close proximity at the
cell membrane, where PDK1 then phosphorylates Akt at Thr308 (Alessi et al.,
1997; Anderson et al., 1998; Stephens et al., 1998). Akt is also phosphorylated in
the hydrophobic motif at Ser473 by a complex containing rictor and mTOR
proteins (Sarbossov et al., 2005).

Although the exact sequence of Akt

phosphorylation at Thr308 and Ser473 is still under investigation and is likely to
differ with respect to brain region and cell type, both sites must be
phosphorylated in order for Akt to be fully activated (Alessi et al., 1996;
Andjelkovic et al., 1996).

Downstream, activated Akt phosphorylates and

inhibits glycogen synthase kinase 3 (GSK3) (Cross et al., 1995), an enzyme that
regulates the function of a multitude of proteins, including metabolic, signaling,
and structural proteins (Grimes and Jope 2001).

GSK3 exists in 2 isoforms,

GSK3α and GSK3β, and are both constitutively active until phosphorylation by
Akt (Woodgett 1990; Sutherland et al., 1993). Although both isoforms are highly
expressed in brain (Woodgett 1990), GSK3β has received particular attention due
to the ability of lithium and other drugs used to treat bipolar and other mood
disorders to phosphorylate and inactivate GSK3β (Klein and Melton 1996;
DeSarno et al 2002; Zhang et al., 2003; Gould et al., 2004; O’Brien et al., 2004; Li et
al., 2007; Fatemi et al., 2009).
Dysfunction of the PI3K/Akt/GSK3 pathway has been implicated in the
pathology of psychological disorders including chronic stress, depression, and
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schizophrenia (Beaulieu et al., 2009). For example, the activity of PI3K and Akt
were significantly decreased in the occipital cortex of suicide victims (with no
recent psychotropic drug consumption) compared to controls (Hsiung et al.,
2003).

In addition, decreases were observed in the activity of Akt (with

subsequent increased activation of GSK3) in schizophrenic patients (Emamian et
al., 2004) and in a mouse model of schizophrenia (Beaulieu et al., 2004). In a rat
model of chronic stress, levels of pAkt were increased in the hypothalamus,
hippocampus, and striatum, with the largest increases observed in the
hypothalamus (Lee et al., 2006), a region containing 5-HT1A receptors that
stimulate hormone responses and activate ERK, but have yet to be studied with
respect to Akt activation.
5-HT1A receptors can activate the PI3K/Akt/GSK3 pathway in vitro and in
vivo. 5-HT1A receptors increase the phosphorylation of Akt in both neuronal
(Adayev et al., 1999; Cowen et al., 2005) and non-neuronal (Hsiung et al., 2005)
cell cultures. The 5-HT1A receptor agonist 8-OH-DPAT has recently been shown
to increase the levels of phosphorylated Akt and GSK3β in vivo in the adult
hippocampus, although the specificity of 5-HT1A receptors for this response has
yet to be determined (Polter et al., 2010 and personal communications). Acute
SSRI treatment increases levels of phosphorylated GSK3β in mouse frontal
cortex, hippocampus, and striatum, which is thought to be due to increased
levels of 5-HT stimulating post-synaptic 5-HT1A receptors to mediate subsequent

activation of Akt (Li et al., 2004). These data indicate that 5-HT1A
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receptors in

vivo likely activate the Akt signaling pathway in the brain and that this signaling
cascade may be involved with the effects of antidepressants.
5-HT1A receptor-mediated phosphorylation of Akt and its downstream target
GSK3β has not been demonstrated in the hypothalamus in an in vivo model.
Given the potential role of Akt in stress responses and effects of antidepressants,
the present studies investigated 5-HT1A receptor signaling of the Akt signaling
pathway in the peripubertal PVN with respect to: (1) the onset and longevity of
5-HT1A receptor-induced phosphorylation of Akt at Thr308 and Ser473 by two
classes of 5-HT1A receptor agonists, (2) potential agonist-dependent differences in
the potency and efficacy of different 5-HT1A receptor agonists to phosphorylated
Akt at each of its respective phosphorylation sites, (3) the 5-HT1A receptor
selectivity of (+)8-OH-DPAT-mediated increases in pAkt, (4) the potential role of
pertussis toxin-sensitive Gα protein subtypes in 5-HT1A receptor-mediated
increases in pAkt, (5) the effects of chronic (7 and 14 days) FLX on 5-HT1A
receptor-mediated phosphorylation of Akt, and (6) the effects of chronic (7 and
14 days) FLX on 5-HT1A receptor-mediated phosphorylation of GSK3β.
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MATERIALS AND EXPERIMENTAL PROCEDURES (for detailed methods,
see Chapter 7)
Animals. Peripubertal male Sprague-Dawley rats (100-125 g) were purchased
from Harlan (Indianapolis, IN). The determination of post-natal day zero (day of
birth) was carried out by the supplier.
Drugs. (+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide [(+)8-OHDPAT] was purchased from Tocris Cookson Inc. (Ellisville, MO). Tandospirone
citrate was a generous gift of Dr. K. Matusubara, Asahikawa Medical College,
Japan. (+)8-OH-DPAT and tandospirone were dissolved in saline (0.9% NaCl)
and were injected at a volume of 1 ml/kg. For the dose-response experiment, the
highest dose of drug was dissolved in saline and lower concentrations were
made by serial dilution.

N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-N-2-

pyridinylcyclohexanecarboxamide maleate salt (WAY100635) was purchased
from Sigma (catalog number W108), and was dissolved in saline (0.9% NaCl) and
injected at a volume of 1 ml/kg. Pertussis toxin (PTX; Bordetella pertussis) was
purchased from EMD Chemicals, Gibbstown, NJ (catalog number 516560), and
was diluted to a concentration of 1 μg/μl with ddH2O. Fluoxetine hydrochloride
was purchased from LKT Laboratories, Inc., St. Paul, MN (catalog number
F4780), and was dissolved in saline (0.9% NaCl) to 10 mg/kg and was injected at
a volume of 2 ml/kg. All drugs were freshly prepared immediately prior to the
injections.
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Experiment 1: Time-dependent 5-HT1A receptor-mediated phosphorylation of
Akt at Thr308 and Ser473. At least 3 days of handling preceded any injections.
Peripubertal male Sprague-Dawley rats (post-natal day 42) were injected with
either saline (1 ml/kg, s.c.), the aminotetralin agonist (+)8-OH-DPAT (0.20
mg/kg, s.c.), or the azapirone agonist tandospirone (10 mg/kg, s.c.).

The

animals were sacrificed by decapitation at 5, 10, 15, 20, or 30 minutes postinjection. The brains were carefully removed from the skull within one minute of
the decapitation and were quickly frozen by submersion in chilled 2methylbutane (-35°C) for 1 minute and then subsequently kept in dry ice for an
additional 10 minutes. Each brain was then securely wrapped and stored at
-80°C prior to dissection for Western blot studies for the determination of
pAkt/Akt levels in the PVN.
Experiment 2: Dose-dependent 5-HT1A receptor-mediated phosphorylation of
Akt at Thr308 and Ser473. At least 3 days of handling preceded any injections.
Peripubertal male Sprague-Dawley rats (post-natal day 42) were injected with
either saline (1 ml/kg, s.c.), (+)8-OH-DPAT (0.04, 0.10, 0.20, or 0.50 mg/kg, s.c.),
or tandospirone (1, 3, 10, or 20 mg/kg, s.c.) and were sacrificed by decapitation at
10 minutes post-injection. The brains were carefully removed from the skull
within one minute of the decapitation and were quickly frozen by submersion in
chilled 2-methylbutane (-35°C) for 1 minute and then subsequently kept in dry
ice for an additional 10 minutes. Each brain was then securely wrapped and
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stored at -80°C prior to dissection for Western blot studies for the determination
of pAkt/Akt levels in the PVN.
Experiment 3:

Determination of 5-HT1A receptor specificity of (+)8-OH-

DPAT-mediated phosphorylation of Akt at Ser473. At least 3 days of handling
preceded any injections. Peripubertal male Sprague-Dawley rats (post-natal day
47) were injected with either saline (1 ml/kg, s.c.) or the 5-HT1A receptor
antagonist WAY100635 (0.10 mg/kg, s.c.) 30 minutes prior to a challenge
injection with either saline (1 ml/kg, s.c.) or (+)8-OH-DPAT (0.20 mg/kg, s.c.).
The animals were sacrificed by decapitation at 15 minutes post-injection. The
brains were carefully removed from the skull within one minute of the
decapitation and were quickly frozen by submersion in chilled 2-methylbutane (35°C) for 1 minute and then subsequently kept in dry ice for an additional 10
minutes. Each brain was then securely wrapped and stored at -80°C prior to
dissection for Western blot studies for the determination of pAkt/Akt levels in
the PVN.
Experiment 4: Determination of the role of PTX-sensitive Gα proteins in 5HT1A receptor-mediated phosphorylation of Akt at Ser473 in the peripubertal
PVN.

Cannula implantation and administration of PTX was performed

according to procedures previously established in adult rats (Garcia et al., 2006),
and detailed in Chapter 7. Seventy-two hours after intracerebral injection of
vehicle (100 mM sodium phosphate + 500 mM NaCl, 0.5 μl/side) or PTX (1
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μg/μl, 0.5 μl/side), the rats were given a systemic challenge injection of saline (1
ml/kg) or (+)8-OH-DPAT (0.20 mg/kg) and were sacrificed by decapitation 15
minutes later (postnatal day 42). The brains were carefully removed from the
skull within one minute of the decapitation and were quickly frozen by
submersion in chilled 2-methylbutane (-35°C) for 1 minute and then
subsequently kept in dry ice for an additional 10 minutes. Each brain was then
securely wrapped and stored at -80°C prior to dissection for Western blot studies
for the determination of pAkt/Akt levels in the PVN.
Experiment 5: Determination of chronic FLX-induced effects on (A) basal and
5-HT1A receptor-mediated increases of pAkt (Thr308) and (B) basal and 5-HT1A
receptor-mediated increases pGSK3β in the peripubertal PVN. Rats were given
an i.p. injection of saline (2 ml/kg) or FLX (10 mg/kg), once per day for either 7
(PD 35-41) or 14 days (PD 28-41). Eighteen hours after the last injection, the rats
(postnatal day 42) were given a systemic challenge injection of saline (1 ml/kg)
or (+)8-OH-DPAT (0.2 mg/kg) and were sacrificed by decapitation 10 minutes
later. The brains were carefully removed from the skull within one minute of the
decapitation.

The brains were quickly frozen by submersion in chilled

isopentane for 1 minute and then subsequently kept in dry ice for an additional
10 minutes. Each brain was then securely wrapped and stored at -80°C prior to
dissection for Western blot studies for the determination of pAkt (Thr308)/Akt
and pGSK3β/GSK3β levels in the PVN.
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RESULTS
1. Experiment 1: 5-HT1A receptor-mediated time-dependent phosphorylation of
Akt at Thr 308 and Ser473. The specific objectives of this experiment were to: (1)
determine the onset and longevity of the 5-HT1A receptor-mediated increases in
(A) pAkt at Thr308 and (B) pAkt at Ser473 in PVN; and (2) identify potential
differences in onset and longevity of the different 5-HT1A receptor agonists to
increase (A) pAkt at Thr308 and (B) pAkt at Ser473 in PVN.
A. Time-course of (+)8-OH-DPAT-induced increases in pAkt (Thr308) in the
peripubertal rat. As shown in figure 34, a single injection of (+)8-OH-DPAT (0.20
mg/kg) produced rapid (≤ 5 minutes) and prolonged increases in pAkt at Thr308.
The magnitude of elevation of (+)8-OH-DPAT-induced pAkt at Thr308 was
about 300% over saline baseline.
The two-way ANOVA for (+)8-OH-DPAT-induced increases in pAkt (Thr308)
in the PVN indicated a significant main effect of challenge drug (saline or (+)8OH-DPAT) [F1,78 = 53.74, p < 0.0001] but no significant main effect of postinjection time [F4,78 = 1.19, p = 0.3219]. There was also no significant interaction
between challenge drug and post-injection time [F4,78 = 1.19, p = 0.3219]. A
Newman-Keuls’ test indicated that (+)8-OH-DPAT increased pAkt at Thr308 in
the PVN over saline at 5, 10, and 15 minutes (p < 0.01), and 20 minutes (p < 0.05).
B.

Time-course of tandospirone-induced increases in pAkt (Thr308) in the

peripubertal rat. As shown in figure 35, a single injection of tandospirone (10
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mg/kg) produced rapid (≤ 5 minutes) and prolonged increases in pAkt at Thr308.
However, the magnitude of elevation of pAkt at Thr308 over saline induced by
(+)8-OH-DPAT was much greater (↑300%, figure 34) than that induced by
tandospirone (↑85%).
The two-way ANOVA for tandospirone-induced increases in pAkt (Thr308)
in the PVN indicated a significant main effect of challenge drug (saline or
tandospirone) [F1,78 = 16.551, p = 0.0001] but no significant main effect of postinjection time [F4,78 = 0.38, p = 0.8200]. There was also no significant interaction
between challenge drug and post-injection time [F4,78 = 0.38, p = 0.8200]. A
Newman-Keuls’ test indicated that tandospirone increased pAkt at Thr308 in the
PVN over saline at 10 minutes (p < 0.05).
C. Time-course of (+)8-OH-DPAT-induced increases in pAkt (Ser473) in the
peripubertal rat. As shown in figure 36, a single injection of (+)8-OH-DPAT (0.20
mg/kg) produced a rapid (≤ 5 minutes) increase (~↑60% over saline) in pAkt at
Ser473 that returned to baseline by 30 minutes post-injection.
The two-way ANOVA for (+)8-OH-DPAT-induced increases in pAkt (Ser473)
in the PVN indicated a significant main effect of challenge drug (saline or (+)8OH-DPAT) [F1,79 = 27.33, p < 0.0001] but no significant main effect of postinjection time [F4,79 = 1.63, p = 0.1771]. There was also no significant interaction
between challenge drug and post-injection time [F4,79 = 1.63, p = 0.1771]. A
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Newman-Keuls’ test indicated that (+)8-OH-DPAT increased pAkt at Ser473 in
the PVN over saline at 5 and 10 minutes (p < 0.01), and 15 minutes (p < 0.05).
D.

Time-course of tandospirone-induced increases in pAkt (Ser473) in the

peripubertal rat. As shown in figure 37, a single injection of tandospirone (10
mg/kg) produced a rapid (≤ 5 minutes) increase (~↑60% over saline) in pAkt at
Ser473 that was comparable in magnitude than that induced by (+)8-OH-DPAT
(figure 36).
The two-way ANOVA for tandospirone-induced increases in pAkt (Ser473) in
the PVN indicated a significant main effect of challenge drug (saline or
tandospirone) [F1,78 = 17.97, p < 0.0001] but no significant main effect of postinjection time [F4,78 = 0.77, p = 0.5480]. There was also no significant interaction
between challenge drug and post-injection time [F4,78 = 0.77, p = 0.5480]. A
Newman-Keuls’ test indicated that tandospirone increased pAkt at Ser473 in the
PVN over saline at 10 minutes (p < 0.05) post-injection.
2. Experiment 2: Dose-dependent 5-HT1A receptor-mediated phosphorylation of
Akt at Thr308 and Ser473 in the peripubertal hypothalamic PVN. The objectives
of this experiment were: to determine potency and efficacy of agonists from
different structural drug classes ((+)8-OH-DPAT, an aminotetralin and
tandospirone, an azapirone) on (A) phosphorylation of Akt at Thr308 and (B)
phosphorylation of Akt at Ser473 in the PVN.
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A. Effects of different doses of (+)8-OH-DPAT on levels of phosphorylated Akt
at Thr308 in peripubertal rat hypothalamic PVN. As shown in figure 38, (+)8OH-DPAT dose-dependently increased levels of pAkt (Thr308) over salinechallenged peripubertal rats. The phosphorylation of Akt at Thr308 induced by
(+)8-OH-DPAT reached levels around 3.5 fold over basal.
The two-way ANOVA for (+)8-OH-DPAT-induced increases in pAkt (Thr308)
in the PVN indicated a significant main effect of challenge drug (saline or (+)8OH-DPAT) [F1,71 = 69.44, p < 0.0001] and a significant main effect of agonist dose
[F3,71 = 12.24, p < 0.0001].

There was also a significant interaction between

challenge drug and agonist dose [F3,71 = 12.24, p < 0.0001]. A Newman-Keuls’
test indicated that (+)8-OH-DPAT increased levels of pAkt (Thr308) in the PVN
over saline at 0.10, 0.20, and 0.50 mg/kg (p < 0.01).
B. Effects of different doses of tandospirone on levels of phosphorylated Akt at
Thr308 in peripubertal rat hypothalamic PVN. As shown in figure 39, most
tested doses of tandospirone maximally increased levels of pAkt (Thr308) over
saline-challenged peripubertal rats (to about 2.5 fold over basal). The maximal
phosphorylation of Akt at Thr308 induced by (+)8-OH-DPAT was higher (~3.5
fold over basal) than tandospirone (~2.5 fold over basal). (+)8-OH-DPAT was
also more potent in phosphorylating Akt at Thr308 (figure 38).
The two-way ANOVA for tandospirone-induced increases in pAkt (Thr308)
in the PVN indicated a significant main effect of challenge drug (saline or
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tandospirone) [F1,71 = 104.89, p < 0.0001] but no significant main effect of agonist
dose (although there was a trend towards significance) [F3,71 = 2.46, p = 0.703].
There was also no significant interaction (although a trend towards significance)
between challenge drug and agonist dose [F3,71 = 2.46, p = 0.703]. A NewmanKeuls’ test indicated that tandospirone increased levels of pAkt (Thr308) in the
PVN over saline at 1 mg/kg (p < 0.05) and at 3, 10, and 20 mg/kg (p < 0.01).
C. Effects of different doses of (+)8-OH-DPAT on levels of phosphorylated Akt
at Ser473 in peripubertal rat hypothalamic PVN. As shown in figure 40, (+)8OH-DPAT dose-dependently increased levels of pAkt (Ser473) over salinechallenged peripubertal rats. (+)8-OH-DPAT increased the phosphorylation of
Akt at Ser473 ~1.75 fold over basal.
The two-way ANOVA for (+)8-OH-DPAT-induced pAkt (Ser473) in the PVN
indicated a significant main effect of challenge drug (saline or (+)8-OH-DPAT)
[F1,71 = 20.55, p < 0.0001] and a significant main effect of agonist dose [F3,71 = 6.37,
p = 0.0008]. There was also a significant interaction between challenge drug and
agonist dose [F3,71 = 6.37, p = 0.0008]. A Newman-Keuls’ test indicated that (+)8OH-DPAT at 0.50 mg/kg increased levels of pAkt (Ser473) in the PVN over
saline (p < 0.01).
D. Effects of different doses of tandospirone on levels of phosphorylated Akt at
Ser473 in peripubertal rat hypothalamic PVN. As shown in figure 41, most
tested doses of tandospirone maximally increased levels of pAkt (Ser473) over
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saline-challenged peripubertal rats (~1.4 fold over basal). (+)8-OH-DPAT was
more potent than tandospirone for this response and had a higher maximal level
of pAkt (Ser473) (~1.75 fold vs. ~1.4 fold over basal) (figure 40).
The two-way ANOVA for tandospirone-induced increases in pAkt (Ser473) in
the PVN indicated a significant main effect of challenge drug (saline or
tandospirone) [F1,71 = 21.97, p < 0.0001] but no significant main effect of agonist
dose [F3,71 = 1.16, p = 0.3307]. There was also no significant interaction between
challenge drug and agonist dose [F3,71 = 1.16, p = 0.3307]. A Newman-Keuls’ test
indicated that tandospirone at 3, 10, and 20 mg/kg increased levels of pAkt
(Ser473) in the PVN over saline (p < 0.05).
3. Experiment 3: Determination of 5-HT1A receptor specificity for (+)8-OHDPAT-mediated phosphorylation of Akt at Ser473.
experiment

was

to

administer

a

specific

5-HT1A

The objective of this
receptor

antagonist

(WAY100635) to block receptor activation to determine if (+)8-OH-DPAT is
acting specifically through 5-HT1A receptors (and not any other subtype of 5-HT
receptors, e.g., 5-HT7) to induce increases of pAkt at Ser473 in the peripubertal
PVN. 5-HT1A receptor-mediated phosphorylation at Ser473 was the focus of this
experiment, since there is some evidence that the phosphorylation of Akt at
Ser473 by the mTOR complex occurs prior to the recruitment of Akt to the
plasma membrane and subsequent phosphorylation at Thr308 by its upstream
kinase PDK1 (Sarbossov et al., 2005).

A.

Effects of WAY100635 treatment on basal and 5-HT1A
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receptor-mediated

increases in levels of pAkt (Ser473) in PVN. As shown in figure 42, (+)8-OHDPAT significantly increased pAkt (Ser473) in the PVN by about 50% over saline.
Treatment with the 5-HT1A receptor antagonist WAY100635 prior to challenge
injection completely blocks (+)8-OH-DPAT-mediated increases in pAkt (Ser473)
in the PVN. WAY100635 had no affect on basal levels of pAkt (Ser473) in the
PVN.
The two-way ANOVA for levels of pAkt (Ser473) in the PVN indicated no
main effect of WAY100635 treatment [F1,25 = 2.73, p = 0.1129] and no significant
main effect of challenge injection [F1,25 = 3.39, p = 0.0791]. However, there was a
significant interaction between treatment and challenge injection [F1,25 = 7.02, p =
0.0147]. The Newman-Keuls’ test indicated that saline treatment/(+)8-OH-DPAT
challenge significantly elevated pAkt (Ser473) in the PVN over the salinetreated/saline-challenged group (p < 0.05) and also that WAY100635 treatment
completely blocked 5-HT1A receptor-induced increases in pAkt (Ser473) in the
peripubertal PVN (p < 0.05).
4. Experiment 4: Determination of the role of PTX-sensitive Gα proteins in 5HT1A receptor-mediated phosphorylation of Akt at Ser473 in the peripubertal
PVN. 5-HT1A receptor-mediated activation of Akt has been shown to be blocked
with pertussis toxin (PTX) in hippocampal cell cultures (Cowen et al, 2005),
indicating that this response may be mediated by PTX-sensitive Gi/o proteins.
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The objective of this experiment was to use PTX to functionally inactivate Gαi/o
proteins (as previously demonstrated in adult rats, Garcia et al., 2006) to
determine if this subset of proteins plays a role in 5-HT1A receptor-mediated
increases of pAkt at Ser473 in the peripubertal PVN. Intra-PVN injection with
PTX decreased levels of Gαi1 and Gαi2, increased levels of Gαo, and had no
effect on levels of Gαi3 and Gαz in the peripubertal hypothalamus (Chapter 4).
5-HT1A receptor-mediated phosphorylation at Ser473 was the focus of this
experiment, as there is some evidence that the phosphorylation of Akt at Ser473
by the mTOR complex occurs prior to the recruitment of Akt to the plasma
membrane and subsequent phosphorylation at Thr308 by its upstream kinase
PDK1 (Sarbossov et al., 2005).
A. Effects of PTX treatment on basal and 5-HT1A receptor-mediated increases in
levels of pAkt (Ser473) in PVN. As shown in figure 43, (+)8-OH-DPAT increased
pAkt (Ser473) in the PVN by about 50% over basal in vehicle-treated rats. In rats
treated with PTX, however, 5-HT1A receptor-mediated increases in pAkt (Ser473)
were not significantly elevated over its respective basal (↑24%). However, PTX
also produced an increase in the basal levels of pAkt (Ser473) (↑23%) in the PVN
that precludes any further increase by 5-HT1A receptor stimulation.
The two-way ANOVA for levels of pAkt (Ser473) in the PVN indicated no
main effect of PTX treatment [F1,37 = 0.28, p = 0.5998] but a significant main effect
of challenge injection [F1,37 = 11.27, p = 0.0020].

There was no significant

interaction between treatment and challenge injection [F1,37
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= 1.55, p = 0.2220].

Although the basal levels of phosphorylated Akt (Ser473) in the PVN increased
by about 23% with PTX treatment, this did not reach statistical significance, nor
did 5-HT1A receptor-stimulated elevations of pAkt in the PTX-treated group
(↑24% over its respective basal and 45% over the vehicle-treated/salinechallenged

group).

The

Newman-Keuls’

test

indicated

that

vehicle

treatment/(+)8-OH-DPAT challenge significantly elevated pAkt (Ser473) in the
PVN over the vehicle-treated/saline-challenged group (p < 0.05) and that PTX
treatment/(+)8-OH-DPAT challenge significantly elevated pAkt (Ser473) in the
PVN over the vehicle-treated/saline-challenged group (p < 0.05).
5. Experiment 5: Determination of chronic FLX-induced effects on (A) basal and
5-HT1A receptor-mediated increases of pAkt (Thr308) and (B) basal and 5-HT1A
receptor-mediated increases of pGSK3β in the peripubertal PVN. Acute injection
with fluoxetine has been shown to increase levels of pGSK3β in the mouse
prefrontal cortex, hippocampus, and striatum, most likely due to the activation
of 5-HT1A receptors (Li et al., 2004). The objective of this experiment was to
determine if chronic FLX injections (once per day for 7 or 14 days) have any
effects on basal or 5-HT1A receptor-mediated pAkt and basal or 5-HT1A receptormediated pGSK3β responses in the peripubertal PVN. The activation of Akt via
phosphorylation at Thr308 was measured, as (+)8-OH-DPAT induced a
phosphorylation of Akt at Thr308 that was greater compared to Ser473 (see dose-
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response experiment, experiment 2 of this chapter), and thus may be more
sensitive to detect changes induced by chronic FLX.
A. Effects of FLX treatment on basal and 5-HT1A receptor-mediated increases in
levels of pAkt (Thr308) in PVN. As shown in figure 44, in the rats treated for 7
days with saline (PD 35-41), (+)8-OH-DPAT increased pAkt (Thr308) in the PVN
(↑313%), consistent with data from experiment 1 of this chapter. (+)8-OH-DPAT
challenge after treatment for 14 days with saline (PD 28-41) increased pAkt
(Thr308) in the PVN, although this response was not as robust (↑109%). For both
7D and 14D chronic treatments, FLX had no significant effect on (+)8-OH-DPATinduced increases in pAkt (Thr308). There was also a non-significant increase
(↑70%) in basal levels of pAkt (Thr308) with 7D FLX.
The two-way ANOVA for levels of pAkt (Thr308) in the PVN indicated no
main effect of 7 days of FLX treatment [F1,22 = 0.02, p = 0.8993] but a significant
main effect of challenge injection [F1,22 = 48.25, p < 0.0001].

There was a

significant interaction between treatment and challenge injection [F1,22 = 4.68, p =
0.0435]. The Newman-Keuls’ test indicated that saline treatment/(+)8-OH-DPAT
challenge significantly elevated pAkt (Thr308) in the PVN over the salinetreated/saline-challenged group (p < 0.01) and also that 7D FLX treatment/(+)8OH-DPAT challenge significantly elevated pAkt (Thr308) in the PVN over the 7D
FLX-treated/saline-challenged

group.

Although

the

basal

levels

of
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phosphorylated Akt (Thr308) in the PVN increased by about 70% with 7 days of
FLX treatment, this did not reach statistical significance.
The two-way ANOVA for levels of pAkt (Thr308) in the PVN indicated no
main effect of 14 days of FLX treatment [F1,23 = 0.04, p = 0.8389] but a significant
main effect of challenge injection [F1,23 = 9.25, p = 0.0064].

There was no

significant interaction between treatment and challenge injection [F1,23 = 0.06, p =
0.8101]. Although the (+)8-OH-DPAT increased levels of phosphorylated Akt
(Thr308) in the PVN in both 14D saline-treated (↑109%) and 14D FLX-treated
(↑92%), this did not reach statistical significance in the Neuman-Keuls post-hoc
test.
B. Effects of FLX treatment on basal and 5-HT1A receptor-mediated increases in
levels of pGSK3β in PVN. As shown in figure 45, (+)8-OH-DPAT increased
pGSK3β in the PVN of rats treated for 7 days with saline (↑114%) and in rats
treated for 14 days with saline (↑150%). Seven days of chronic FLX significantly
attenuated (+)8-OH-DPAT-induced increases (to only 30% over basal) in pGSK3β,
and 14D FLX partially attenuated (+)8-OH-DPAT-induced increases (to 80% over
basal) in pGSK3β.
The two-way ANOVA for levels of pGSK3β in the PVN indicated no main
effect of 7 days of FLX treatment [F1,23 = 2.26, p = 0.1480] but a significant main
effect of challenge injection [F1,23 = 10.35, p = 0.0043]. There was a trend towards
a significant interaction between treatment and challenge injection [F1,23 = 3.29, p
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= 0.0846]. The Newman-Keuls’ test indicated that saline treatment/(+)8-OHDPAT challenge significantly elevated pGSK3β in the PVN over the salinetreated/saline-challenged group (p < 0.01).

Seven days FLX treatment

significantly attenuated increases in pGSK3β induced by (+)8-OH-DPAT
challenge compared to chronic saline treatment (p < 0.05).
The two-way ANOVA for levels of pGSK3β in the PVN indicated no main
effect of 14 days of FLX treatment [F1,23 = 1.48, p = 0.2384] but a significant main
effect of challenge injection [F1,23 = 20.68, p = 0.0002]. There was no significant
interaction between treatment and challenge injection [F1,23 = 1.77, p = 0.1984].
The Newman-Keuls’ test indicated that (+)8-OH-DPAT challenge significantly
elevated pGSK3β in the PVN over the saline challenge in both the 14D salinetreated (p < 0.01) and 14D FLX-treated (p < 0.05) groups.
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Figure 34. (A) Time-course of (+)8-OH-DPAT-induced elevations of pAkt at Thr308 in
peripubertal rat hypothalamic PVN. *, ** indicates significant difference (p < 0.05 and p < 0.01,
respectively) from the saline-challenged group (two-way ANOVA and Newman-Keuls multiplerange test). N = 7-8 per group. (B) Representative western blot of pAkt (Thr308) (above) and Akt
(below) from the PVN of rats treated with either saline or (+)8-OH-DPAT.
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Figure 35. (A) Time-course of tandospirone-induced elevations of pAkt at Thr308 in peripubertal
rat hypothalamic PVN. * indicates significant difference (p < 0.05) from the saline-challenged
group (two-way ANOVA and Newman-Keuls multiple-range test). N = 7-8 per group. (B)
Representative western blot of pAkt (Thr308) (above) and Akt (below) from the PVN of rats
treated with either saline or tandospirone.
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Figure 36. (A) Time-course of (+)8-OH-DPAT-induced increases in phosphorylated Akt at Ser473
in the peripubertal rat hypothalamic PVN. *, ** indicates significant difference (p < 0.05 and p <
0.01, respectively) from the saline-challenged group; + indicates significant difference (p < 0.05)
from 5 minute (+)8-OH-DPAT-challenged group (two-way ANOVA and Newman-Keuls
multiple-range test). N = 8 per group. (B) Representative western blot of pAkt (Ser473) (above)
and Akt (below) from the PVN of rats treated with either saline or (+)8-OH-DPAT.
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Figure 37. (A) Time-course of tandospirone-induced increases in phosphorylated Akt at Ser473 in
the peripubertal rat hypothalamic PVN. ** indicates significant difference (p < 0.01) from the
saline-challenged group (two-way ANOVA and Newman-Keuls multiple-range test). N = 7-8
per group. (B) Representative western blot of pAkt (Ser473) (above) and Akt (below) from the
PVN of rats treated with either saline or tandospirone.
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Figure 38. (A) Effects of different doses of (+)8-OH-DPAT on phosphorylation of Akt at Thr308 in
the peripubertal rat hypothalamic PVN at 10 minutes post-injection. ** indicates significant
difference (p < 0.01) from the saline-challenged group; +,++ indicates significant difference (p <
0.05 and p < 0.01, respectively) from the 0.04 mg/kg (+)8-OH-DPAT-challenged group; ##
indicates significant difference (p < 0.01) from the 0.10 mg/kg (+)8-OH-DPAT-challenged group
(two-way ANOVA and Newman-Keuls multiple-range test). N = 6-12 per group. (B)
Representative western blot of pAkt (Thr308) (above) and Akt (below) from the PVN of rats
treated with either saline or (+)8-OH-DPAT.
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Figure 39. (A) Effects of different doses of tandospirone on phosphorylation of Akt at Thr308 in
the peripubertal rat hypothalamic PVN at 10 minutes post-injection. *, ** indicates significant
difference (p < 0.05 and p < 0.01, respectively) from the saline-challenged group; +, ++ indicates
significant difference (p < 0.05 and p < 0.01, respectively) from the 1 mg/kg tandospironechallenged group (two-way ANOVA and Newman-Keuls multiple-range test). N = 6-12 per
group. (B) Representative western blot of pAkt (Thr308) (above) and Akt (below) from the PVN
of rats treated with either saline or tandospirone.
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Figure 40. (A) Effects of different doses of (+)8-OH-DPAT on the phosphorylation of Akt at
Ser473 in the peripubertal rat hypothalamic PVN at 10 minutes post-injection. ** indicates
significant difference (p < 0.01) from the saline-challenged group; ++ indicates significant
difference (p < 0.01) from the 0.04 mg/kg (+)8-OH-DPAT-challenged group; ## indicates
significant difference (p < 0.01) from the 0.10 mg/kg (+)8-OH-DPAT-challenged group (two-way
ANOVA and Newman-Keuls multiple-range test). N = 6-12 per group. (B) Representative
western blot of pAkt (Ser473) (above) and Akt (below) from the PVN of rats treated with either
saline or (+)8-OH-DPAT.
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Figure 41. (A) Effects of different doses of tandospirone on the phosphorylation of Akt at Ser473
in the peripubertal rat hypothalamic PVN at 10 minutes post-injection. * indicates significant
difference (p < 0.05) from the saline-challenged group (two-way ANOVA and Newman-Keuls
multiple-range test). N = 6-12 per group. (B) Representative western blot of pAkt (Ser473) (above)
and Akt (below) from the PVN of rats treated with either saline or tandospirone.
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Figure 42. (A) The effects of either saline or the 5-HT1A receptor antagonist WAY100635 on basal
and 5-HT1A receptor-mediated increases in pAkt (Ser473) in the peripubertal rat hypothalamic
PVN. * indicates significant difference (p < 0.05) from the respective saline-challenged group; #
indicates significant difference (p < 0.05 from the saline treated/(+)8-OH-DPAT challenged
group (two-way ANOVA and Newman-Keuls multiple-range test). N = 6-8 per group. (B)
Representative western blot of pAkt (Ser473) (above) and Akt (below) from the PVN of rats
treated with saline or WAY100635 and subsequently challenged with either saline or (+)8-OHDPAT.
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Figure 43. (A) The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on
basal and 5-HT1A receptor-mediated increases in pAkt (Ser473) in the peripubertal rat
hypothalamic PVN. * indicates significant difference (p < 0.05) from the respective salinechallenged group (two-way ANOVA and Newman-Keuls multiple-range test). N = 6-12 per
group. (B) Representative western blot of pAkt (Ser473) (above) and Akt (below) from the PVN
of rats treated with vehicle or PTX and subsequently challenged with either saline or (+)8-OHDPAT.
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Figure 44. The effects of (A) 7 days and (B) 14 days of chronic FLX injections on basal and 5-HT1A
receptor-mediated increases in pAkt (Thr308) in the peripubertal rat hypothalamic PVN. **
indicates significant difference (p < 0.01) from the respective saline-challenged group (two-way
ANOVA and Newman-Keuls multiple-range test). N = 5-6 per group. (C) Representative western
blot of pAkt (Thr308) (above) and Akt (below) from the PVN of rats treated with sal or FLX and
subsequently challenged with either saline or (+)8-OH-DPAT. 7D treatment is on the left and
14D treatment is on the right.
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Figure 45. The effects of (A) 7 days and (B) 14 days of chronic FLX injections on basal and 5-HT1A
receptor-mediated increases in pGSK3β in the peripubertal rat hypothalamic PVN. *, ** indicates
significant difference (p < 0.05 and p < 0.01, respectively) from the respective saline-challenged
group; # indicates significant difference (p < 0.05) from the respective vehicle-treated group (twoway ANOVA and Newman-Keuls multiple-range test). N = 6 per group. (C) Representative
western blot of pGSK3β (above) and GSK3β (below) from the PVN of rats treated with sal or FLX
and subsequently challenged with either saline or (+)8-OH-DPAT. 7D treatment is on the left
and 14D treatment is on the right.
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DISCUSSION
Stressors suffered during childhood and adolescence (e.g., bullying, home
displacement as with Hurricane Katrina, and abuse) and mental disorders such
as depression have all been linked to hypothalamic dysfunction (Vaillancourt et
al., 2007; Lopez-Duran et al., 2009; Vigil et al., 2010; Hankin et al., 2010).
Preclinical studies have determined that, in a rat model of chronic stress, levels of
pAkt were increased in the hypothalamus, hippocampus, and striatum, with the
largest increases observed in the hypothalamus (Lee et al., 2006).

5-HT1A

receptor agonists have been shown to increase levels of phosphorylated Akt and
its downstream effectors in vitro (Adayev et al., 1999; Cowen et al., 2005; Hsiung
et al., 2005) and in vivo (Polter et al., 2010). The studies described in this chapter
provide the first demonstration that 5-HT1A receptors can activate Akt via
phosphorylation of Thr308 and Ser473 in the rat hypothalamus, and the first to
characterize this signal transduction pathway and its regulation by fluoxetine in
the peripubertal PVN.
Our data reveal that the agonist (+)8-OH-DPAT mediates phosphorylation of
Akt specifically via 5-HT1A receptors in the peripubertal PVN. (+)8-OH-DPAT
elevated levels of pAkt at Ser473 in the PVN, which was completely blocked by
pretreatment with the 5-HT1A receptor antagonist WAY100635. Recent evidence
reveals that phosphorylation of Akt at Ser473 (within the hydrophobic motif of
the protein) may promote recruitment of Akt to the plasma membrane and
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enhances the interaction between Akt and PDK1, leading to the subsequent
phosphorylation of Akt at Thr308 (Sarbossov et al., 2005). Therefore, we did not
measure levels of pAkt Thr308 in this experiment but, considering that
phosphorylation of Akt at Ser473 most likely precedes that of Thr308, we would
expect that (+)8-OH-DPAT-mediated increases in pAkt at Thr308 (as measured in
other experiments in this chapter) is primarily by 5-HT1A receptors.
Both Thr308 and Ser473 must be phosphorylated in order to fully activate Akt
(Alessi et al., 1996). Each of these sites is phosphorylated by different (and most
likely independently regulated) upstream kinases: PDK1 phosphorylates Thr308
(Alessi et al., 1997; Anderson et al., 1998; Stephens et al., 1998), and the
rictor/mTOR complex has recently been identified as the kinase for Ser473
(Sarbassov et al., 2005). We have shown that injection with two different 5-HT1A
receptor agonists, (+)8-OH-DPAT and tandospirone, resulted in a rapid
phosphorylation of Akt at both Thr308 and Ser473, although the magnitude of
phosphorylation varied with agonist. (+)8-OH-DPAT induced a higher maximal
effect and was more potent than tandospirone in phosphorylating Akt at both
Thr308 and Ser473. These data indicate that (+)8-OH-DPAT is a “full” agonist
and

tandospirone

a

“partial”

agonist

in

5-HT1A

receptor-mediated

phosphorylation of Akt in the peripubertal PVN. Therefore, (+)8-OH-DPAT may
more effectively couple to the pathway initiating PDK1 phosphorylation of Akt
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at Thr308 and the raptor/mTOR-mediated phosphorylation of Akt at Ser473 than
tandospirone.
A previous study had shown that 5-HT1A receptor-mediated activation of Akt
in hippocampal cell cultures can be blocked with pertussis toxin (PTX) treatment
(Cowen et al., 2005), indicating that 5-HT1A receptor-mediated activation of Akt
could be dependent on PTX-sensitive Gi/o proteins. In experiment 4 of this
chapter, we determined that intra-PVN injection with PTX prevented significant
elevations of 5-HT1A receptor-mediated phosphorylation of Akt at Ser473.
Therefore, since Gαi1 and Gα2 proteins were the only Gα proteins reduced with
PTX treatment (Chapter 4), these proteins may be playing a role in 5-HT1A
receptor-mediated phosphorylation of Akt. However, considering that

PTX

treatment also increased basal levels of phosphorylated Akt at Ser473, this could
have precluded obtaining a significant (+)8-OH-DPAT-induced increase above
basal. Therefore, we cannot rule out the possibility that 5-HT1A receptors may be
signaling via Gαi3, Gαo, or Gαz to mediate the phosphorylation and activation
of Akt in the peripubertal PVN.

Additionally, the PTX-induced increase in

hypothalamic Gαo proteins may produce the elevations in basal pAkt (Ser473).
Alternatively, 5-HT1A receptor-mediated Akt activation could be mediated by a
mechanism other than one mediated by G proteins. Akt can directly associate
with Gβγ subunits in rat brain extracts (Konishi et al., 1995). Akt can also be
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activated in a G protein-independent, β-arrestin dependent manner, as has been
demonstrated in fibroblast cell lines (Goel et al., 2002; Povsic et al., 2003).
Akt activation leads to an increase in phosphorylated GSK3β, which
inactivates this constitutively active protein kinase (Cross et al., 1995). In mice,
acute injection with fluoxetine increases levels of pGSK3β in the mouse
prefrontal cortex, hippocampus, and striatum, which is most likely due to a
synaptic increase in 5-HT and subsequent activation of 5-HT1A receptors (Li et al.,
2004). However, it was not known if the 5-HT1A receptor-mediated activation of
the Akt pathway in the peripubertal PVN was subject to regulation upon chronic
treatment with FLX.

We determined that 5-HT1A receptor-mediated

phosphorylation of Akt is generally not affected with either 7 or 14 days of FLX.
However, 14 days of injections with either saline or FLX rendered the animals
hyporesponsive to the effects of (+)8-OH-DPAT on 5-HT1A receptor-mediated
phosphorylation of Akt. This effect was also observed with the 5-HT1A receptormediated activation of ERK (Chapter 4). There may be stress-related effects upon
an additional 7 days of injection. Alternatively, starting injections at PD 28 (as
with the 14 day treatment paradigm used) as opposed to PD 35 (as with the 7 day
treatment paradigm used) may have exposed the animals to injection stress at a
critical point in postnatal development.

Although we did not observe any

specific FLX-induced effects on 5-HT1A receptor-mediated activation of Akt, its
downstream target GSK3β was differentially affected by the 7 and 14 day chronic

treatments.
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There was no hyporesponsive effect of 14 days of injection (as

observed with (+)8-OH-DPAT challenge on pERK and pAkt) in either saline or
FLX-treated animals on phosphorylated levels of GSK3β. We observed almost a
complete desensitization of (+)8-OH-DPAT-induced increases in pGSK3β with 7
days FLX treatment. With 14 days of FLX treatment, this desensitization is not as
marked. Either the levels of pGSK3β elicited by (+)8-OH-DPAT were starting to
recover or, alternatively, starting treatment earlier in postnatal development was
not having a robust effect on (+)8-OH-DPAT-stimulated pGSK3β. FLX could
possibly be modulating the protein levels or activity of a pGSK3β-specific
phosphatase, which may account for the differential effects on GSK3β but not
Akt phosphorylation.
hippocampal

levels

Duric et al. determined that chronic stress increases
of

a

phosphatase

specific

for

MAPK,

and

that

antidepressants normalize the levels of this phosphatase (Duric et al., 2010).
More closely linked with the Akt/GSK3β signaling pathway, protein levels of
PP1 phosphatase, the primary phosphatase for GSK3β in COS-7 cell cultures
(Hernandez et al., 2010), were increased in the frontal cortex and hippocampus of
adult rats subjected to a model of depression compared to sham rats (Feng et al.,
2003). Therefore, chronic FLX may be regulating the protein levels or activity of
phosphatases specific to GSK3β.
Together, these data provide the first in vivo demonstration that 5-HT1A
receptors can activate Akt in the peripubertal PVN. Given the previous studies

demonstrating that 5-HT1A
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receptors can stimulate hormone responses and

activate ERK activation in the peripubertal PVN, these findings are the first to
show that 5-HT1A receptors can mediate the concomitant activation of three
signaling pathways in peripubertal hypothalamic PVN and that chronic FLX can
regulate downstream targets of 5-HT1A receptor-mediated Akt pathways in the
peripubertal PVN in vivo.

CHAPTER 7
DETAILED METHODS
ANIMALS
Male Sprague-Dawley rats were purchased from Harlan (Indianapolis, IN).
The determination of post-natal day zero (day of birth) was carried out by the
supplier. All animals had 2-3 days to acclimate to their home cage and were
housed two per cage in a room controlled for temperature (20-22°C), humidity
(50-55%), and illumination (12h: 12h light/dark cycle; lights on at 07:00 h). Food
and water were available ad libitum.

All procedures were conducted in

accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals as approved by Loyola University Institutional Animal Care
and Use Committee (IACUC). Every effort was made to minimize suffering and
discomfort to the animals. The number of rats per group was the minimum
needed to obtain statistically meaningful evaluation of the data. Our power
analysis and past experience indicate that a minimum of 8 rats per group is
needed to obtain hormone data that can be analyzed statistically because ACTH
and oxytocin are “stress hormones” (Jezova et al., 1993; Jezova et al., 1996) and
some rats may be more sensitive to stress effects of handling and injection.
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HORMONE DETERMINATIONS
Blood collection and centrifugation.

After sacrifice, trunk blood was

collected in centrifuge tubes containing 0.3 M ethylenediamine tetraacetic acid
solution (EDTA, pH 7.4; 0.25 ml for peripubertal or prepubertal rats and 0.50 ml
for adult rats). The blood was centrifuged at 3000 x g for 40 minutes at 4°C and
the plasma was divided into aliquots. Plasma aliquots were stored at -80°C until
the respective hormones were determined by radioimmunoassay.
Plasma oxytocin radioimmunoassay.

Plasma levels of oxytocin were

determined by a double antibody assay using methods modified from Li et al.
(1997). First, plasma was extracted the day before the start of the assay. Rat
plasma (0.80 ml) was mixed with 1.6 ml ice cold acetone and centrifuged at
1600xg, at 4°C for 30 min. Then, the supernatant was added to 4 ml ice cold
petroleum ether and thoroughly mixed by inverting the tube several times. This
mixture was centrifuged at 1600xg, at 4°C for 15 min.

The top layer was

aspirated and discarded and the remaining solution was dried by blowing air
into the tubes at 4°C. A known quantity of oxytocin standard was added to
several tubes of normal rat plasma; these tubes were used to determine the
efficiency of the extraction. The tubes containing the dried extract were stored
overnight at 4°C.
On the day of the assay, the dried extract was reconstituted in 0.80 ml of
assay buffer (0.05 M phosphate buffer, pH 7.4, containing 0.125% bovine serum
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albumin, 0.01% sodium azide and 0.001 M EDTA). The reconstituted plasma
extract (100 μl or 200 μl, each in duplicate) and oxytocin standards (Bachem Fine
Chemicals, Torrance, CA) were incubated with 0.1 ml of rabbit anti-oxytocin
serum (1:5,000 dilution) in a total volume of 0.4 ml for 24 hr at 4°C.

125I-oxytocin

(Du Pont-NEN, Boston, MA, 3000 cpm, 0.1 ml) was then added to the tubes and
incubated for 72 hr at 4°C. Next, 0.1 ml goat anti-rabbit γ-globulin (1:20 dilution)
was added to each of the tubes, followed by 0.1 ml of normal rabbit serum (1:120
dilution). After incubation for 24 hr, the tubes were centrifuged at 2300xg, at 4°C
for 20 min. The supernatant was decanted, and the radioactivity in the pellet was
counted for 5 min by a Micromedic 4/200 plus γ counter and analyzed from the
standard curve using the RIA-AID computer program (Robert Maciel Associates,
Arlington, MA). The concentration of plasma oxytocin was calculated with a
correction factor based on the recovery of the extraction. The sensitivity limit of
this assay is 1 pg/tube, and the intra- and interassay variabilities are 8.1% and
8.6%, respectively.
Plasma ACTH radioimmunoassay. This assay is a double-antibody assay
and was performed as previously described (Van de Kar et al., 1989). Briefly,
plasma from each rat (unextracted plasma samples, 10 μl and 50 μl each in
duplicate) and ACTH standards (Calbiochem, Los Angeles, CA) were incubated
with 0.1 ml of rabbit anti-ACTH antibody (IgG Corp, Nashville, TN) in a total
volume of 0.2 ml for 24 hr at 4°C. 125I-ACTH tracer (DiaSorin, Inc., Stillwater, MN)
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was then added to the tubes and incubated for 48 hr at 4°C. Next, 0.1 ml goat
anti-rabbit γ-globulin (1:20 dilution) was added to each of the tubes. After
incubation for 24 hr, 1.5 ml cold PBS buffer (0.01 M phosphate buffer + 0.15 M
NaCl, pH 7.6) were added to each of the tubes. The tubes were then centrifuged
at 2300xg, at 4°C for 40 min. The supernatant was decanted, and the radioactivity
in the pellet was counted for 5 min by a Micromedic 4/200 plus γ counter and
analyzed from the standard curve using the RIA-AID computer program (Robert
Maciel Associates, Arlington, MA). The sensitivity limit of this assay is 0.25
pg/tube, and the intra- and inter-assay variability is 4.2% and 14.6%, respectively
(Van de Kar et al., 1989).
Plasma testosterone radioimmunoassay.

This assay is a solid-phase

radioimmunoassay, based on testosterone-specific antibody immobilized to the
wall of a polypropylene tube. The Coat-A-Count® Total Testosterone kit was
purchased from Siemens (Los Angeles, CA). Briefly, plasma from each rat (50 μl,
in duplicate) was placed in an antibody-coated tube and incubated with 1.0 ml of
125I-testosterone

for 3 hours at 37°C with light shaking. After this incubation, the

supernatant was decanted, and the radioactivity in the pellet was counted for 3
min by a Micromedic 4/200 plus γ counter and analyzed from the standard curve
using Microsoft Excel. The sensitivity limit of this assay is 4 ng/dl, and the intraand inter-assay variability is 7.3% and 11.0%, respectively.
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WESTERN BLOTTING
Microdissection of brain areas of interest. Brains were placed in a cryostat
at -12°C. A 650 μm coronal section including the PVN was cut from each brain.
This section was placed on a glass slide and adhered onto slides with Tissue Tek.
The slides were then placed on a large deep Petri dish on an ice/salt mixture (to
maintain the temperature at -5°C). The hypothalamic PVN was dissected from
its slice as a triangular “punch” (Crane et al., 2007; Serres et al., 2000a).
In the pertussis toxin experiment (Chapter 4), brains from each of the
treatment groups (vehicle and PTX) had the whole hypothalamus dissected
immediately after the brain was removed from the skull.

Each whole

hypothalamus was placed in a tube and immediately frozen in liquid nitrogen.
In the developmental G protein study (Chapter 4), the frontal cortex was
removed from each frozen brain, and the olfactory bulbs were separated from
cortical tissue and discarded. An additional 1100 μm coronal section including
the hippocampus was also cut after the PVN section. The hippocampus was
removed from its respective coronal section with the use of a small angular
blade. Each of these respective brain regions were placed in individual 1.5 ml
eppendorf tubes and stored at -80°C until prepared for western analysis.
Tissue preparation for the determination of pERK/ERK, pAkt/Akt, and
pGSK3β/GSK3β.

The tissue preparation was performed using methods

modified from Crane et al. (2007), and all procedures were conducted at 4°C
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unless otherwise noted. Briefly, the PVN was homogenized in 10 mM Tris buffer
(pH 7.6) containing 100 mM NaCl, 1 mM EDTA, 2 mM activated sodium
orthovanadate, and 50 mM NaF with additional protease inhibitors purchased in
a cocktail (1 μg/10 mg of tissue; Sigma, St. Louis, MO). This homogenate was
stored at -80°C until ready for Western blot analysis. A bicinchoninic acid (BCA)
assay (Pierce Chemical, Rockford, IL) was performed to quantify total protein as
per the manufacturer’s microplate procedure.
Tissue preparation for the determination of the levels of G proteins. All
procedures were conducted at 4°C unless otherwise indicated. The tissues (PVN,
hippocampus, frontal cortex, or whole hypothalamus) were homogenized in 50
mM Tris buffer (pH 7.7) containing 150 mM NaCl, 10% sucrose, 0.5 mM
phenylmethanesulfonyl fluoride (PMSF) and additional protease inhibitors
purchased as a cocktail (1 μl/30 mg of tissue; Sigma, St. Louis, MO). After
centrifugation at 20,000 x g for 60 min, the supernatant was collected, aliquoted,
and stored at -80°C for Western blot analyses of cytosol-associated protein levels.
The pellets (containing the membrane-associated proteins) were solubilized and
resuspended in 20 mM Tris buffer (pH 8), containing 1 mM EDTA, 100 mM
NaCl, 1% sodium cholate, and 1 mM dithiothreitol, plus the protease inhibitory
cocktail (1 μl/30 mg of tissue). The resuspended homogenates were placed on a
shaker for 1 h at 4°C, followed by centrifugation at 40,000 x g for 60 min. The
supernatant was collected, aliquoted, and stored at -80°C for Western blot
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analyses of membrane-associated protein levels. Protein concentrations were
measured using a bicinchoninic acid (BCA) protein assay kit (Pierce Chemical,
Rockford, IL) (Li et al., 1996).
Separation of proteins using electrophoresis. This assay was performed
using methods modified from Li et al. (1996) and Crane et al. (2007). Protein (1-7
μg per lane) was loaded on 12.5% polyacrylamide gel and separated by
electrophoresis (200 constant volts, 60-70 minutes). Proteins were subsequently
electrophoretically transferred onto a nitrocellulose membrane (100 constant
volts, 50-60 minutes).

After transfer, the nitrocellulose membranes were

incubated for 1 hour at room temperature on a shaker in a blocking solution of
0.1 M phosphate-buffered saline (PBS) containing 5% bovine serum albumin and
0.1% Tween-20 when probing for phosphorylated proteins or 0.1 M PBS
containing 0.2% I-block (Tropix, Inc.) and 0.05% Tween-20 when probing for
non-phosphorylated proteins. The blot was then incubated in primary antibody
overnight at 4°C on a shaker (with an intermediate washing step of 2 x 2 minutes
with 0.1 M PBS with 0.1% Tween-20 for phosphorylated proteins). Primary
antibodies (from Cell Signaling: pERK, ERK, pAkt (Ser473), pAkt (Thr308), Akt,
pGSK3β, and GSK3β; from Santa Cruz: Gαz and Gαi1; from Upstate: Gαi3/o; from
Chemicon: Gαi2; and from ICN Biomedicals: actin) were diluted in the same
blocking solution used. The blots were then washed (2 x 5 minutes, 1 x 10
minutes) in 0.1 M PBS with 0.1% Tween-20 and subsequently incubated in goat
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anti-rabbit-HRP-conjugated (for pERK, ERK, Gαi3/o, and Gαz) or goat antimouse-HRP-conjugated (for Gαi1, Gαi2, and actin) for 1 hour at room temperature
on a shaker. HRP-labeled protein bands were detected with ECL (Amersham
Chemical Co.) and captured on film as per the manufacturer’s protocol (Crane et
al., 2007; Li et al., 1996).
Immunoblot film analysis. Films were analyzed densitometrically using
Scion Image software (Scion Corporation, Frederick, MD).

The gray-scale

density readings were calibrated using a transmission step-wedge standard. The
integrated optical density (IOD) of each band was calculated as the sum of
optical densities of all the pixels within the area of the band outlined. An area
adjacent to the outlined protein band was used to calculate the background
optical density of the film and was subtracted from the IOD for each band. To
control for inter-gel variability, the resulting IOD for each protein band was then
divided by the average IOD from the control group (i.e., saline-challenged)
protein bands contained in the same blot. Since tissue samples were measured on
three independent gels, the mean “% of control” obtained from the three gels
represent the data for each rat. The mean % of control for phosphorylated ERK,
Akt, GSK3β, or G for each animal was divided by the mean % of control for the
respective non-phosphorylated or actin protein level to control for differences in
gel loading (modified from Crane et al., 2007).
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STEREOTAXIC SURGERY AND PERTUSSIS TOXIN INJECTION
For the pertussis toxin experiment, rats were anesthetized with a mixture of
ketamine and xylazine (100 mg ketamine plus 7 mg xylazine per ml, 1.4 ml/kg,
i.p.) and a double-barreled guide cannula (26 gauge, 1.2 mm center-to-center
distance, Plastics One, Roanoke, VA) with its corresponding dummy cannula
inserted inside was implanted into the brain above both sides of the
paraventricular nucleus at the following stereotaxic coordinates: 1.6 mm caudal
with respect to bregma, -0.6 mm lateral with respect to lambda, and 6.0 mm
ventral from the skull surface. All cannula implantations were performed on rats
that were at least PD 31. Rats were allowed to recover for several days before
further treatment.

Administration of PTX was performed according to

procedures previously established in adult rats (Garcia et al., 2006). An injection
cannula was inserted through the implanted guide cannula above the PVN, and
rats received an intracerebral injection of vehicle (100 mM sodium phosphate +
500 mM NaCl, 0.5 μl/side) or PTX (1 μg/μl, 0.5 μl/side) over 1 minute. The
injection cannula was left in situ for an additional 1 minute before removal. The
brains were visually inspected during dissection to ensure proper implantation
of the cannula.
IMMUNOHISTOCHEMISTRY
Immersion Fixation of Brain Tissue. This protocol was adapted from Khan
and Watts, 2004.

Immediately after harvest, brains were placed in ice-cold
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sodium acetate-buffered 4% paraformaldehyde (pH 6.5) and were then stored at
4°C. After 24 hours, each brain was removed from the fixative, gently blotted
dry, and placed in sodium borate-buffered 4% paraformaldehyde (pH 9.5) at 4°C
for 48 hours. Brains were then transferred to 0.1 M sodium phosphate buffered
4% paraformaldehyde (pH 7.4) and 20% glycerol at 4°C for 1-2 days (until brains
had sunk to the bottom of the container).

Sections were cut on a sliding

microtome in the coronal plane at 30 μm and stored as serial sets of one section in
every twelve in ethylene-glycol based cryoprotectant solution and stored at -20°C
until processed.
Colocalization of Oxytocin and pERK. For double-labeling for oxytocin and
pERK, labeling protocols with immunofluorescence detection were adapted from
Garcia-Ovejero et al., 2002; Khan and Watts et al., 2004; Khan et al., 2007; Lorenz
et al., 2005. All washes and incubations were performed on free floating sections
with shaking at room temperature unless otherwise indicated.

First, brain

sections were rinsed 3 times for 10 minutes each with Tris-buffered saline (TBS)
(50 mM Tris and 150 mM NaCl, pH 7.4). The slices were then transferred to TBS
containing 0.3% Triton X-100 for 50 minutes to permeabilize the sections.
Sections were then incubated for 72 h at 4°C with anti-oxytocin rabbit polyclonal
antiserum (Calbiochem) at a concentration of 1:1000 and mouse anti-phosphop44/42 MAPK (ERK1/2) monoclonal antiserum (Cell Signaling) at a
concentration of 1:800 in antibody solution (TBS + 2% normal goat serum).
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Sections were then rinsed three times for 5 min each in TBS. Next, the slices were
incubated with a combination of secondary antibodies for 2 hours at RT:
Invitrogen goat anti-rabbit conjugated to Alexa568 (1:200) and Vector
biotinylated goat anti-mouse (1:250) in secondary solution (TBS + 2% normal
goat serum + 1% Triton X-100). After three washes of 10 min each (TBS), the
slices were incubated with streptavidin conjugated to Alexa488 (Invitrogen; 1:200
in TBS) for 2 hours at RT. Lastly, the slides were washed again with TBS for
three times 10 min each and two times 15 min each. Sections were mounted on
gelatin-coated slides, allowed to dry for 30-40 minutes and then coverslipped
with Fluoro-gel (Electron Microscopy Science #17985) and subsequently stored in
a foil-wrapped box at 4°C. The sections were allowed to dry thoroughly and
were later analyzed using an Olympus IX-81 fluorescent microscope.
Additionally, some slides were analyzed with a confocal microscope (Zeiss
LSM510) at a higher magnification to confirm localization of fluorescent markers.
DATA ANALYSIS
The data are represented as group means and the standard errors of the
means (S.E.M.). GB-STAT software (Dynamic Microsystems, Inc.) was used for
all statistical analyses.
For the immunohistochemistry experiment, to quantify the number of PVN
neurons labeled for oxytocin or 5-HT1A receptor-stimulated pERK, two sections
from each rat were selected for analysis. These sections corresponded in plane
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and rostrocaudal position most closely to that represented in plate 26 of Paxinos
and Watson, 1998. For each fluorophore (Alexa488 and Alexa568), a stack of 30
images (1 μm per image) was obtained for each half of the PVN using an
Olympus IX-81 fluorescent microscope.

Each 1 μm-thick image was

deconvolved using MicroTome Deconvolution 7.0 (VayTek, Fairfield, IA) and
compressed into one composite image by ImagePro v6.3 (Scitech, Preston,
Victoria, Australia). Therefore, 4 composite images were obtained for each rat
for each fluorophore. Using Image J (NIH), each composite image was inverted
so that the cell labeling for either oxytocin or pERK appeared as shades of gray
on a white background. Then, optical density for each image was determined by
first calculating the density of the shaded pixels in an 850 pixel by 950 pixel area
(encompassing either the left or right half of the PVN), which was then compared
to a calibrated optical density step tablet. The integrated density is defined as the
product of the pixel area and the optical density. Also, the total cell count for
each composite image was obtained using particle analysis in the ImageJ
program. Therefore, the cell density is defined as the number of particles within
the 850 x 950 pixel area for each composite image. The average of the integrated
density and cell density was calculated from the values for each composite image
(4 per rat). Confocal images were processed using Zeiss LSM Image Browser and
ImageJ.

CHAPTER 8
GENERAL DISCUSSION
The serotonin 1A (5-HT1A) receptor was one of the first serotonin receptor
subtypes to be investigated with respect to its pharmacological functions and
regional distribution in brain. Although the somatodentritic 5-HT1A autoreceptor
population has received much attention due to its involvement in the therapeutic
efficacy of various drugs used to treat mood disorders, postsynaptic 5-HT1A
receptors on non-serotonergic cells may also be involved with antidepressantinduced neuroadaptations.

Post-synaptic 5-HT1A receptors are localized in

various brain regions such as the hippocampus, frontal cortex, and
hypothalamus (Kia et al., 1996a; Kia et al., 1996b; Blier and Ward 2003; Marvin et
al., 2010), where they can initiate a variety of signal transduction cascades
(Raymond et al., 2001). 5-HT1A receptors in the hypothalamus are involved in
the serotonergic stimulation of various hormones and regulation of the
hypothalamic-pituitary-adrenal (HPA) axis. Recent studies have also shown that
hypothalamic 5-HT1A receptors can activate extracellular signal regulated kinase
(ERK) (Sullivan et al., 2005; Crane et al., 2007), a protein kinase involved with
many functions including gene expression, mitosis, differentiation, cell
survival/apoptosis,

learning,

memory,
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neuroplasticity,

and

receptor
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desensitization (Marshall 1995; Pouysségur and Lenormand 2003; Trincavelli et
al., 2002). However, the majority of information on 5-HT1A receptor signaling
has been obtained from in vitro studies in cells or in vivo studies in adult animal
models. Similarly, studies on the mechanisms of 5-HT1A receptor signaling in
vivo in hypothalamic paraventricular nucleus (PVN) have also utilized adult
animal models.

Prior to these dissertation studies, there have been no

comparable studies on 5-HT1A receptor signaling in the peripubertal
hypothalamic PVN. Considering the significant contribution of the serotonergic
system over brain development around the time of sexual maturation (WhitakerAzmitia 2001), the role of serotonin in regulating neuroendocrine function, and
that serotonergic modulation (e.g. with antidepressant treatment) produces
responses that are distinct and more long-lasting than those produced in adults
(Maciag et al., 2006; Ansorge et al., 2004; Taravosh-Lahn et al., 2006; Oh et al.,
2009), this dissertation investigated 5-HT1A receptor-mediated signaling
pathways in the hypothalamic PVN of peripubertal rats.
Previous studies demonstrated, in the adult rat hypothalamic PVN, 5-HT1A
receptors activate independent signaling pathways (utilizing different Gα
protein subtypes):

Gαz proteins exclusively mediate the 5-HT1A receptor-

induced increase in plasma levels of oxytocin and adrenocorticotropin hormone
(ACTH) (Serres et al., 2000a) and concomitantly activate the mitogen-activated
protein kinase (MAPK) ERK via pertussis toxin-sensitive Gαi/o proteins (Crane

et al., 2007; Garcia et al., 2006; Sullivan et al., 2005).
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These pathways are

independent, as blockade of ERK signaling does not alter 5-HT1A signaling of
hormone responses (Jia et al., 2007).
The present studies provide the first in vivo evidence that 5-HT1A receptors in
the peripubertal PVN mediate the concomitant activation of multiple hormone
and kinase signaling responses.

More specifically, these dissertation studies

demonstrated that 5-HT1A receptors stimulate increases in plasma levels of
oxytocin and ACTH, phosphorylation of ERK, and phosphorylation of protein
kinase B (Akt). We have also determined that Gα proteins may be uniquely
regulated in the peripubertal PVN and that these proteins may be playing a
broader

or

different

role

in

5-HT1A

receptor-mediated

signaling

and

desensitization in the peripubertal PVN than previously established in the adult
PVN. The data also demonstrate that 5-HT1A receptor-mediated pathways may
be differentially responsive to different classes of 5-HT1A agonists. (+)8-OHDPAT (an aminotetralin), acted as a “full” agonist on the 5-HT1A receptormediated neuroendocrine and kinase responses. In contrast, tandospirone (an
azapirone) exhibited “partial” agonist activity with regards to Akt activation
despite “full” agonist activity in stimulating increases in both oxytocin and
ACTH and in the activation of ERK. 5-HT1A receptor-mediated activation of ERK
in the peripubertal PVN is a rapid and prolonged response, unlike the rapid but
transient nature of this response observed in the adult PVN. These studies also
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suggest that ERK activation may be expressed only in certain populations of
neuroendocrine cells in the peripubertal PVN. We have also determined that 5HT1A receptor-mediated increases in the phosphorylation of GSK3β were
attenuated in fluoxetine-treated peripubertal rats in the absence of changes in
Akt activation. These data suggest that fluoxetine may be altering phosphatase
activity or that Akt may not be the kinase responsible for GSK3β
phosphorylation in PVN or at this developmental age.
These unique aspects of 5-HT1A receptor signaling in the peripubertal brain
may be involved with differences in therapeutic and/or side effects of SSRIs in
adult vs. young patients or may represent novel drug targets to treat mood
disorders in children and adolescents.
5-HT1A receptor signaling in the peripubertal PVN
In the peripubertal PVN, activation of 5-HT1A receptors leads to increases in
plasma levels of both oxytocin and ACTH hormones and increases the levels of
activated (phosphorylated) ERK (pERK) in the PVN (Chapter 3). Furthermore,
we

determined

that

5-HT1A

receptor

activation

increases

activated

(phosphorylated) Akt (pAkt) in the peripubertal PVN (Chapter 6).
5-HT1A receptors activate the mitogen activated protein kinase (MAPK) ERK in the
peripubertal PVN. In the adult PVN, activation of ERK is a rapid but transient
response, as the aminotetralin “full” agonist (+)8-OH-DPAT significantly
elevates levels of activated ERK at 5 minutes which returns to basal levels by 15
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minutes post-injection (Crane et al., 2007). Tandospirone, an azapirone “partial”
agonist at postsynaptic 5-HT1A receptors, also increases pERK in the adult rat
PVN (Sullivan et al., 2005) although the time- and dose-dependence of
tandospirone on 5-HT1A receptor-mediated pERK responses has not been
determined in the adult PVN. In the peripubertal PVN, (+)8-OH-DPAT and
tandospirone also produced rapid (≤ 5 minutes) increases in pERK. However, in
contrast to adult PVN, 5-HT1A receptor-mediated activation of ERK in the
peripubertal PVN was prolonged, remaining elevated over basal at least 30
minutes after injection. These data demonstrate that (+)8-OH-DPAT produced a
more prolonged 5-HT1A receptor-mediated increase in pERK in the PVN of
peripubertal rats as compared to that previously published in adult PVN. Agedependent effects on ERK signaling have also been demonstrated in response to
peptide-induced activation of NMDA receptors in the spinal cord of rats (Chiu et
al., 2010).

Prolonged ERK activation in the PVN of peripubertal rats could

impact a variety of cellular functions under the control of ERK. In a variety of
mammalian cell lines, the duration of ERK signaling is associated with distinct
cell behavior (Traverse et al., 1992; Nguyen et al., 1993; Mansour et al., 1994;
Sharp et al., 1997; Whalen et al., 1997; Murphy et al., 2002; Murphy et al., 2004;
Sinnett-Smith et al., 2004).

For example, prolonged but not transient ERK

activation was associated with (1) neuronal differentiation in PC-12 cells
(Traverse et al., 1992), (2) nuclear translocation of ERK in PC12 cells (Nguyen et
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al., 1993), and (3) c-fos accumulation and DNA synthesis in Swiss 3T3 cells
(Sinnett-Smith et al., 2004). In consideration of our previous findings that ERK is
required

for

SSRI-induced

desensitization

of

5-HT1A

receptor-mediated

neuroendocrine responses in the adult PVN, a more prolonged ERK signaling in
the immature brain could potentially induce a more rapid desensitization of 5HT1A receptor-mediated hormone responses upon administration of SSRIs.
In Chapter 5, we demonstrated that cells in the peripubertal PVN that were
immunoreactive for oxytocin were localized distinct from cells displaying
immunoreactivity for 5-HT1A receptor-mediated pERK. Our preliminary data
suggested that these markers were localized in distinct cell populations in the
adult PVN as well. These data are consistent with the literature suggesting that
little to no receptor-stimulated ERK is observed in oxytocin-containing cells
(Wang et al., 2006; Blume et al., 2009; Jankord et al., 2010). In the adult PVN,
intact ERK signaling is necessary for SSRI-induced desensitization of 5-HT1A
receptor-mediated oxytocin neuroendocrine responses (Jia et al., 2007).

The

findings of the current study suggest that the effects of ERK on SSRI-induced
desensitization of 5-HT1A receptor-mediated oxytocin responses in the adult PVN
may be induced via a cell-to-cell mechanism rather than via a more direct
intracellular communication between signaling pathways.

Nevertheless, the

present immunohistochemical studies indicate that 5-HT1A receptors mediating
oxytocin responses exhibit a different localization than those 5-HT1A receptors

responsible for the activation of ERK.
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It is currently unknown if ERK is

necessary for SSRI-induced desensitization of 5-HT1A receptor-mediated oxytocin
responses in the peripubertal PVN. If so, the current data suggest that similar
cell-to-cell mechanisms are likely operative in the immature brain. In contrast,
receptor-stimulated pERK localizes with corticotrophin releasing hormone
(CRH)-immunoreactive cells in the PVN (Khan et al., 2007). Consistent with
these findings, we have preliminary data that suggest, in the peripubertal PVN,
5-HT1A

receptor-mediated

pERK

immunoreactivity

localized

with

cells

immunoreactive for CRH. Since CRH-containing cells can project to other areas
of the PVN (Sakanaka et al., 1987), and that 5-HT1A receptor-mediated activation
may occur in CRH containing cells, it is possible that CRH-containing could exert
a wide range of control over multiple cell subtypes within the PVN and in other
areas of the hypothalamus.
5-HT1A receptors activate protein kinase B (Akt) in the peripubertal PVN. Due to
recent evidence linking the PI3K/Akt/GSK3 pathway to the pathology of
psychological disorders including chronic stress, depression, and schizophrenia
(Beaulieu et al., 2009) and actions of psychoactive drugs (Beaulieu et al., 2004; Li
et al., 2004), 5-HT1A receptor signaling of Akt was investigated in the
peripubertal PVN (Chapter 6). These studies are among the first to identify that
activation of a G protein coupled receptor results in the phosphorylation of Akt
in the hypothalamus in vivo.

The PI3K/Akt pathway had been classically
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characterized as being activated via growth factor receptors such as tyrosine
kinase receptors. However, recent studies show that GPCRs (e.g. D2 dopamine
and 5-HT1A receptors) also can activate this pathway (Beaulieu et al., 2005;
Adayev et al., 1999; Cowen et al., 2005; Hsiung et al., 2005). For full activation,
Akt must be phosphorylated at two residues, Thr308 and Ser473. Each of these
sites is phosphorylated by different upstream kinases: PDK1 phosphorylates
Thr308 (Alessi et al., 1997; Stephens et al., 1998) and mTOR has been identified as
the kinase for Ser473 (Sarbassov et al., 2005). Phosphorylation at Ser473 by
mTOR appears to occur in the cytoplasm and subsequently assists in the
recruitment of Akt to the plasma membrane and so that it can be phosphorylated
at Thr308 by PDK1 (Andjelkovic et al., 1997; Scheid and Woodgett, 2003).
Activation of 5-HT1A receptors in vivo resulted in increases in phosphorylated
Akt in the peripubertal PVN. In the current studies, injection with two different
structural classes of 5-HT1A receptor agonists, (+)8-OH-DPAT and tandospirone,
resulted in a rapid phosphorylation of Akt at both Thr308 and Ser473, although
(+)8-OH-DPAT appeared to induce a higher magnitude of phosphorylation at
both Akt phosphorylation sites.

Considering that Akt may be first

phosphorylated at Ser473 by mTOR, it is conceivable that (+)8-OH-DPAT (at 0.20
mg/kg) may induce more effective coupling of 5-HT1A receptors to the activation
of mTOR than tandospirone.

Alternatively, (+)8-OH-DPAT may be more

efficacious than tandospirone in activating 5-HT1A receptors responsible for the
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phosphorylation of Akt. This will be discussed further in another section of this
chapter.
5-HT1A receptor-mediated activation of Akt in peripubertal vs. adult PVN
was examined in a separate study (data not shown). Both adult and peripubertal
(PD 42) rats were given a challenge injection of 0.20 mg/kg (+)8-OH-DPAT and
sacrificed 10 minutes later. 5-HT1A receptor-mediated phosphorylation of Akt
was significantly less in the adult PVN than peripubertal PVN at both Thr308
(75% over basal in adult PVN compared to 100% over basal in peripubertal PVN)
and Ser473 sites (40% over basal in adult PVN compared to 79% over basal in
peripubertal PVN) (Petrunich-Rutherford et al., unpublished data).

5-HT1A

receptors in the adult PVN could potentially be less effective in activating the
PI3K/Akt pathway than in young rats.

However, considering that 5-HT1A

receptor-mediated increases in pERK are rapid and transient in the adult PVN
(Crane et al., 2007), it is more likely that 5-HT1A receptor-mediated increases in
pAkt may display a more transient time course of activation in the adult PVN
than that observed in peripubertal PVN. In either case, a more prolonged 5-HT1A
receptor-mediated activation of Akt in the peripubertal PVN could potentially
impact a wide variety of cellular functions.
Together, these data provide the first in vivo demonstration that 5-HT1A
receptors can activate Akt in the peripubertal PVN. Given the previous studies
demonstrating that 5-HT1A receptors can stimulate hormone responses and
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activate ERK in the peripubertal PVN (Chapter 3), these findings are the first to
show that 5-HT1A receptors can mediate the concomitant activation of multiple
downstream kinase effectors in peripubertal hypothalamic PVN.
5-HT1A receptor-mediated neuroendocrine responses and activation of ERK in the
peripubertal PVN: independent pathways? In the adult rat hypothalamic PVN, 5HT1A receptors mediate neuroendocrine and ERK kinase responses via separate
and independent pathways mediated by separate subsets of Gα proteins. The
data from the current studies suggest that 5-HT1A receptor-mediated signaling of
neuroendocrine responses and ERK activation may also be independent in the
peripubertal PVN, although the role of G proteins in these signaling pathways
were harder to discern. As previously mentioned, the immunohistochemical
study indicated that 5-HT1A receptor-mediated activation of ERK does not occur
on oxytocin-containing cells in the peripubertal PVN, indicating that increases in
plasma levels of oxytocin and increases in PVN levels of pERK are activated in
separate cell groups and therefore via independent pathways (Chapter 5).
Furthermore, it seems unlikely that 5-HT1A receptor-mediated pERK contributes
to the increases observed in plasma concentrations of oxytocin and ACTH,
considering that 0.10 mg/kg (+)8-OH-DPAT significantly increased plasma
levels of oxytocin and ACTH but did not significantly increase pERK levels in the
peripubertal PVN (Chapter 3).

However, these studies did not directly

determine the independence of 5-HT1A receptor-mediated pathways and merely

suggest a possible independence of 5-HT1A
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receptor-mediated neuroendocrine

responses and activation of ERK in the peripubertal PVN. The specific roles of
Gα proteins in 5-HT1A receptor-mediated signaling in the peripubertal PVN were
also investigated; these findings are discussed further in another section of this
chapter.
In the literature, it is not clear whether or not Akt and ERK protein kinase
pathways are activated as a result of one shared pathway or multiple
independent pathways. In a transfected Chinese hamster ovary (CHO) cell line,
both the 5-HT1A receptor-mediated activation of ERK and Akt were reported to
be pertussis toxin-sensitive and PI3K-dependent (Hsiung et al., 2005). However,
the 5-HT1A receptor-mediated activation of Akt, but not 5-HT1A receptormediated ERK, is PI3K-dependent in the hippocampal neuron-derived cell line
HN2-5 (Adayev et al., 1999).

At this point, it appears that the

dependence/independence of ERK and Akt phosphorylation depends on the cell
type. The current studies indicated that ERK and Akt phosphorylation follow a
similar time course (i.e. elevated within 5 minutes of agonist injection, remained
elevated until around 15 minutes post-injection, and slowly returned to basal
levels). Therefore, we are unable to say with certainty if ERK activation leads to
Akt phosphorylation or vice versa, or if these pathways are independently
stimulated in the peripubertal PVN.
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“Full” vs. “partial” agonism at 5-HT1A receptor-mediated responses in the
peripubertal PVN.
In the literature, (+)8-OH-DPAT is considered a “full” agonist and
tandospirone is considered a “partial” agonist at post-synaptic 5-HT1A receptors.
However, most studies have examined the 5-HT1A receptor mediated-responses
induced by these agonists in cell cultures or in brain regions other than the
hypothalamus. The studies from Chapter 3 indicated that both (+)8-OH-DPAT
and tandospirone had comparable maximal efficacies in stimulating oxytocin,
with (+)8-OH-DPAT being a more potent agonist than tandospirone.

The

maximal efficacies of (+)8-OH-DPAT and tandospirone on ACTH responses
were also comparable, and maximally effective doses of the aminotetralin or
azapirone agonists appear to produce comparable increases in pERK in PVN.
Therefore, both (+)8-OH-DPAT and tandospirone act as “full” agonists on 5HT1A receptor-mediated neuroendocrine responses and ERK activation in the
peripubertal PVN.

However, in Chapter 6, it appeared that the maximal

increases of pAkt at both Thr308 and Ser473 induced by (+)8-OH-DPAT are
greater than that induced by tandospirone.

Therefore, with respect to Akt

activation, (+)8-OH-DPAT may be considered a “full” agonist and tandospirone
a “partial” agonist in contrast with the data demonstrating that both drugs are
“full” agonists on 5-HT1A receptor-mediated neuroendocrine and ERK responses
(as reported in Chapter 3). These data demonstrated that the classification of
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agonists as “full” or “partial” are dependent on the respective receptor-mediated
response, despite the fact that multiple responses can be stimulated by the same
receptor in the same brain region.
Effects of chronic fluoxetine on 5-HT1A receptor signaling in the peripubertal
PVN
In the adult rat PVN, 5-HT1A receptor-mediated neuroendocrine and kinase
pathways are differentially regulated by selective serotonin reuptake inhibitors
(SSRIs). Chronic treatment with SSRIs decreases levels of Gαz proteins and
desensitizes 5-HT1A receptor-mediated oxytocin and ACTH hormone responses
(Raap et al., 1999) but has no effect on levels of Gαi/o proteins and does not
desensitize the 5-HT1A receptor-mediated increase in pERK in the PVN (Jia et al.,
2006).

Furthermore, intact ERK signaling is necessary for SSRI-induced

desensitization of 5-HT1A receptor-mediated neuroendocrine responses, since
pharmacological blockade of MAPK kinase (the activating kinase for ERK)
during SSRI treatment abolishes both the SSRI-induced desensitization of 5-HT1A
receptor signaling of hormone responses and reductions in associated Gαz
proteins (Jia et al., 2007).

In the peripubertal brain, chronic fluoxetine also

desensitizes 5-HT1A receptor-mediated oxytocin and ACTH responses (Chen et
al., 2006); however, neither 7 nor 14 days of fluoxetine treatment had any effect
on either membrane- or cytosol-associated Gαz protein levels in the peripubertal
hypothalamus (Chapter 4). Gz is the exclusive Gα protein mediator of increases

in plasma hormone concentrations stimulated by 5-HT1A
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receptor activation in

the adult and the only Gα protein reduced by SSRIs in the adult brain (Serres et
al., 2000a; Jia et al., 2006). Therefore, the data from the current fluoxetine study
described in Chapter 4 suggest that either 5-HT1A receptor-mediated
neuroendocrine responses are mediated via a different subset of Gα protein(s) in
the peripubertal PVN or that SSRIs desensitize 5-HT1A receptor-mediated
neuroendocrine responses in the peripubertal PVN via a different mechanism—
one not dependent on the downregulation or reductions in the levels of Gz
proteins. Differences in the roles and regulation of G proteins will be discussed
further in the section on the unique regulation of Gα proteins in the peripubertal
brain.
We also determined that chronic fluoxetine (7 and 14 days) had differential
effects on the ERK and Akt kinase pathways.

5-HT1A receptor-mediated

phosphorylation of ERK and phosphorylation of Akt is generally not affected
with either 7 or 14 days of fluoxetine. However, 14 days of injections with either
saline or fluoxetine rendered the animals hyporesponsive to the effects of (+)8OH-DPAT on 5-HT1A receptor-mediated activation of ERK (Chapter 4) and on 5HT1A receptor-mediated phosphorylation of Akt (Chapter 6). Given the blunted
response in chronic saline-treated rats, there may be stress-related effects due to
the additional 7 days of injection in the peripubertal period.

Alternatively,

starting injections at PD 28 (as with the 14 day treatment paradigm used) as
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opposed to PD 35 (as with the 7 day treatment paradigm used) may have
exposed the animals to injection stress at a critical point in postnatal
development.

Although we did not observe any specific fluoxetine-induced

effects at the level of Akt, its downstream target GSK3β was differentially
affected by the 7 and 14 day chronic treatments. There was no hyporesponsive
effect of 14 days of injection (as observed with (+)8-OH-DPAT challenge on
pERK and pAkt) in either saline or fluoxetine-treated animals on phosphorylated
levels of GSK3β. We did observe almost a complete desensitization of (+)8-OHDPAT-induced increases in pGSK3β with 7 days fluoxetine treatment. With 14
days of fluoxetine treatment, this desensitization is not as marked, suggesting
some neuroadaptive response to fluoxetine in the developing peripubertal brain.
Alternatively, starting treatment earlier in postnatal development may not be
having a robust effect on (+)8-OH-DPAT-stimulated pGSK3β, or fluoxetine could
possibly be modulating the protein levels or activity of a pGSK3β-specific
phosphatase, which may account for the differential effects on GSK3β but not
Akt phosphorylation.
Unique regulation of Gα proteins in the peripubertal PVN.
Developmental differences in the regulation of 5-HT1A receptor-associated Gα
proteins in the PVN. With regards to protein levels of 5-HT1A receptor-associated
Gα proteins, we determined that Gαo proteins, but none of the other Gα protein
subtypes tested, exhibit age-dependent increases. Gαi1, Gαi2, Gαi3, and Gαz
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proteins (but not Gαo proteins) are present in the PVN, hippocampus, and
frontal cortex at their adult levels in both prepubertal (PD 28) and peripubertal
(PD 42) rats, whereas Gαo proteins steadily increase with age. This is consistent
with a previously published study that determined that levels of Gα proteins
change throughout several brain regions during early postnatal development.
Gαi1, Gαi2, and Gα3 proteins reach adult levels around postnatal day 18 in the
cortex, thalamus, and hippocampus, whereas Gαo proteins continue to increase
past early postnatal development in these regions (Ihnatovych et al., 2002).
Together, these data indicate that, besides Gαo, all other Gα proteins with the
capacity to couple to 5-HT1A receptors are present in the peripubertal PVN at
levels similar to that in the adult PVN. The developmental increase in Gαo
proteins may impact 5-HT1A receptor signaling if the lower density of Gαo
proteins in peripubertal vs. adult PVN alters the effective coupling of the 5-HT1A
receptor to the respective signaling pathways in the brain of younger vs. adult
rats. For example, if the relative abundance of other proteins (like Gαi3 and Gαz)
makes it less likely for the 5-HT1A receptor to couple to Gαo, then Gαo proteins
may be precluded from signaling in a manner similar to that in the adult brain.
Unfortunately, the limitation of western blotting is that comparisons cannot be
made between the relative levels of Gα proteins to one another. The results from
other experiments, however, indicate that there may be some other difference in
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the Gα proteins (and not just the physical availability) that may explain
differences in 5-HT1A receptor signaling in the peripubertal vs. adult PVN.
In Chapters 4 and 6, we intended to thoroughly investigate the specific roles
of Gα proteins in 5-HT1A receptor signaling in the peripubertal PVN. However,
we discovered some key differences in the regulation of Gα proteins that
prevented the determination of the specific roles that these Gα proteins play in 5HT1A receptor-mediated signaling in the peripubertal PVN. These differences in
regulation are described in the next few paragraphs, and the conclusions that we
made regarding the specific roles of Gα proteins in 5-HT1A receptor-mediated
signaling pathways are discussed in the next section in this chapter.
Pertussis toxin (PTX) is a bacterial toxin that catalyzes the addition of an
ADP-ribose group to a c-terminal cysteine residue on Gαi1, Gαi2, Gαi3, and Gαo
proteins, which functionally inactivates these respective proteins.

PTX-

insensitive Gαz proteins lack this critical cysteine residue necessary for PTXinduced ADP ribosylation. In the adult rat in vivo, an intra-PVN injection with
PTX induces a significant decrease (~50%) in the amount of each of the PTXsensitive Gα proteins in the hypothalamus at 72 hours post-injection (Garcia et
al., 2006). This reduction is not due to an alteration in the antibody recognition
of the ADP-ribosylated Gα proteins, since in vitro incubation of adult
hypothalamic membranes with PTX has no effect on the levels of Gα proteins
measured with western blotting (Petrunich-Rutherford et al., unpublished data).

213
In contrast to the effects of PTX in adults, in peripubertal rats, an intra-PVN
injection of PTX did not reduce all subsets of Gαi/o proteins in the
hypothalamus (as in the adult) but only reduced Gαi1 and Gαi2. Gαi3 protein
levels in the hypothalamus remained unchanged and Gαo protein levels in the
hypothalamus increased two-fold. It is important to note that there may have
been changes in specific Gα proteins at the level at the PVN that were masked by
changes in the whole hypothalamus.

However, considering the same Gα

proteins were measured in the whole hypothalamus with a comparable
incubation time of drug (72 hours) in this study as the one previously published
in adults (Garcia et al., 2006), these data indicate that there may be a
developmental difference in the PTX-sensitivity of Gα proteins in the
hypothalamus.

Although unlikely, a difference in the Gαi3/Gαo protein

structure may be preventing ADP ribosylation in the peripubertal rat brain. It is
more likely that there is a difference in post-translational modifications of the
proteins that may be preventing ADP ribosylation and subsequent reduction in
membrane-associated levels of these proteins. There is also a possibility that a
72-hour incubation time is not sufficient (or is perhaps too short) to functionally
inactivate Gαi3 and Gαo proteins. It could be that Gαi3 and Gαo proteins are
more resilient to ADP-ribosylation and begin to recover from the effect of the
toxin or are replenished by transcription and translation of their respective genes
before the end of the three-day time period. Indeed, the increased levels of Gαo
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may be due to a robust compensatory increase to the initial effects of PTX. There
has been one other study comparing the effects of PTX in peripubertal vs. adult
brain: using adult rat brain membranes, GABAB receptor/G protein binding was
reduced upon incubation with PTX in cortex, hippocampus, and cerebellum but
not the striatum. However, when PTX was incubated with peripubertal rat brain
membranes, GABAB receptor/G protein binding was reduced in striatum and
hippocampus but not cortex or cerebellum (Knott et al., 1993). In either case, in
vivo or in vitro, it seems as if certain Gα proteins (namely Gαi3 and Gαo) have not
functionally matured in the peripubertal brain and may possibly impact the
signaling of the 5-HT1A receptor in the PVN and other regions in the brain.
We also observed developmental differences in the PVN upon chronic
treatment with fluoxetine in the peripubertal rat. Chronic fluoxetine reduces
levels of Gαz proteins in the PVN of adult rats.

Our preliminary studies

indicated that, in the peripubertal PVN, chronic fluoxetine did not reduce Gαz
proteins but did reduce Gαi3 and Gαo (Chen et al., 2006). However, upon
replicating the treatment paradigm for both 7 and 14 days, we determined that
chronic fluoxetine did not reduce Gαz proteins but also did not reduce any of the
other

Gα

proteins

(cytosol-associated

or

membrane-associated)

in

the

peripubertal PVN (Chapter 4). Therefore, SSRIs may be desensitizing 5-HT1A
receptor-mediated neuroendocrine responses in the peripubertal PVN via a
different mechanism as opposed to reducing levels of Gαz proteins in the
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hypothalamus, as in the adult. For example, SSRI treatment in peripubertal rats
may be affecting the function of regulators of G protein signaling (RGS) proteins.
The RGSZ protein functions to deactivate Gαz subunits and is present in the
hypothalamus.

Members of the RGSZ protein family have been shown to

influence mu receptor signaling in the central nervous system by sequestering
Gα proteins (Garzon et al., 2005).

SSRIs may be causing RGSZ proteins to

inactivate or sequester, but not cause a reduction in the levels of Gαz proteins in
the peripubertal hypothalamus.

Alternatively, chronic fluoxetine may be

altering the balance of G proteins in lipid rafts, and subsequently the signaling
activity of these proteins, as has been observed with chronic escitalopram (an
SSRI) on Gs proteins in vitro (Zhang and Rasenick, 2010).
Roles of 5-HT1A receptor-associated Gα proteins in the PVN. Intra-PVN injection
with PTX caused a reduction of hypothalamic levels of Gαi1 and Gαi2 proteins
and increased Gαo proteins (Chapter 4, figure 13). We found no significant
reductions in 5-HT1A receptor-mediated neuroendocrine responses; therefore,
this data suggests that Gαi3, Gαo, and/or Gαz could potentially mediate 5-HT1A
receptor stimulation of hormone responses in the PVN of peripubertal rats. It is
likely that Gαi3, Gαo, and/or Gαz proteins may mediate 5-HT1A receptor
activation of ERK considering that there were also no significant reductions of 5HT1A receptor-mediated phosphorylation of ERK in the PVN. However, the
PTX-induced increases in Gαo may be responsible for the elevations observed in

basal levels of activated ERK in the PVN.
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Similarly, we observed slightly

elevated basal levels of phosphorylated Akt at Ser473, although this increase did
not reach statistical significance. This increase in basal levels of pAkt may have
precluded any further increase in pAkt at Ser473 by 5-HT1A receptor activation.
Therefore, 5-HT1A receptors may be signaling via Gαi1 or Gαi2 proteins to
mediate Akt activation, although we cannot completely rule out any potential
contribution of Gαi3, Gαo, or Gαz in mediating the phosphorylation and
activation of Akt in the peripubertal PVN.
To determine the specific Gα protein contribution to 5-HT1A receptormediated signaling pathways in the peripubertal PVN, a more selective method
is necessary, like adenoviral-delivered siRNA for Gαi3 and Gαo proteins. This
will be discussed further in the last section of this chapter.
Alternate signaling mediators of 5-HT1A receptor-mediated responses in peripubertal
PVN. Although the studies in this dissertation have focused on the contributions
of Gα proteins to 5-HT1A receptor-mediated signaling in the peripubertal PVN,
many studies have revealed that GPCRs can mediate the signaling of ERK and
Akt via Gβγ subunits or even via β-arrestin. Gβγ subunits have been shown to
activate ERK (Goubaeva et al., 2003; Mukhin et al., 2000) and Akt (Konishi et al.,
1995; Guzmán-Hernández et al., 2009); therefore, Gβγ could potentially mediate
5-HT1A receptor-mediated responses rather than G proteins in the peripubertal
PVN.

Although β-arrestin has been classically involved with receptor
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desensitization, uptake, and degradation, in certain situations it can serve as a
signaling mediator for GPCR/G protein-independent signaling. For example, βarrestin has been shown to activate ERK in response to activation by (1) β2
adrenergic receptors (Shenoy et al., 2006), (2) GPR54 receptors (Pampillo et al.,
2009), and (3) angiotensin II receptors (Ahn et al., 2004). Either Gβγ subunits or
β-arrestin could be potential second messengers for G protein-independent
signaling of the respective 5-HT1A receptor-mediated responses in the
peripubertal PVN.
It is also possible that 5-HT1A receptor-mediated activation of protein kinase
pathways could be due to transactivation of growth factor receptors by the 5HT1A receptor in the PVN. One potential growth factor receptor is insulin-like
growth factor 1 receptor (IGF-1R). IGF-1R has been localized to the PVN (Saeed
et al., 2007) and can be transactivated by another GPCR, the GABAB receptor.
Transactivation

of

IGF-1R

by

GABAB

results

in

increased

levels

of

phosphorylated Akt in primary cerebellar granule neurons (Tu et al., 2010).
Although the interaction of 5-HT1A receptor with IGF-1R pathways has not been
examined in the hypothalamus in vivo, 5-HT1A receptors have been shown to
regulate IGF-1R mRNA and protein levels in the spinal cord (Bonnefont et al.,
2007).
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Clinical significance: some implications for therapeutic strategies for children
and adolescents.
Differences observed in hypothalamic 5-HT1A receptor signaling and the
properties of Gα proteins and their signaling may only make up a fraction of
developmental differences in brain function between a developing animal and an
adult animal.

For example, there are differences observed between the

peripubertal and adult groups in: (1) cocaine-induced behavior (Laviola et al.,
1995; Schramm-Sapyta et al., 2004); (2) nicotine-induced sensitization of cocaine
responses (Collins and Izenwasser 2004); (3) motor activity and cortex activation
in response to an NMDA receptor modulator (Pesic et al., 2010); and (4) receptor
regulation induced by treatment with a tricyclic antidepressant (Deupree et al.,
2007).

One study observed that there was no overall differences in the

magnitude of behavior induced by bupropion (an antidepressant used in treating
nicotine addiction) in the peripubertal and adult animals, but that the developing
animals may be more sensitive to lower doses of the drug. Furthermore, in
neuroendocrine neurons, a balance between GABA and glutamate (NMDA and
AMPA) receptor subtypes controls intracellular levels of calcium. One group has
observed a developmental shift in the levels of AMPA receptors controlling this
as the animal matures (Constantin et al., 2010). These studies along with the
studies described in this dissertation have serious implications for the use and
abuse of drugs by children and adolescents. Even a developmental difference
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that seems inconsequential (such as a more prolonged activation of ERK) may
have far-reaching consequences, such as with the effectiveness of antidepressant
drugs used in children and adolescents, the side effect profile of psychotropic
drugs in younger populations, and the permanence of brain changes upon
maturation. Some observations of young animals treated with a variety of drugs
reveal later alterations of adult behavior and brain function:

(1) ethanol

treatment alters locomotor behavior as an adult (Roskam and Koch, 2009) and (2)
nicotine increases anxiety behavior and alters CRH and neuropeptide Y systems
(Slawecki et al., 2005).
Future directions for the present studies
There are several courses of action that could be pursued to further clarify the
mechanisms of 5-HT1A receptor-mediated signaling and desensitization in the
peripubertal PVN.
First of all, a few of the pharmacological tools employed in these studies
(namely PTX and fluoxetine) did not produce the anticipated effects on Gα
proteins.

To completely clarify the role of specific Gα proteins in 5-HT1A

receptor-mediated neuroendocrine responses and kinase activation, a more
specific tool such as adenoviral-delivered siRNA or antisense oligonucleotides
for the specific Gα proteins must be utilized. This will also assist in determining
if 5-HT1A receptor-mediated pathways in the peripubertal PVN are independent
and, if so, if these pathways are mediated by separate subsets of Gα proteins.
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It may also be important to determine if ERK or Akt protein kinase pathways
contribute to the respective 5-HT1A receptor-mediated responses. In a separate
experiment, we gave peripubertal rats an intra-PVN injection of the PI3K
inhibitor LY294002 to assess the role of Akt’s upstream kinase PI3K in 5-HT1A
receptor-mediated signaling of neuroendocrine, ERK, and Akt responses in the
peripubertal PVN.

Although 5-HT1A receptor-mediated oxytocin and ACTH

responses, but not pERK responses, were partially reduced, there were no
significant effects of the PI3K inhibitor on the phosphorylation of Akt at either
Thr308 or Ser473 (Petrunich-Rutherford et al., unpublished data). Therefore, it
may be possible that PI3K may contribute to 5-HT1A receptor-mediated
neuroendocrine responses in the peripubertal PVN. An alternative explanation
for the lack of PI3K inhibition on 5-HT1A receptor-mediated ERK and Akt kinase
responses could be that 5-HT1A receptors may be activating ERK and Akt via a
PI3K-independent mechanism, which has been observed in other systems (Alessi
et al., 1996; Sable et al., 1997; Yano et al., 1998).
Further research is necessary to determine specifically which cells contain 5HT1A receptor-mediated pERK in peripubertal PVN. Currently, a protocol for
immunohistochemical double labeling of CRH and 5-HT1A receptor-stimulated
pERK is in progress to optimize colocalization of these markers in both
peripubertal and adult PVN using perfused rather than post-fixed brain tissue.
Thus far, it appears that some of the factors involved with perfusion (anesthesia,
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stress, perfusion itself) increases basal levels of ERK such that further stimulation
of 5-HT1A receptors by (+)8-OH-DPAT can not be clearly discerned.

More

studies are necessary to determine the impact of these factors on ERK stimulation
in the PVN.
As mentioned previously, in the adult PVN (Petrunich-Rutherford et al.,
unpublished data), 5-HT1A receptors increase the phosphorylation of Akt;
however, the full time course and dose-responsiveness has not been investigated
in this age group with either (+)8-OH-DPAT or tandospirone.

Also, it is

unknown at this time whether tandospirone acts as a “full” or “partial” agonist
at 5-HT1A receptor-mediated oxytocin, ACTH, pERK, and pAkt responses in the
adult PVN. It would be interesting to determine if the actions of tandospirone in
the adult PVN are different compared with the “full” agonist actions on
neuroendocrine responses and pERK yet “partial” agonist on pAkt responses in
the peripubertal PVN.
Another key piece of information would be to determine if intact ERK or Akt
signaling pathways are necessary for SSRI-induced desensitization of 5-HT1A
receptor-mediated

neuroendocrine

responses

in

the

peripubertal

PVN.

Furthermore, considering that 5-HT1A receptor-mediated phosphorylation of
GSK3β (but not 5-HT1A receptor-mediated activation of its upstream kinase Akt)
was desensitized following chronic fluoxetine, another potential area for study is
the regulation of phosphatases responsible for dephosphorylating ERK and Akt
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upon chronic antidepressant or acute 5-HT1A receptor stimulation. Phosphatases
have been implicated in stress and the effects of chronic antidepressants in other
models. In the hippocampus, chronic stress increases hippocampal levels of a
phosphatase specific for MAPK, and antidepressants normalize the levels of this
phosphatase (Duric et al., 2010).

The protein level of PP1 phosphatase (the

primary phosphatase for GSK3β in COS-7 cell cultures, Hernandez et al., 2010),
was increased in the adult frontal cortex and hippocampus in a rat model of
depression (Feng et al., 2003).

Therefore, pursuing the regulation of

phosphatases in the peripubertal and adult PVN may represent a new and
exciting research area.
In conclusion, although several facets of 5-HT1A receptor-mediated signaling
in the peripubertal PVN have been determined, it seems that even more
questions have been generated about the signaling and regulation of this
receptor in the immature brain, and much more research is needed to fully
elucidate the role of this receptor in mood disorders and the effects of
antidepressants.
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